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ABSTRACT 
The regulation of whole body energy balance is regulated by the endocrine system. 
Nesfatin-1 is a newly identified multifunctional metabolic peptide with insulinotropic, endocrine, 
glucoregulatory, fat reducing and cardiovascular functions. There is no evidence on 
NUCB2/nesfatin-1 during development. While nesfatin-1 is meal responsive, it is unknown 
whether macronutrients regulate its secretion. Is endogenous nesfatin-1 critical for energy 
balance? The central hypothesis of this thesis research is that the tissue specific expression of 
NUCB2/nesfatin-1 is regulated developmentally, and by nutrients, and that the endogenous 
NUCB2/nesfatin-1 is critical for the maintenance of energy homeostasis. The specific objectives 
of this research were to determine the developmental, and nutrient regulated expression of 
NUCB2/nesfatin-1, and to characterize the metabolic phenotype of mice lacking 
NUCB2/nesfatin-1. There were three key findings made in this research. First, it was found that 
NUCB2/nesfatin-1 presents an ontogenic pattern of expression in the gastroenteropancreatic 
tissues and serum of rats. An age-dependent co-expression of related peptides, ghrelin and its 
processing enzyme, ghrelin-O-acyl transferase (GOAT), and nesfatin-1 processing prohormone 
convertases were also found in the endocrine pancreas. Second, it was determined that the 
NUCB2 mRNA expression and NUCB2/nesfatin-1 secretion in mice are influenced by nutrients 
in a tissue specific manner in vitro and in vivo, and it depends on the duration of exposure to 
specific diets tested. This research identified macronutrients as major regulators of endogenous 
NUCB2/nesfatin-1. Third, a sexually dimorphic effect of NUCB2/nesfatin-1 disruption in mice 
was found, with alterations in body weight, food intake, insulin secretion, glucose homeostasis 
and energy homeostasis. These data support a metabolic role for endogenous nesfatin-1. 
Together, this research provides important new information on developmental and cell specific 
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regulation of nesfatin-1 expression, nutrient regulation of its expression and secretion, and an 
essential role for endogenous nesfatin-1 in maintaining energy homeostasis.  For example, 
endocrine pancreas is an abundant source of nesfatin-1. Absence of endogenous nesfatin-1 
causes defects in insulin secretion from islet beta cells, and alters glucose homeostasis. 
Exogenous nesfatin-1 causes a reduction in body weight. NUCB2 gene disruption resulted in 
abnormal body weight, further confirming that nesfatin-1 indeed influences body mass. 
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MGN3-1.........................................................................................................mouse ghrelinoma 3-1 
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PCR..........................................................................................................polymerase chain reaction 
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RIA......................................................................................................................radioimmunoassay 
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VMN............................................................................................................................ventro-medial  
WT.......................................................................................................................................wildtype 
ZI....................................................................................................................................zona incerta  
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Chapter 1 
Introduction 
1.1 The Nervous and Hormonal Systems: Integrators of Homeostasis 
The emergence of multicellular organisms involves, in large part, the communication of 
multiple signalling systems (Stoka, 1999). These systems are organized in a structured network 
to carry out several signals from one cell to another, either between or within multiple 
environmental compartments. Communication on a cellular level is defined as chemical 
signalling, sensing, and response, which is central to evolutionary history (Stoka, 1999).  
Chemical signals are in the form of information molecules which include hormones, 
bioregulators, receptors, transducers, effectors and secondary messengers (Stoka, 1999). As we 
know, vertebrates being multicellular, are made up of several tissues and organs that constitute 
the circulatory, respiratory, digestive, musculoskeletal and nervous systems. To function 
properly, these organs systems must communicate with each other to ensure that the 
physiological homeostasis is maintained (Nussey and Saffron, 2001). Two systems ensure that 
communication is achieved between the organs systems: the nervous and the hormonal 
(neuroendocrine) system (Nussey and Saffron, 2001).  
 The nervous system allows rapid transmission of information to several regions of the 
body within fractions of seconds. Information is communicated from neurons to other neurons or 
peripheral tissues through electrical signals along axons. These signals stimulate the release of 
chemical neurotransmitters into the synaptic cleft between pre- and post-synaptic neurons 
(Hiller-Sturmhöfel and Bartke, 1999). Neurotransmitters bind to receptors on target cells to 
mediate their signal via intracellular signalling cascades (Hiller-Sturmhöfel and Bartke, 1999). In 
addition to neurotransmitters, neurons and cells also communicate via chemical messengers that 
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are derived from fatty acids, cholesterol and amino acids. The most diverse group of chemical 
messengers are comprised of linked amino-acids, known as peptides (Nussey and Saffron, 2001). 
To date, there are several different types of peptide hormones discovered.  Peptide hormones can 
range in size from 3 to over 200 amino acids. The hormones are transported via the blood to their 
target cells. Some hormones have few target cells whereas other hormones have numerous target 
cells throughout the body (Nussey and Saffron, 2001). Conversely, the hormone system relies on 
the production and release of these peptide hormones from various organ systems to bind to their 
receptors inducing a chemical signal either by endocrine, paracrine, autocrine and/or intracrine 
mechanisms (Nussey and Saffron, 2001). The interaction between the hormone and their 
respective receptors triggers a cascade of biochemical reactions implementing the cell’s 
regulatory action. Hence, both communication systems complement each other to respond to 
changes in the internal and external environments (Nussey and Saffron, 2001). 
1.1.1 Hormone synthesis 
Most hormones require the transcription of a single gene, although there are some 
hormones that consist of multiple subunits that are derived from several genes. The initial RNA 
undergoes modification to form the messenger RNA. Introns are excised and the 3’ and 5’ of the 
RNA are altered (Nussey and Saffron, 2001). The mature RNA is used as a template for the 
assembly of amino acids via the transfer RNA on the endoplasmic reticulum. Inside the 
endoplasmic reticulum, the protein translated from mRNA, moves into the golgi apparatus by 
fission. Secretory granules are formed from the budding of the golgi apparatus (Nussey and 
Saffron, 2001). These prohormones are stored and secreted from the secretory granules within 
the cell. Peptidases cleave the prohormones into biologically active hormones prior to their 
release into the cytoplasm (Nussey and Saffron, 2001).  
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1.1.2 Mechanism of Hormonal Action 
Hormones are involved in a variety of functions, some of which include, reproduction, 
sexual differentiation, development and growth, regulation of metabolism and nutrient supply 
(Hiller-Sturmhöfel and Bartke, 1999). A single hormone may induce one or multiple functions 
and each function may be modulated by several hormones. Hormones exist in several classes: 
steroids, amino acid derivatives, polypeptides and proteins. Mostly the hormone’s class define 
the basis of their putative action. The hormone classes differ in the molecular structure and 
chemical properties. As of result of structural differences, their mechanisms of action are diverse 
(Hiller-Sturmhöfel and Bartke, 1999). Steroids, mainly produced from the adrenal cortex and 
gonads, have a molecular structure similar to cholesterol. These molecules can enter into the 
cells and bind to their receptors present in the cytoplasm or in the nucleus.  The hormone-
receptor complex binds to the DNA regulating the activation of genes specific to the hormone 
bound (Hiller-Sturmhöfel and Bartke, 1999). Amino acid derivatives mediate their action similar 
to that of steroids, which are mainly secreted from the thyroid gland and the adrenal medulla.  In 
contrast, proteins and polypeptides are chains of amino acids found primarily in the 
hypothalamus, pituitary gland and several peripheral organs (Hiller-Sturmhöfel and Bartke, 
1999). They are usually derived as inactive prohormones which are then cleaved into one or 
more active proteins. Due to their complex structure, they are incapable of entering the cells and 
thereby interact with receptors on the cell surface to initiate their cell specific function (Hiller-
Sturmhöfel and Bartke, 1999).  
1.1.3 Hormones Involved in the Regulation of Energy Balance 
To maintain the body’s homeostasis and to respond to changes in the environment, it is 
vital that hormone production and secretion be tightly controlled (Murphy and Bloom, 2006). 
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Homeostasis is a process that is tightly regulated in order to maintain constant energy reserves 
over a long period of time. In order to maintain a constant energy balance, energy intake, 
determined by feeding behavior, thermogenesis and energy expenditure must be regulated. These 
components of energy balance are modulated by two interconnected, yet separate systems 
(Murphy and Bloom, 2006). The first system is identified as a short-term system that controls the 
beginning and termination of ingestion depending on the quality and quantity of nutrient 
availability. Neural and hormonal signals from the peripheral sources convey their information 
on the nutritional contents in the gastrointestinal tract. The second system is a long term system 
that works to maintain stable energy reserves and constant body weight (Murphy and Bloom, 
2006). During feeding, excess energy consumed is stored for later use in the form of fats and 
carbohydrates. Both systems work together to balance the energy reserves in response to the 
changing environmental conditions (Murphy and Bloom, 2006). Gastrointestinal hormones are 
modulated as a result of short term regulation of hunger and satiety, which tend to have less 
influence on food intake and body weight which are controlled by long term regulation. 
Therefore, the body relies predominantly on the long-term system, which includes hormones 
such as leptin secreted by adipose tissue and insulin from the pancreas to maintain a constant 
energy balance (Murphy and Bloom, 2006).  
1.1.4 Neuroendocrine Control of Feeding   
The gastrointestinal tract secretes several hormones for different physiological actions 
(Schwartz et al., 2000, Boguszewski and Van der Lely, 2015). Appetite, satiety regulation, 
gastrointestinal tract functional, nutrient digestion, absorption, distribution and energy 
homeostasis are regulated by a complex system of central and peripheral effects that interact in 
order to modulate nutrient ingestion (Schwartz et al., 2000, Boguszewski and Van der Lely, 
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2015). Central control of gut hormones are mainly due to actions of two distinct neuronal 
populations present within the arcuate nucleus (ARC) of the hypothalamus (Schwartz et al., 
2000, Boguszewski and Van der Lely, 2015). These neuron populations are identified as ‘first 
order neurons’ because of their contact with circulation and are key targets of appetite regulatory 
factors, serving as the central neuronal processors of orexigenic (appetite stimulatory) and 
anorexigenic (appetite inhibitory) signals. The first neuron population consists of anorexigenic 
neurons that express pro-opiomelanocortin and cocaine- and amphetamine-related transcripts 
(POMC/CART). In contrast, the second orexigenic neurons express neuropeptide Y and agouti-
related peptide (NPY/AgRP). These neurons project on to ‘second-order neurons’ residing in 
other regions, which include the paraventricular nucleus (PVN), dorso-medial nucleus (DMN), 
ventro-medial nucleus (VMN) and the lateral hypothalamus (LH) (Schwartz et al., 2000, 
Boguszewski and Van der Lely, 2015).  This peripheral information is then integrated with 
behavioral, hormonal and nutritional inputs coming from the periphery and higher cortical 
centers. The orexigenic and anorexigenic neuron groups are interconnected at several regions of 
the central nervous system (Schwartz et al., 2000). Activation of one neuronal group leads to the 
activation of other neurons via neural firing that modulates the transcription and translation of 
multiple genes involved in regulating energy balance. In addition, the blood brain barrier (BBB) 
is important for the gastrointestinal-brain axis, by modulating hormone transportation (Schwartz 
et al., 2000). 
The gastrointestinal tract secretes many anorexigenic factors, which include 
cholecystokinin (CCK), peptide YY (PYY), oxyntomodulin (OXM), gastric inhibitory 
polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). The stomach mucosa secretes ghrelin 
and nucleobindin-2/nesfatin-1 (NUCB2/nesfatin-1) that are mainly involved in regulating food 
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intake and increasing energy expenditure (Schwartz et al., 2000, Boguszewski and Van der Lely, 
2015). Due to the scope of our research, this chapter will only focus on NUCB2/nesfatin-1 and 
ghrelin, that aid in playing major roles in feeding and energy homeostasis. 
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1.2 Nucleobindins 
Nucleobindins are a class of multidomain Ca
2+
 binding proteins that interact with nucleic 
acids and different regulatory proteins, thereby playing an important role in various signaling 
pathways. Initially, nucleobindin was identified as a transcription factor as it demonstrated the 
ability to bind to DNA fragments in vitro, thus the name nucleobindin (Miura et al., 1992). To 
date, two nucleobindins, nucleobindin-1 (NUCB1) and nucleobindin-2 (NUCB2) (Lin et al., 
1998, Miura et al., 1992) have been identified. Although two separate and unlinked genes encode 
for these proteins, human NUCB1 and NUCB2 exhibit 62% amino acid sequence 
identity (Valencia et al., 2008). The first focus of this chapter is to summarize the most recent 
findings on the functional significance of NUCB2 and its encoded protein, nesfatin-1. 
1.2.1 Discovery of Nucleobindin-2 and Nesfatin-1 
NUCB2 belongs to the EF-hand family of calcium-binding proteins (Moncrief et al., 
1990, Lee et al., 1991, Nakayama et al., 1992). These proteins share a structural motif of calcium 
binding domain known as the EF-hand (Moncrief et al., 1990, Lee et al., 1991, Nakayama et al., 
1992). The name EF-hand was coined by Kretsinger and Nockolds (Kretsinger et al., 1973) to 
visually describe the calcium-binding motif they observed in parvalbumin, a calcium-binding 
protein (Henrotte et al., 1952, Celio et al., 1981). Several proteins with the EF-hand motif have 
been extensively characterized and were shown to undergo several genetic processes including 
splicing, translocation, fusion and gene replication. Phylogenetic analyses were conducted to 
determine the primary ancestor of these proteins. This approach helps to understand the origin of 
the protein and how it changed during evolution. From recent discoveries, one protein that 
demonstrated rooted phylogeny from the EF-hand domain is nucleobindin-2/NEFA (Nucleic 
Acid/DNA binding/EF-hand/acidic amino acid rich region) (Nakayama et al., 1992). 
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Phylogenetic and sequence analysis has shown that through a series of genetic 
modifications, such as duplication and fusion, NEFA arised from the UR/CTER EF-hand 
domains (Nakayama et al., 1992). This common domain led to the formation of a four-domain 
precursor ancestor. With ultimate steps of domain deletion, duplication and fusion, two 
sequences were fused together leading to NEFA-N and NEFA-C (Nakayama et al., 1992). A 
signal peptide is present at the N-terminal region of NEFA-N, and two functional EF-hand 
calcium binding domains are present at the N-terminal region of NEFA-C (Nakayama et al., 
1992). With subsequent divergence of this precursor protein sequence with other domains such 
as the heptad repeat domain, a putative hydrophilic DNA-binding region and a leucine zipper 
region resulted in the genetic evolution of NEFA. Gene duplication of NEFA led to the 
formation of nucleobindin-2 and NEFA-like proteins (Nakayama et al., 1992). 
 The initial discovery of nucleobindin came from research conducted in lupus-prone 
MRL/l mice. These mice are known to secrete large amounts of antibodies targeted against 
single stranded and double stranded DNA (Theofilopoulos et al., 1985). A cell line (KML1-7) 
that produced a soluble protein which induced the formation of antibodies against ss and ds DNA 
in-vivo and in-vitro was established from the MRL/1 mice (Kanai et al., 1986, Kanai et al., 
1990). From this cell line, a 55-kDa protein was purified (Kanai et al., 1992) and the gene 
encoding this protein was later cloned (Miura et al., 1992). Despite the fact that this protein is 
secreted and consists of a signal peptide, its capability to bind to DNA resulted in the name, 
nucleobindin. Since nucleobindin is found in the sera of MRL/l mice, it has a possible role in the 
development of autoimmune disorders of MRL/l mice (Kanai et al., 1993).  
 While studying the cDNA libraries of human acute lymphoblastic leukemia KM3 cell 
line for screening common acute lymphoblastic leukemia antigens, a protein sequence that was 
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identical to nucleobindin was identified, suggesting it to be an isoform of nucleobindin 
(Barnikol-Watanabe et al., 1994). This protein was produced in the plasma membrane and 
cytosol, and was secreted into the culture medium. It was found to have a molecular mass of 55 
KDa protein band determined by SDS-PAGE (Barnikol-Watanabe et al., 1994). Structural 
characteristics depicted that it consisted of a nuclear localization signal with an amino acid 
region present between the two EF-hand motifs, demonstrating to have sequence similarity to 
NEFA at 61.56%. As a result of its sequence similarity to NEFA it was instead named as 
nucleobindin-2 (Karabinos et al., 1996). While investigating small proteins in the mineral phase 
of the bone tissue led to the discovery of nucleobindin in some other organisms. A 63-KDa 
protein from the mineralized matrix of the bovine bone was characterized (Wendel et al., 1995). 
This protein shared structural similarity with mouse and human nucleobindin, where the 
presence of N-terminal signal sequence, two EF-hand motifs, a heptad repeat-leucine zipper 
regions and a bipartite-nuclear localization signal was observed (Wendel et al., 1995).  
 The gene organization of nucleobindin is conserved across many species. Some of the 
organisms have untranslated regions at both their 3’ and 5’ ends with more than 11 exons in their 
gene (Guo et al., 2007). The size of the nucleobindin gene in every organism determines the 
number of the introns in these genes. With an increase in the gene size, an increase in the number 
of introns is observed (Aradhyam et al., 2010). Despite differences observed in the C-terminal 
region of the gene and incidence of exon shuffling, the primary structure of the nucleobindin 
gene is highly conserved across various species (Aradhyam et al., 2010). Differences in the gene 
structure despite the presence of conserved sites may raise the possibility of species- and tissue-
specific functions as a consequence of the evolution of this gene. Analysis of the amino acid 
sequence suggests a clear difference of this gene and its processing in organisms (Kanuru et al., 
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2009, Miura et al., 1994). More complex organisms tend to have multiple isoforms of 
nucleobindin whereas simple organisms express a single polypeptide chain. The degree of 
conservation is greater in the highly evolved organisms in comparison to the less complex 
organisms. Differences in the function and expression of these nucleobindin isoforms are yet to 
be determined (Kanuru et al., 2009, Miura et al., 1994).  
 In evolution, a single ancestral domain undergoes several genetic modifications in time, 
giving rise to multiple genes implicated in various functions. It is believed that NUCB2 and 
nucleobindin-1 (NUCB1) arose from a single EF-hand domain (Karabinos et al., 1996). Both 
NUCB1 and NUCB2 belong to a homologous gene family (Miura et al., 1992).  The NUCB2 
gene structure is highly conserved across various species. The NUCB2 gene in rats shares a high 
percentage similarity to NUCB2 of other species including: 87.4% homology to humans (Homo 
sapiens) and 95.7% to mice (Mus musculus) (Oh-I et al., 2006). In cyprinids, there is a high 
conservation of NUCB2 gene between goldfish (Carassius auratus) and zebrafish (Danio rerio) 
(Gonzalez et al., 2010). A broad phylogenetic analysis of NUCB2 gene sequence identified 
several isoforms of NUCB2 within one species, which include NUCB2A and NUCB2B. The 
differences in these isoforms are attributed mainly to the number of exons and introns present in 
the gene (Gonzalez et al., 2010). For instance, NUCB2A and NUCB2B gene sequences in 
zebrafish (Danio rerio), medaka (Oryzias latipes) and stickleback (Gasterosteus aculeatus) are 
composed of 13 exons by 12 introns (Gonzalez et al., 2010). In contrast, as a result of the 
deletion of exon 1 in both fugu (Takifugu rubripes) and green pufferfish (Tetraodon 
nigroviridis), the genes are composed of 12 exons and 11 introns (Gonzalez et al., 2010). The 
presence of these isoforms in teleost fishes could be a result of independent tetraploidization, 
named 3R, identified as the third stage of genome replication (Christoffels et al., 2004, Jaillon et 
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al., 2004). The nesfatin-1 region of NUCB2A sequences in goldfish shares a high percentage 
homology with the NUCB2A isoform of teleosts which includes: 94% to zebrafish (Danio rerio), 
91% to medaka (Oryzias latipes), 86% to stickleback (Gasterosteus aculeatus), 84% to green 
pufferfish (Tetraodon nigroviridis), and 83% to fugu (Takifugu rubripes) (Gonzalez et al., 2010). 
The nesfatin-1 region of NUCB2A sequences in goldfish shares a higher percentage similarity to 
NUCB2 gene in other species which includes: 64% to Western clawed frog (Xenopus tropicalis), 
66% to chicken (Gallus gallus), 57% to mouse (Mus musculus), and 63% to humans (Homo 
sapiens) (Gonzalez et al., 2010). Figure 1.1 is a phylogram showing evolutionary relationships 
of NUCB1 and NUCB2 sequences in vertebrates. Further elucidation of gene structure and 
function in individual species will be an important aspect of future nesfatin-1 research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Evolutionary Relationships of NUCB1 and NUCB2 Sequences in Vertebrates 
Figure 1.1. A phylogram showing relationships between NUCB1 and NUCB2 sequences among 
vertebrates. The details of sequences used to create this figure are listed in our previous 
publication Gonzalez et al., 2010. The phylogram is created using the program Treeview 
(http://taxonomy.zoology.gla.ac.uk/rod/treeview.html).  
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 In 2006, Oh-I and colleagues identified a novel protein named nesfatin-1, which is 
encoded in NUCB2, and found in several hypothalamic and brainstem neurons of rats (Oh et al., 
2006). Nesfatin-1 is the N-terminal fragment of NUCB2 and the name stands for the acronym 
NEFA/nucleobindin-2 Encoded Satiety- and Fat-Influencing proteiN-1 (Oh et al., 2006, Shimizu 
et al., 2009). Reports to date implicate a role for nesfatin-1 in inducing satiety [Oh et al., 2006, 
Shimizu et al., 2009, Maejima et al., 2009, Stengel et al., 2009a, Su et al., 2010, Atsuchi et al., 
2010, Yosten et al., 2010, Goebel et al., 2010), development (Garcia-Galiano et al., 2010), 
regulation of blood glucose (Su et al., 2010), gonadotrope regulation (Su et al., 2010), gut 
motility (Stengal et al., 2009), stress mediation (Goebal et al., 2009), adipose differentiation 
(Ramanjaneya et al., 2010) and hypertension (Yosten et al., 2010). Prohormone convertases (PC 
1/3 and PC 2) are the enzymes proposed to cleave NUCB2 precursor protein to nesfatin-1 (Oh et 
al., 2006, Lee et al., 1999). Upon cleavage of NUCB2 by PCs, 3 smaller proteins: nesfatin-1 (82 
amino acids), nesfatin-2 (79 amino acids), and nesfatin-3 (231 amino acids) are expected to be 
produced (Oh et al., 2006). Recent study determined the protein expression of nesfatin-1 in  
PC 1/3 deficient patients (Catli et al., 2013). Congenital PC 1/3 deficiency is a very rare 
syndrome with abnormal prohormone processing, early-onset obesity, small intestinal 
dysfunction, impaired glucose homeostasis. These patients have low levels of nesfatin-1 protein 
in circulation suggesting that decreased levels of nesfatin-1 may be one of the contributing factor 
for the development of obesity (Catli et al., 2013). 
The C-terminal fragments of NUCB2, nesfatin-2 and nesfatin-3 have no known 
biological effects in comparison to nesfatin-1 (Oh-I et al., 2006). The mid-segment of nesfatin-1 
(M30) from amino acids 23 to 53 is identified as the bioactive core that induces the anorectic 
response. The M30 region of nesfatin-1 shows a great degree of sequence identity among the 
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nesfatin-1 encoded in both NUCB1 and NUCB2 (Gonzalez et al., 2010). It has been shown that 
intraperitoneal injections of M30 in db/db, ob/ob and diet-induced obese mice significantly 
decreases food intake (Shimizu et al., 2009). Also, recent studies on nesfatin-1 (30-59; M30) but 
not the N- and C- terminal fragment, showed that intracerebroventricular injection induced 
satiety in the dark phase with reduced meal number 4 hours post injection. These studies further 
support previous studies that nesfatin-1(30-59) is the active core of nesfatin-1 (1-82) that induces 
the satiety effect (Stengel et al., 2012a).  
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1.2.2 Tissue-Specific Expression of NUCB2/Nesfatin-1: Comparative Aspects 
Nesfatin-1 is present in various regions of the brain and peripheral tissues that are 
involved in the regulation of feeding and appetite and it is been suggested that the neuronal 
effects of nesfatin-1 are mediated through a G-protein coupled receptor.  
1.2.2.1 Region-Specific Expression of NUCB2/Nesfatin-1 in Mammals and Non-
Mammals 
1.2.2.1.1 Mammals 
  The broad distribution of NUCB2/nesfatin-1 in the hypothalamus and regions of the 
brainstem which are primarily involved in the regulation of food intake supports a crucial role 
for this protein in the maintenance of energy homeostasis. In mammals, NUCB2 is expressed in 
the rat brain, mainly in the hypothalamic paraventricular nucleus (PVN), arcuate nucleus (ARC), 
lateral hypothalamus (LHA), supraoptic nucleus (SON), and the zona incerta (ZI) of the 
thalamus (Oh et al., 2006). NUCB2/nesfatin-1 immunopositive cells are also localized in the 
brainstem of rats, in the nucleus tractus solitarius (NTS), Edinger Westphal (EW), dorsal motor 
nucleus of vagus (DMNV; Xia et al., 2012), and caudal raphe nuclei (Oh et al., 2006, Foo et al., 
2008, Brailoiu et al., 2007, Geobel-Stengel et al., 2011). In addition, NUCB2/nesfatin-1 
immunoreactivity was detected in cortical areas including piriform, insular, cingulate and 
somatomotor cortices, the limbic system including amygdaloid nuclei, hippocampus and septum, 
the basal ganglia, bed nucleus of the stria terminalis (Geobel-Stengel et al., 2011). Colocalization 
of NUCB2/nesfatin-1 with neuropeptide regulators of appetite, like proopiomelanocortin, 
cocaine- and amphetamine-regulated transcript, melanin concentrating hormone and 
neuropeptide Y (Brailoiu et al., 2007, Foo et al., 2008, Fort et al., 2008, Price et al., 2008) has 
been reported. In addition, co-immunostaining of NUCB2/nesfatin-1 was found with 
16 
 
vasopression, oxytocin, cocaine amphetamine regulated transcript and melanin concentrating 
hormone (Kohno et al., 2008). Histamine H1 receptor (H1-R) expression was co-immunoreactive 
with NUCB2/nesfatin-1 expression in the PVN of the hypothalamus (Gotch et al., 2013). Mature 
nesfatin-1 elution peak was obtained from the cerebrospinal fluid and rat hypothalamic extracts 
during high performance liquid chromatography (HPLC) (Oh et al., 2006). Studies have also 
shown that NUCB2 is found in the sympathetic and parasympathetic preganglion neurons in rats 
(Goebel et al., 2009). NUCB2/nesfatin-1 immunoreactivity was detected in the raphe nuclei, 
Edinger-Westphal nucleus, locus coeruleus (LC), lateral parabrachial nucleus, ventrolateral 
medulla (VLM) and dorsal vagal complex (Geobel-Stengel M et al., 2011). Nesfatin-1 is able to 
cross the blood-brain barrier without saturation, which suggests that peripherally administered or 
produced nesfatin-1 could reach the brain to elicit its central actions (Pan et al., 2007, Price et al., 
2007). In addition to the brain, NUCB2/nesfatin-1-like immunoreactivity was found in 
the anterior pituitary gland of rats (Stengel et al., 2009a) and mouse (Chang et al., 2015). As 
many studies determine NUCB2 localization in the brain regions, researches have branched into 
determining their expression in domestic animals as well. The presence of NUCB2/nesfatin-
1 neurons was also evident in the VLM, DVC, PVN, ARC and SON of pig brain, supporting 
previous studies.  Study also reveals that these NUCB2 neurons are activated during 
deoxynivalenol (DON) intoxication in the pig (Gaige et al., 2013). DON is a major mytotoxin 
product from Fusarium species responsible for mycotoxicosis in many farm animals (Gaige et 
al., 2013).  
NUCB2/nesfatin-1 is also found in several peripheral tissues. In the pancreas, 
NUCB2/nesfatin-1 is expressed in the insulin producing beta-cells of rats, mice and humans (Foo 
et al., 2010, Gonzalez et al., 2009, Stengal et al., 2009). However, NUCB2/nesfatin-1 
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immunoreactivity is not found in the glucagon producing alpha-cells (Foo et al., 2010, Gonzalez 
et al., 2009, Stengal et al., 2009), pancreatic polypeptide cells (Foo et al., 2010) and somatostatin 
producing D-cells  (Foo et al., 2010). In the stomach, NUCB2/nesfatin-1 was found in the gastric 
X/A-like cells located in the lower and middle third region of the gastric mucosal glands (Zhang 
et al., 2010). In the periphery, decreased NUCB2 mRNA expression levels were also found in 
the gastric endocrine glands of rodents during fasting and increase in NUCB2 mRNA in the 
stomach (Stengel et al., 2009b). Similarly, NUCB2/nesfatin-1 positive enteroendocrine cells 
were also observed in the anterior part of the goldfish gastrointestinal tract (Gonzalez et al., 
2010; Kerbel et al., 2012). NUCB2/nesfatin-1 expression is also observed in the adipose tissue of 
mouse and humans (Ramanjaneya et al., 2010). The expression of NUCB2 mRNA was highest 
in the subcutaneous adipocytes in both mice and humans (Ramanjaneya et al., 2010). During the 
differentiation of preadipocytes to adipocytes, NUCB2 mRNA and nesfatin-1 protein synthesis 
increases (Ramajaneya et al., 2010). In rats NUCB2/nesfatin-1 expression was also observed in 
the liver, with moderate expression in the subcutaneous and visceral fat mass as well as the 
interscapular brown adipose tissue (iBAT) (Osaki et al., 2012). Weak expression of 
NUCB2/nesfatin-1 was found in the skeletal muscle (gastronemious) and fat tissue. In this study 
they found that a lesion in the ventromedial hypothalamus region of rats increased the expression 
of NUCB2/nesfatin-1 in the white adipose tissue (Osaki et al., 2012). NUBC2/nesfatin-1 was 
increased in the subcutaneous and visceral fat mass in comparison to the skeletal muscle mass 
(gastronemious) (Osaki et al., 2012).  
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1.2.2.1.2 Non-Mammals 
In contrast to mammals, fish express two NUCB2 isoforms: NUCB2A and NUCB2B. 
Nesfatin-1 has been identified in zebrafish (Hatef et al., 2014, Gonzalez et al., 2012b, Kerbal et 
al., 2012, Lin et al., 2014), goldfish (Gonzalez et al., 2010, Kerbel et al., 2012) and Ya fish (Lin 
et al., 2014). NUCB2 in goldfish was found in the nucleus lateralis tuberis (NLT) (Gonzalez et 
al., 2010), the teleostean homologue of the mammalian arcuate nucleus (Cerda-Reverter et al., 
2003, Peng et al., 1994, Kerbel et al., 2012). The NLT of goldfish is considered a key region of 
the brain that regulates food intake (Cerda-Reverter et al., 2003, Peng et al., 1994). Similarly, 
abundance of nesfatin-1 expression was also detected in the brain and olfactory bulbs of frogs, 
especially in the hypothalamic regions involved in the regulation of food intake (Senejani et al., 
2014).  
In zebrafish, both NUCB2A and NUCB2 mRNAs are most abundant in the liver, while 
less expression was found in other tissues including the brain and gut. NUCB2/nesfatin-1-like 
immunoreactivity was detected in the mucosal layer cells of zebrafish anterior gastrointestinal 
tract. NUCB2 mRNA expression is found in multiple tissues of goldfish as well, with highest 
expression in the liver, followed by pituitary, with lowest expression found in the muscle and gill 
(Gonzalez et al., 2010). Similarily, the Ya-fish NUCB2A mRNA expressed ubiquitously in 
various organs. Expression was found high in the hepatopancreas, hypothalamus, intestines, 
gonad, pituitary and kidney (Lin et al., 2014). NUCB2 mRNA was also detected in the olfactory 
bulbs, hypothalamus, telencephalon, midbrain and hindbrain, adipose tissue, ovary, eye, kidney, 
and midgut (Gonzalez et al., 2010).  In agreement with this, most recent studies have identified 
NUCB2/nesfatin-1 immunoreactivity in the goldfish pituitary, and goldfish and zebrafish ovarian 
theca and/or follicular cells (Gonzalez et al., 2012b).  
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1.2.2.2 G-Protein Coupled Receptors (GPCRs) - potential receptors of nesfatin-1? 
The identity of the nesfatin-1 receptor currently remains unknown. However, there are 
several lines of evidence that suggest that the neuronal effects of nesfatin-1 are mediated via a G-
protein coupled receptor (GPCR) (Brailoiu et al., 2007, Iwasaki et al., 2009). Preliminary 
findings suggest that GPR3, GPR6 and/or GPR12 are potential receptors for nesfatin-1 (Mori et 
al., 2008, Osei-Hyiaman et al., 2011). Nesfatin-1 can cause an increase in the intracellular 
calcium concentrations in cultured hypothalamic neurons of rats, an effect that was attenuated by 
pertussis toxin, a calcium channel blocker (Brailoiu et al., 2007).  It is suggested that nesfatin-1 
interacts with the G-protein-coupled receptor causing an increase in the intracellular calcium 
concentration mediated via the N-type and L-type calcium channels (Brailoiu et al., 2007, 
Iwasaki et al., 2009). In the vagal afferent ganglion of mice, nesfatin-1 stimulates an influx of 
calcium ions through N-type channels present in these neurons (Iwasaki et al., 2009). Nesfatin-1 
stimulates an influx of calcium ions mediated by the L-type calcium channels present in the 
insulin producing beta-cells (Nakata et al., 2011). Although the nesfatin-1 receptor remains 
unknown, it appears that the effects of nesfatin-1, at least on the neurons and the beta cells are 
elicited via a calcium mediated pathway.  
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1.2.3 Biological Actions of Nesfatin-1 in Mammals and Fish 
Nesfatin-1 has multiple biological actions in rodents, which include stress modulation 
(Ueta et al., 2003), thermogenesis (Fan et al., 2005; Konczol et al., 2012), osteogenesis (Li et al., 
2013), energy expenditure (Gonzalez et al., 2012a), development (Mohan et al., 2012), 
pregnancy (Garces et al., 2014), autonomic response (Maejima et al., 2013), visceral 
hypersensitivity (Jia et al., 2013), sleep regulation (Vas et al., 2013) and cardiac functions 
(Angelone et al., 2012, Brailoiu et al., 2013). The NUCB2 gene sequences in rodents and teleosts 
have been shown to be highly conserved (Gonzalez et al., 2010), which suggests that some 
functions of nesfatin-1 amongst these species are similar.  
1.2.3.1 Nesfatin-1 Regulation of Feeding and Metabolism 
1.2.3.1.1 Nesfatin-1 Mediated Inhibition of Feeding 
Nesfatin-1-induced inhibition of feeding is a common function that has been 
characterized in both rodents and goldfish. NUCB2/nesfatin-1 is expressed in various 
hypothalamic regions and the brainstem of rodents that play a major role in the inhibition of 
feeding (Maejima et al., 2009). In mammals, nesfatin-1 is a meal-responsive hormone (Stengel et 
al., 2009a, Gonzalez et al., 2012a). The SON and PVN play a major role in appetite regulation 
(Balthasar et al., 2005, Horvath et al., 2006, Morton et al., 2006, Schwartz et al., 2000). In 
rodents, NUCB2 mRNA expression was decreased upon fasting in the hypothalamic neurons. 
Upon re-feeding, SON and PVN neurons were activated with an increase in NUCB2 mRNA 
expression (Garcio-Galiano et al., 2010, Kohno et al., 2008). In addition, the SON, PVN along 
with subfornical organ (SFO) are involved in body fluid regulation. A recent study has shown 
that the NUCB2 mRNA was increased 2 to 3 fold in the SFO, SON and PVN following a 48 
hour water deprivation in a time dependent manner. This study suggested that NUCB2/nesfatin-1 
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is a critical peptide involved in dehydration-induced anorexia (Yoshimura et al., 2014).  Also, a 
study on PVN expressing nesfatin-1 neurons, determined that insulin and glucose directly 
interact with and increase the cytosolic calcium concentrations in nesfatin-1 neurons in the PVN, 
thereby inducing satiety (Gantulga et al., 2012).  There are many glucosensing neurons located in 
the hypothalamus that are involved in glucoprivic feeding and homeostatic control of blood 
glucose. Nesfatin-1 injection into the PVN, LHA, VMN of the hypothalamus of ad libitum fed 
rats during the dark phase excited most of the glucose-inhibited neurons and inhibited most of 
the glucose-excited neurons. This study suggested that nesfatin-1 inhibits feeding by modulating 
the excitability of glucosensing neurons in the PVN, LHA, VMN, regions involved in feeding 
behavior (Chen et al., 2012). Nesfatin-1 influenced the excitability of glucose-inhibited neurons 
in the dorsal vagal complex (DVC), inhibiting food ingestion (Dong et al., 2014). Nesfatin-1 
injection studies in the fourth cerebral ventricle of chronically cannulated rats helped determine 
that 2 μg of nesfatin-1 is a sufficient dose to inhibit food intake during the dark phase for more 
than 3 hours as well inhibit vagally stimulated secretion of gastric acid (Xia et al., 2012).   
Nesfatin-1 has also been studied in gastrointestinal function. Nesfatin -1 has shown to 
regulate the activity of gastric distention sensitive neurons and gastric motility mediated via the 
melanocortin pathway in the central nucleus of the amygdala (Wang et al., 2014). Nesfatin-1 
injection has been shown to activate the DMNV in the medulla in vivo and also trigger calcium 
signaling in cultured DMNV neurons (Xia et al., 2012). It was found that the hyperphagic 
feeding mechanism in Tsumura Suzuki obese diabetes (TSOD) mice is different from that of 
db/db mice, which lack a leptin receptor. It was found that TSOD mice had decreased levels of 
NUCB2 mRNA in the hypothalamus of age-matched non-diabetic control Tsumura Suzuki non 
obese Mice (TSNO) but no change in db/db mice. This finding suggests that NUCB2-mediated 
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signaling could be disrupted in the hypothalamus of TSOD mice (Miyata et al., 2012).   
Corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone (TRH), and 
hypothalamic neuronal histamine act as anorexigenics in the hypothalamus along with nesfatin-1 
(Gotch et al., 2013). Histamine increased nesfatin-1 expression and nesfatin-1 increased brain 
CRH and TRH levels. Histidine decarboxylase inhibitor (α-fluoromethyl histidine; FMH), a 
CRH antagonist and anti-TRH antibody attenuated nesfatin-1-suppressed feeding in rats. This 
study suggests that CRH, TRH and hypothalamic neural histamine may mediate the satiety 
effects on nesfatin-1 on feeding behavior (Gotch et al., 2013).  Also, neuro-circuits in the ARC 
and PVN secrete neuropeptides in the hypothalamus, which in turn can regulate 
NUCB2/nesfatin-1 neurons in a dual manner. NPY inhibits, while α-MSH activates 
NUCB2/nesfatin-1 neurons to elicit its effects on feeding (Sedbazar et al., 2014).  
1.2.3.1.2 Mechanism of Nesfatin-1 In Vivo Action on Food Intake 
Several other studies in rodents confirm that central and/or peripheral administration of 
nesfatin-1 causes a reduction in food intake (Oh et al., 2006, Shimizu et al., 2009, Maejima et al., 
2009, Stengal et al., 2009, Su et al., 2010, Atsuchi et al., 2010, Yosten et al., 2010, Goebel et al., 
2010, Gonazalez et al., 2012) and water intake (Yosten et al., 2010, Yosten et al., 2012). The 
method of administration unravels several mechanistic pathways that NUCB2/nesfatin-1 could 
elicit it action.  
Intracerebroventricular (ICV) injection of nesfatin-1 into the third ventricle (3V) in 
leptin-resistant Zucker (db/db) rats caused a reduction in food intake (Oh et al., 2006). The effect 
on food intake was attenuated when a melanocortin receptor antagonist SHU9119 was co-
administered with nesfatin-1. This suggests that NUCB2/nesfatin-1 acts via a leptin-independent 
melanocortin-dependant signaling pathway (Oh et al., 2006).  Recent evidence further confirms 
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these findings that NUCB2/nesfatin-1 neurons in the PVN are directly influenced by leptin, 
mediating its anorexigenic effect (Darambazar et al., 2015).  Nesfatin-1 ICV and intraperitoneal 
(IP) injections cause a reduction in food intake in goldfish (Gonzalez et al., 2010, Kerbel et al., 
2012). It has been shown that ICV injection of nesfatin-1 inhibits gastric emptying in rats 
(Stengel et al., 2009a). This specific role of nesfatin-1 is not yet studied in teleosts. Further, 
cholecystokinin (CCK) has shown to activate NUCB2/nesfatin-1 neurons in the PVN and NTS 
mediated via a corticotropin-releasing hormone (CRH)2-receptor-dependent pathway (Stengal et 
al., 2009). When astressin2-B, a CRH receptor antagonist was coinjected with nesfatin-1, the 
effects of nesfatin-1 on food intake in rats were attenuated (Stengal et al., 2009). Under 
conditions of stress in rats, nesfatin-1 was shown to stimulate other hormones which include 
CRH, noradrenalin, and serotonin neurons of the rat hypothalamus (Yoshida et al., 2010). 
NUCB2/nesfatin-1 may also act via the central oxytocin system, where studies have shown that 
nesfatin-1 stimulates the release of oxytocin from the PVN neurons (Maejima et al., 2009). 
Oxytocin release sends a message to the NTS pro-opiomelanocortin (POMC) neurons in the 
brainstem, which results in the inhibition of food intake independent of the leptin mediated 
pathway (Maejima et al., 2009). In addition, oxytocin receptor antagonist, H4928, suppressed the 
effects of nesfatin-1 on food intake. These results suggest that nesfatin-1 may act via an oxytocin 
mediated pathway (Maejima et al., 2009) to elicit the satiety effect. Other studies suggest that 
nesfatin-1 may directly influence the POMC neurons in the ARC nucleus stimulating the release 
of alpha-melanocortin stimulating hormone, thus activating the oxytocin neurons in the PVN 
(Yosten et al., 2010). Furthermore, it was shown that nesfatin-1 hyperpolarizes neuropeptide Y 
(NPY) neurons in the ARC nucleus resulting in an inhibition of food intake (Price et al., 2008). 
The mammalian equivalent of the arcuate nucleus in goldfish is the NLT (Cerda-Reverter et al., 
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2003, Peng et al., 1994), where other neuropeptides are present, suggesting that nesfatin-1 may 
interact with these appetite regulators in modulating food intake. Studies have shown that 
NUCB2/nesfatin-1 colocalized with pSEK1, which is a downstream target of mammalian target 
of rapamycin (mTOR). mTOR activity and gastric NUCB2/nesfatin-1 were downregulated by 
fasting and was found to be high in high fat diet induced obese mice. Inhibition of mTOR 
activity by rapamycin affects and attenuates the expression of NUCB2 mRNA in gastric tissues 
of both lean and obese mice as well as in MIN6 cells. This study suggests that modulation of 
mTOR signaling regulates gastric NUCB2/nesfatin-1 expression (Li et al., 2012).      
1.2.3.2 Nesfatin-1 Regulation of Insulin Secretion and Glucose Metabolism 
NUCB2/nesfatin-1 immunoreactivity in the insulin producing pancreatic beta cells 
provides the first evidence that NUCB2/nesfatin-1 might influence glucose metabolism (Foo et 
al., 2010, Gonzalez et al., 2009). In hyperglycemic db/db mice, nesfatin-1 administration resulted 
in an anti-hyperglycemic effect (Su et al., 2010). Upon the use of PPAR-γ antagonist, GW9662 
or the AMPK inhibitor, compound C, the anti-hyperglycemic effect of nesfatin-1 was attenuated 
suggesting that nesfatin-1 is mediated via the insulin signaling pathway (Su et al., 2010). In 
addition, NUCB2/nesfatin-1 immunoreactivity was low in the isolated islets of Goto-Kakizaki (a 
T2DM model) rats in comparison to Wistar control rats (Foo et al., 2010). Isolated islets of 
Wistar rats, when incubated in high glucose, released NUCB2/nesfatin-1 in vitro. Furthermore, 
there was a significant decrease of nesfatin-1 levels 30 minutes post-glucose intraperitoneal 
injection and an increase at 120 and 240 minutes post-injection (Foo et al., 2010). NUCB2 
mRNA expression and NUCB2/nesfatin-1 immunoreactivity was higher in the pancreatic islets 
of high fat diet induced obese, type 2 diabetic mice (Gonzalez et al., 2011). NUCB2 mRNA and 
NUCB2/nesfatin-1 immunoreactivity was attenuated, but still detectable in the pancreatic islets 
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of streptozotocin (STZ)-induced type 1 diabetic mice (Gonzalez et al., 2011). Nesfatin-1 
stimulates glucose dependent insulin secretion in isolated mouse pancreatic beta-cells (Nakata et 
al., 2011, Gonzalez et al., 2011). Nesfatin-1 infusion caused a significant increase in physical 
activity, energy derived from fat and total number of feeding bouts. Simultaneously, it caused a 
significant reduction in duration of feeding bouts, respiratory exchange ratio and energy derived 
from carbohydrates (Gonzalez et al., 2012a). In an oral glucose tolerance test in ab libitum fed 
rats infused with nesfatin-1, significantly increased amounts of circulating insulin levels were 
detected (Gonzalea et al., 2012). However, no changes in glucose levels coincided with this 
insulin increase. Nesfatin-1 stimulates glucose uptake in the white adipose tissue and inhibits 
glucose uptake in L6 muscle cells (Gonzalez et al., 2012a). Also, it is found that mRNA 
expression of two regulators of gluconeogenesis, phosphoenolpyruvate carboxykinase (PEPCK) 
and glucose-6-phosphatase (G6PC) were upregulated following nesfatin-1 infusion (Gonzalez et 
al., 2012a). These findings suggest that nesfatin-1 has tissue specific effects on glucose uptake 
and it influences production of glucose. These tissue specific peripheral effects are likely causing 
the lack of changes in glucose, when insulin levels were elevated. In contrast to rodents, goldfish 
under fasted conditions have increased NUCB2 mRNA expression in the liver (Gonzalez et al., 
2010). This upregulation of NUCB2 suggests that nesfatin-1 might be involved in the regulation 
of glucose metabolism in the liver of fasted goldfish. 
1.2.3.3 Nesfatin-1 Metabolic Control of Reproduction 
NUCB2/nesfatin-1 also plays a major role in the reproduction of rodents and teleost 
fishes (Garcio-Galiano et al., 2013; Gonazalez et al., 2012). NUCB2/nesfatin-1 
immunoreactivity was evident in human, rat and mouse testes and rat ovaries (Garcio-Galiano et 
al., 2010). NUCB2/nesfatin-1 immunoreactivity was also found in Leydig cells suggesting its 
26 
 
possible role in testosterone production. During the pubertal period of female rats, NUCB2 
mRNA and protein expression was significantly higher in the hypothalamus (Garcio-Galiano et 
al., 2010). There was a nine fold increase in circulating LH levels at 15 min post-ICV injection 
of nesfatin-1 after a 48-hour fast (Garcio-Galiano et al., 2010). During pubertal maturation, 
central injection of anti-NUCB2 morpholino oligonucleotides caused a decrease in ovarian 
weight, delayed vaginal opening and reduction in circulating levels of LH in pubertal female rats 
(Garcio-Galiano et al., 2010). In adult female rats, no changes to LH and FSH pre-ovulatory 
levels were found as a result of central injection of nesfatin-1 or anti-NUCB2 morpholino 
oligonucleotides (Garcio-Galiano et al., 2010). In addition, these researchers have also 
determined the presence of NUCB2/nesfatin-1 in the testis, where its expression was found to be 
regulated by developmental, metabolic, and hormonal cues and multiple Leydig cell-derived 
factors (Garcio-Galiano et al., 2012). NUCB2 mRNA was found in the rat, mouse, and human 
testes, where NUCB2/nesfatin-1 protein was identified in interstitial mature Leydig cells. 
NUCB2/nesfatin-1 content in rats was suppressed after fasting and was increasing along the 
puberty-to-adult transitional phase (Garcio-Galiano et al., 2012). NUCB2/nesfatin-1 became 
expressed in Sertoli cells upon Leydig cell elimination in rats. Human choriogonadotropin 
replacement enhanced NUCB2/nesfatin-1 mRNA and peptide levels. Testicular 
NUCB2/nesfatin-1 expression was found to be up-regulated by pituitary LH (Garcio-Galiano et 
al., 2012). Also, nesfatin-1 increased human choriogonadotropin-stimulated testosterone 
secretion using rat testicular explants ex vivo. The findings from these studies suggest that 
nesfatin-1 plays a vital role in energy homeostasis, puberty onset, and gonadal function in the 
testis (Garcio-Galiano et al., 2012). On the other hand, in domestic animals, i.c.v. injection of 
nesfatin-1 increases LH secretion and also affects the gonadotropic axis of prepubertal pigs 
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(Lents et al., 2013). Studies have also shown that NUCB2/nesfatin-1 was found highest in the 
pituitary regulating reproduction via the hypothalamic-pituitary ovarian axis (Chung et al., 
2014). In humans, plasma nesfatin-1 was found to be high in circulation in patients with 
polycystic ovary syndrome (PCOS), suggesting that nesfatin-1 might play a role in the 
development of PCOS (Ademoglu et al., 2014).  
NUCB2/nefatin-1 immunoreactivity was evident within the cellular areas of the rostral 
pars distalis (RPD) and pars intermedia (PI) of goldfish anterior pituitary (Gonzalez et al., 
2012b). NUCB2/nesfatin-1 immunoreactivity was also evident in the goldfish and zebrafish 
ovaries (Gonzalez et al., 2012b). Peripheral injection of nesfatin-1 in goldfish caused a 
significant reduction in circulating LH levels (Gonzalez et al., 2012b). Nesfatin-1 treatment has 
also been shown to decrease mRNA expression of hypothalamic hypophysiotropic hormones 
sGnRH and cGnRH (Gonzalez et al., 2012b). Nesfatin-1 also causes a suppression of oocyte 
maturation in zebrafish ovaries (Gonzalez et al., 2012b). In contrast, studies have been conducted 
to determine whether energy availability after spawning can affect plasma levels of nesfatin-1 in 
female rainbow trout fish (Oncorhynchus mykiss), (Caldwell et al., 2014). It was observed that 
plasma nesfatin-1 was not affected by long-term food restriction and does not aid in the 
prediction of rematuration in these fish (Caldwell et al., 2014). Overall, nesfatin-1 acts directly 
on all three tissues in the hypothalamo-pituitary-ovarian axis to regulate reproduction in teleosts.  
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1.2.4 Summary  
NUCB2 gene organization and nesfatin-1 sequence are very highly conserved among 
species studied from the animal kingdom. Many studies have been conducted in recent years to 
unravel the functions of NUCB2/nesfatin-1. Figure 1.2 summarizes the actions of nesfatin-1 in 
various groups of animals in which nesfatin-1 has been studied. In humans, rodents and teleost 
fishes, studies demonstrate tissue-specific expression of NUCB2/nesfatin-1. In rodents and 
humans, NUCB2/nesfatin-1 plays a major role in energy balance and glucose metabolism. In 
rodents and teleost fishes, nesfatin-1 plays a major role in the regulation of food intake, energy 
balance, and reproduction. In addition, several studies have been shown that in rodents, nesfatin-
1 is also involved in the regulation of gastric emptying, development, stress modulation, 
thermogenesis, and cardiovascular functions. While all these studies unequivocally enhanced our 
understanding on nesfatin-1 biology, several aspects of nesfatin-1 still remain poorly understood. 
This necessitates future research on NUCB2 and nesfatin-1 using multiple model organisms. 
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Figure 1.2 Nesfatin-1 is an Emerging Multifunctional Protein 
Figure 1.2. A diagram listing the biological actions of nesfatin-1 in Teleosts (Yellow), Rodents 
(Orange), and Humans (Green) are listed separately. Overlapping regions of circles show 
functions or features that are common in one or more groups 
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Regulation of Energy Balance During Growth 
Growing rat pups undergo major transitions in food intake. Fetal growth is mainly 
dependent on mother’s nutrition. A decrease in the size of the neonatal pups is evident from 
mothers who are fed decreased amount of food compared to mothers fed ad libitum (Ferr´e et al., 
1986, Ferr´e et al., 1977, Lorenz et al., 1982). Fetuses receive glucose, lactate and amino acids 
through the placenta, but at birth, the main source of energy intake comes from mother’s milk 
(Ferr´e et al., 1986, Ferr´e et al., 1977, Lorenz et al., 1982). It has been observed that anatomical 
variation in peptide levels exists during pregnancy and in fetuses, and peptide levels can be 
modified due to changes in nutrition which could result in morphological and metabolic changes 
(Ferr´e et al., 1986, Ferr´e et al., 1977, Lorenz et al., 1982). Rat pups at post-natal day 1 regulate 
their milk intake depending on how much deprived they are of energy (Ferr´e et al., 1986, Ferr´e 
et al., 1977, Lorenz et al., 1982). In suckling rats, the regulation of milk intake is based on the 
distension by gastrointestinal fill. This response is controlled by the vagus nerve activity rather 
than by the hypothalamus at early stages of development (Lorenz et al., 1982). Energy regulation 
by milk intake at this early stage favours for optimizing growth and is restricted by full stomach 
to prevent over eating. Thus, in suckling pups, energy balance is regulated by short term 
regulation of milk intake rather than long term regulation (Ferr´e et al., 1986, Ferr´e et al., 1977, 
Lorenz et al., 1982). A few weeks later, when the pups begin to wean, they begin to make a 
steady conversion to high-carbohydrate, low-fat adult diet where their main energy source is 
mediated by feeding and drinking (Ferr´e et al., 1986, Ferr´e et al., 1977, Lorenz et al., 1982). 
Energy balance is modulated during development by changes in mRNA expression and protein 
levels of many orexigenic and anorexigenic peptides localized in both central and peripheral 
tissues (Stoka, 1999). An important orexigenic hormone, involved in appetite regulation during 
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development is ghrelin. Ghrelin and nesfatin-1 share several commonalities in their expression 
and processing, but have opposing physiological actions. The second focus of this chapter is to 
discuss the biological importance of ghrelin and its processing enzyme, GOAT, and to compare 
ghrelin and nesfatin-1, two predominant metabolic regulators in animals. 
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1.3 Ghrelin 
Synthetic growth hormone secretagogues (GHS) with potent growth hormone (GH)-
secreting properties were developed in 1970 (Bowers. 2001). These GHS bind to the GH 
secretagogue receptor (GHS-R) that was cloned in 1996 (Howard et al., 1996). This receptor is 
known to be expressed in both peripheral and central organs and is highly conserved from teleost 
fish to humans (Howard et al., 1996).  In 1999, a 28 amino acid orexigenic peptide known as 
ghrelin was discovered in gastric extracts, which was the first natural ligand of the GHS-R 
(Kojima et al., 1999). The major active product of the ghrelin gene is ghrelin (amino acids 24 o 
51) derived from posttranslational processing of preproghrelin (117 amino acids) by prohormone 
convertase (PC) 1/3. A 23 amino acid peptide named obestatin (amino acid 76 to 98) is also 
derived from preproghrelin, but in contrast to ghrelin, obestatin is proposed to have anorexigenic 
properties (Zhu et al., 2006). Ghrelin is secreted into the circulation as both acylated (‘active’) 
and des-acylated ghrelin. Figure 1.3 provides an overview of cellular events leading to the 
synthesis and secretion of ghrelin.  
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Figure 1.3 An Overview of Ghrelin Synthesis and Secretion 
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Figure 1.3.  Schematic Illustration of the Post-Translational Processing of Ghrelin Gene. 
Preproghrelin mRNA is transcribed from the ghrelin gene in the nucleus.  A precursor 
peptide is formed in the ER following the translation of preproghrelin mRNA which 
consists of a signal peptide, mature ghrelin and a C-terminal peptide. After the cleavage of 
the signal sequence by signal peptide peptidase, pro-ghrelin is produced either as acylated 
proghrelin or unacylated proghrelin. Acylated proghrelin is produced when ghrelin O-acyl 
transferase (GOAT; ) in the ER translocates octanoyl-CoA ( ) to acylate pro-ghrelin before it 
reaches the Golgi where prohormone convertases 1/3 (PC 1/3; ) post-translationally cleave 
acylated or unacylated pro-ghrelin to form mature ghrelin forms. Acylated ( ), unacylated (
), and other shorter forms of ghrelin ( ) are packaged into vesicles from the Golgi and 
released into blood circulation. 
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Both forms of ghrelin, des-acyl ghrelin and acylated ghrelin exist in the stomach in 
significant amounts. In circulation, des-acyl ghrelin is present in greater amounts than acylated 
ghrelin (Kitamura et al., 1998). Thus far, there have been no studies that have shown that des-
acyl ghrelin possess any endocrine function (Baldanzi et al., 2002). Ghrelin in the plasma binds 
to high-density lipoprotein (HDLs) that consists of amino acids that are either esterase, 
paraoxonase and clusterin (Beaumont et al., 2003). The acylation of a hydroxyl group of one of 
its serine residues (Ser 3) by n-octanoic acid is a unique characteristic to ghrelin, which is 
necessary for the binding of ghrelin to GHS-R (Kojima et al., 1999). The enzyme that facilitates 
this modification is ghrelin-O-acyl transferase (GOAT) (Yang et al., 2008, Gutierrez et al., 
2008). A review on GOAT will be provided at the latter half of this chapter. The amino acid 
sequence of ghrelin in mammals is highly conserved, especially the 10 amino acids in the NH2 
termini are identical. In non-mammals, ghrelin has also been identified in amphibians, birds and 
fishes. The amino acid sequence of ghrelin in fish varies in their length and their acyl 
modification, thus existing in variant forms.   
1.3.1 Ghrelin mRNA and Protein Expression in Tissues 
In the brain, ghrelin is found in the hypothalamic arcuate nucleus, where other appetite 
regulatory peptides are found (Kojima et al., 1999, Lu et al., 2002).   Ghrelin is expressed in very 
low amount in the brain (Hosoda et al., 2002, Kojima et al., 1999). Ghrelin is also found in the 
pituitary gland, where is it found to influence the release of growth hormone (Korbonit et al., 
2001a, Korbonit et al., 2001b). At birth, ghrelin expression levels are high and gradually decline 
with puberty (Korbonit et al., 2001a, Korbonit et al., 2001b).  
Ghrelin is found to be expressed predominantly in the stomach in all vertebrate species 
(Ariyasu et al., 2001).  Immunohistochemical analysis and in-situ hybridization indicates that 
ghrelin containing cells are endocrine cells (Date et al., 2000, Rindi et al., 2002). Ghrelin is 
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primarily secreted in the X/A cells of the oxyntic glands (Solcia et al., 1975) expressed 
abundantly in the mucosal layer of the fundus of the stomach (Kojima et al., 1999).  The X/A-
like cells are identified to be round and compact, as electron dense granules filled with ghrelin 
(Date et al., 2000). They account for 20% of the endocrine cell population in the oxyntic glands. 
Also, sexual dimorphism is observed in the expression of ghrelin gene and ghrelin cell 
differentiation in the stomach (Sakata et al., 2002). The concentration of ghrelin is age and 
gender dependent.  In the fetal stomach and at birth, ghrelin concentration is low and gradually 
increases until 5 weeks of age (Hayashida et al., 2002). Ghrelin-immunoreactive cells are also 
present in the duodenum, jejunum, ileum and colon (Sakata et al., 2002). The concentration of 
ghrelin decreases gradually from the duodenum to the colon (Date et al., 2000). In addition, 
ghrelin is also found in the pancreas. Ghrelin in identified in a new cell type identified as the 
epsilon (Ɛ) cell (Wierup et al., 2004).  Ghrelin-RIA and HPLC has determined that both ghrelin 
and des-acyl ghrelin exist in the rat pancreas (Date et al., 2002). Ghrelin expressing cells in the 
pancreas are numerous from mid-gestation to early postnatal periods, comprising 10% of all 
endocrine cells. It gradually decreases after birth. Total ghrelin concentration and ghrelin mRNA 
are 6 to 7 fold higher in the fetal pancreas than in the fetal stomach. Therefore the onset of 
pancreatic ghrelin precedes gastric ghrelin. On the other hand, gastric ghrelin is low at prenatal 
periods and increases after birth (Hayashida et al., 2002). Pancreatic ghrelin is moreover not 
affected by fasting (Kishimoto et al., 2003). Nkx2.2 is an important protein required for the 
differentiation of islet β and α cells, and a study has identified that the mice lacking Nkx2.2 have 
all their β-cells replaced by ghrelin producing cells (Prado et al., 2004). Ghrelin is also expressed 
in the kidney in the glomerulli (Gnanapavan et al., 2002, Mori et al., 2000). In addition, ghrelin-
immunoreactive cells are detected in the cytotrophoblast cells in the first-trimester of human 
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placenta (Gualillo et al., 2001). Ghrelin-immunoreactive cells have also been identified in the 
interstitial Leydig cells and in Sertoli cells (Barreiro et al., 2002, Tena-Sempere et al., 2002).   
Ghrelin is also expressed in cell lines, some of which that include, human thyroid 
medullary carcinoma cell line TT (Kanamoto et al., 2001), kidney-derived cell line NRK-49F 
(Mori et al., 2000), gastric carcinoid ECC10 cells (Kishimoto et al., 2003, and the cardiomyocyte 
cell line HL-1 (Iglesias et al., 2004). A recent discovery identified the mouse ghrelinoma 3-1 
(MGN3-1) cells from a gastric ghrelin-producing cell tumor derived from ghrelin-promoter 
Simian virus 40-T-antigen transgenic mice. These cells produce ghrelin that is 5000 times higher 
than that observed in TT cells. These cells as well produce GOAT and PC 1/3 that are required 
for the acyl modification and maturation of ghrelin. The newly established MGN3-1 is currently 
a useful tool for in vitro study of ghrelin production and secretion (Iwakura et al., 2010). 
1.3.2 Biological Actions of Ghrelin 
Ghrelin plays a major role in hormone secretion. Ghrelin stimulates the secretion of GH 
both in vitro and in vivo in a dose-dependent manner (Arvat et al., 2000, Arvat et al., 2001, Date 
et al., 2002, Kojima et al., 1999, Peino et al., 2000, Takaya et al., 2000). Ghrelin in humans 
stimulates increases in ACTH, prolactin and cortisol (Arvat et al., 2000, Takaya et al., 2000).  
Ghrelin is a potent appetite stimulatory peptide. The levels of ghrelin in circulation increase prior 
to meal and decrease post meal, which suggest its potential role in meal initiation. Ghrelin 
stimulates appetite by binding to GHS-R, which activates neuropeptide Y/agouti-related protein 
(NPY), which are potent orexigenic agents in the arcuate nucleus of the hypothalamus (ARH) 
(Chen et al., 2004). Rats have increased food intake when ghrelin is injected into the cerebral 
ventricles (Kamegai et al., 2001, Nakazato et al., 2001, Shintani et al., 2001, Tschop et al., 2000, 
Wren et al., 2000a). Intracerebroventricular, intravenous and subcutaneous injections of ghrelin 
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have been shown to increase food intake (Nakazato et al., 2001, Tschop et al., 2000, Wren et al., 
2000b). 
In addition, ghrelin stimulates adipogenesis to promote a positive energy balance by 
mediating GHS-R-independent pathways (Tschop et al., 2000). This effect is independent of 
food intake (Tschop et al., 2000). Also, studies have found that ghrelin gene expression in the 
stomach is high when fasting and attenuated when leptin and interleukin (IL)-1β is administered 
(Asakawa 2001, Kim et al., 2003, Toshinai et al., 2001). Study suggests that ghrelin produces a 
positive energy balance by decreasing energy expenditure and promoting food intake by 
blocking IL-1β-induced anorexia. Studies have identified that ghrelin is further involved in 
gastric acid secretion (Tschop et al., 2000), gut motility (Trosello et al., 2003), insulin and 
gastrin secretion (Prado et al., 2004) and the cardiovascular system (Nagaya et al., 2001).  
Furthermore, a study conducted  on neonates treated with ghrelin during the first 2 weeks after 
birth, have shown increased eye and vaginal opening than the saline treated group, which 
signifies its additional role in growth (Torsello et al., 2003). Ghrelin influences insulin secretion, 
but there is much controversy as some studies have shown that ghrelin inhibits insulin secretion 
while others show that it stimulates insulin secretion (Adeghate et al., 2002, Broglio et al., 2001, 
Date et al., 2002, Lee et al., 2002, Reimer et al., 2003). Ghrelin increases insulin secretion from 
islet cells in high glucose compared to low glucose medium (Date et al., 2002). In rat hepatoma 
cell line, H4-II-E cells, ghrelin inhibited the effect of insulin on PEPCK mRNA levels, 
suggesting that it may be involved in the regulation of gluconeogenesis in vivo.  
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Ghrelin Function is Dependent on GOAT 
The unique structure of ghrelin, its expression in multiple tissues and its biological 
functions is groundbreaking in the field of endocrinology. Among all bioactive peptides in 
literature, ghrelin by far is the only peptide that is modified by a fatty acid that requires an n-
octanoyl modification that is essential for it for function (Yang et al., 2008, Gutierrez et al., 
2008). Addition of this acyl group is critical for the growth hormone releasing activity and 
several other actions of ghrelin described above. However, the process of acylation, as well as 
the possible enzyme(s) behind this process remained unsolved. Meanwhile, in the unrelated area 
of enzyme research, several new ideas were forming. Specifically, Hofmann (2000), using novel 
combinations of bioinformatics tools, identified a family of O-acyl transferases that catalyses the 
O-acylation reaction. These findings were rooted in genetic studies performed earlier on 
Drosophilia, based on a gene called porcupine (Kadowaki et al., 1996). Porcupine has conserved 
regions that is also found in many membrane bound hydrophobic enzymes that are involved in 
translocating long chain fatty acids to membrane bound hydroxyl receptors. These enzymes were 
called membrane-bound O-acyl transferases (MBOATs) (Kadowaki et al., 1996). This advance 
in the MBOAT research eventually led to the discovery of what we know now as the Ghrelin O-
Acyl Transferase (GOAT) 
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1.4 GOAT 
GOAT was identified independently by two research groups, and was reported to the 
scientific community in two elegant articles (Yang et al., 2008, Gutierrez et al., 2008) published 
months apart in 2008. In the article that came first in the public domain, Yang et al., (2008) 
determined that the mouse genome encodes for 16 membrane bound MBOAT protein sequences 
produced by 11 genes. Later studies on cultured endocrine cells lines co-transfected with 
preproghrelin sequence and MBOATs, revealed that one of these MBOATs catalyzed the 
octanoylation of ghrelin. This MBOAT facilitating ghrelin acylation was then named GOAT 
(Yang et al., 2008). There were 11 catalytic regions that are highly conserved in all 16 MBOAT 
sequences in the mouse genome. The conserved regions contain the putative asparagine and 
histidine residues that are thought to take part in the catalytic reactions (Yang et al., 2008). A 
series of transfection experiments demonstrated that octanylation of ghrelin was facilitated by 
GOAT in three different murine endocrine cell lines. When mouse pituitary AtT-20 cells, rat 
insulinoma INS-1 cells, and mouse insulinoma MIN-6 cells were co-transfected with 
preproghrelin and GOAT, acylated ghrelin was produced. Mutation of the serine at position 3 to 
alanine prevented the acyl modification of ghrelin by GOAT, indicating that the presence of a 
third serine is essential for GOAT-dependent octanylation of ghrelin (Yang et al., 2008). Overall, 
these results by Yang and colleagues (2008) provide the first reported experimental evidence for 
GOAT. Meanwhile, the second group led by Gutierrez et al. (2008) studied ghrelin octanoylation 
in vitro using human medullary thyroid carcinoma (TT) cells to identify which member of the 
MBOAT family is involved in ghrelin acylation. Less than 10% of ghrelin protein secreted by 
the TT cells were acylated, leading them to think that there is a low expression of the acylating 
machinery in TT cells (Gutierrez et al., 2008). Silencing the GOAT gene in the TT cells using 
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several GOAT specific siRNAs resulted in an inhibition of ghrelin acylation. Gene silencing of 
other MBOAT members present in the TT cells did not affect ghrelin octanoylation, implicating 
solely GOAT in the acylation of ghrelin. In addition, HEK-293 cells that express neither ghrelin 
nor GOAT, when co-transfected with preproghrelin and GOAT, started secreting octanoylated 
ghrelin (Gutierrez et al., 2008). Further experiments conclusively showed that ghrelin 
octanoylation was only achieved with GOAT, although these cells were co-expressed with other 
members of the MBOAT family, including MBOAT1, MBOAT2, MBOAT3, MBOAT5, human-
BB1, porcupine, and FKSG89. The replacement of the conserved histidine residue in GOAT to 
alanine (H338A) inhibited its activity, demonstrating further that GOAT is a member of the 
MBOAT protein family (Gutierrez et al., 2008). Also, HEK-293 cell medium treated with a 
variety of substrate lipids, including tetradecanoic acid caused acylation of ghrelin. This suggests 
that GOAT could use a selection of fatty acids in addition to octanoic and decanoic acid to 
acylate ghrelin (Gutierrez et al., 2008).  
1.4.1 GOAT mRNA and Protein Expression in Tissues 
Yang et al. found that the highest levels of GOAT mRNA expression were limited to the 
stomach and intestine followed by the testis of mice (Gonzalez et al., 2008). In rats, GOAT 
mRNA expression is also identified in the hypothalamus, stomach, intestine, ovary, serum, 
placenta, muscle, heart, and adrenal glands (Gonzalez et al., 2008). Gutierrez et al., (2008) 
demonstrated that in humans GOAT transcript levels are most abundant in the stomach and 
pancreas. From these results, it is highly evident that the stomach is the main tissue for acyl 
ghrelin production and changes in the secretion of acylated ghrelin can modulate changes in 
metabolism of many species (Gutierrez et al., 2008). GOAT immunopositive ghrelin cells found 
in mice (95%) are higher in comparison to rats (56%) in the stomach (Stengel et al., 2010). 
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GOAT mRNA and protein are present in the whole pancreas, isolated islets and INS-1 cells. 
GOAT immunopositive cells are mainly localized in the periphery of rat islets (An et al., 2010). 
In diet-induced obese (DIO) and ob/ob mice, it was found that the GOAT mRNA levels were 
decreased in the pituitary in comparison to the hypothalamus. Although GOAT mRNA 
expression increased in the pituitary after a 24 hour fast, it increased in the hypothalamus at 48 
hours of fasting. GOAT is also expressed in the hypothalamus and pituitary of mice (Gahete et 
al., 2010). Overall, GOAT appears to be predominantly expressed in the gut, brain and the 
pancreas, three tissues that play major roles in feeding and energy homeostasis.   
 GOAT expression is modulated by nutrition. For instance, mice in a state of negative 
energy balance, or fasted for 24 or 48 hours have shown increased GOAT expression. While, in a 
positive energy balance state, GOAT expression decreases (Gahete et al., 2010, Xu et al., 2009). 
However, in another study performed by Gonzalez et al., (2008) there was no change in GOAT 
mRNA expression after 48 hours of fasting in rats. Meanwhile, they found that chronic 
malnutrition achieved by 70% restriction in food intake for 21 days led to an increase in GOAT 
expression in the gastric mucosa (Gonzalez et al., 2008). This is contradictory to another study 
where 35% of dietary food restriction for 5 months significantly reduced the levels of GOAT 
expression in the stomach (Reimer et al., 2010). Furthermore, a study by Kirchner et al. (2009) 
found that when mice are fed ad libitum, expression of GOAT was evidently high but decreased 
after 12, 24, 36, and 48 hours of fasting. While variations exist between tissues, species and 
strains, it is important to learn that metabolic status influences the expression of GOAT. These 
data suggest that GOAT is possibly linked to metabolic regulation.  
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1.4.2 Biological Actions of GOAT 
GOAT is the only known enzyme that acylates ghrelin. However, it is possible that 
GOAT might have other effects on homeostasis, especially by acting on other hormones or 
physiological processes. In line with this possibility, a very recent study by Kang and colleagues 
(Bando et al., 2012) showed that GOAT has a crucial role in the regulation of bile acid 
reabsorption. GOAT null mice exhibited an approximately 2.5 fold increase in secondary bile 
acids. GOAT null mice have an increase in the expression of ileal sodium dependant bile acid 
transporter mRNA and protein in both the biliary tract and the gastrointestinal (GI) tract. A 
similar ~10 fold increase in the solute carrier family 5 (Slc5a12), a sodium/glucose co-
transporter was also detected in the small intestine and bile duct. This study provides the first 
glimpse of GOAT effects unrelated to ghrelin (Bando et al., 2012). More studies are essential to 
identify the physiology of GOAT and complete functional implications of GOAT absence. 
As GOAT protein is highly similar across many vertebrates, the function of GOAT is 
conserved across species (Gutierrez et al., 2008). HEK-293 cells transfected with rat, mouse or 
zebrafish GOAT resulted in successful octanoylation of human ghrelin, demonstrating that the 
function of GOAT is highly conserved across vertebrates (Gutierrez et al., 2008). Further studies 
on GOAT gene knockout mice, confirmed that GOAT is the critical lipid acyl transferase for 
acylating ghrelin as there was no detectable levels of octanoylated ghrelin in the GOAT 
knockout mice compared to wild-type controls (Gutierrez et al., 2008). GOAT knockout mice 
produced large amounts of des-acyl ghrelin only, and were unable to produce acyl ghrelin. 
Collectively, these results from Gutierrez and colleagues (Gutierrez et al., 2008) confirmed Yang 
et al.’s (2008) findings and strengthened the notion that GOAT is the enzyme responsible for 
ghrelin acylation.  
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 As GOAT is co-expressed with ghrelin in the pancreas, GOAT has been implicated in the 
regulation of insulin secretion and glucose metabolism. GOAT knockout mice fasted for 16 
hours have increased insulin secretion and improved glucose tolerance (Zhao et al., 2010). In 
addition, GOAT knock-out mice provided with a 60% caloric restriction diet develop severe 
hypoglycaemia, with 2% reduction in body fat compared to wild type mice and were morbid 
after 7 days (Zhao et al., 2010). When these mice were infused with ghrelin or GH, their blood 
glucose reached normal levels and prevented death. These studies suggest that caloric deficiency 
can modulate the expression of ghrelin and GH levels in the absence of GOAT and thus 
implicate its role in glucose metabolism (Zhao et al., 2010). Recently, GOAT has been 
associated with anorexia nervosa as a result of genetic variations found in the GOAT gene. 
 Ghrelin has been actively pursued as a potential anti-obesity target. Discovery of GOAT 
led to a new line of translational research aimed to develop GOAT inhibitors. The idea behind 
this approach is to inhibit GOAT, thereby inhibiting synthesis of active ghrelin, which is 
involved in stimulating a positive energy balance and inhibiting insulin secretion. Thus far, two 
effective GOAT inhibitors have been validated. The first one developed by Yang and colleagues 
(Soriano-Guillen et al., 2004) is a potent inhibitor of GOAT activity in vitro. The first and rather 
extensive in vivo characterization of a different type of GOAT inhibitor named GO-CoA-Tat was 
reported by Barnett and colleagues (Yang et al., 2008). In vivo administration of GO-CoA-Tat 
resulted in a significant reduction in body weight, an increase in glucose stimulated insulin 
secretion (GSIS). This effect is mediated by inhibiting UCP2, which has negative effects on 
GSIS. It was also found that islet GOAT mRNA expression is inhibited by insulin, and that the 
insulin effects on GOAT are mediated via the PI3 kinase/AkT pathway and by inhibiting the 
GOAT promoter activity (Barnett et al., 2010). These results clearly indicate an important role 
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for GOAT on insulin synthesis and secretion from pancreatic islets. Collectively, the data 
obtained from GOAT null mice and studies using GOAT inhibitors clearly indicate a role for 
GOAT in the regulation of energy balance. These metabolic effects of GOAT appear to be 
mediated mainly via its modulatory roles on ghrelin. At least one study suggests that the 
intraislet ghrelin/GOAT is not responsible for modulating insulin secretion. Bando et al., (2012) 
developed a new mouse strain that has intraislet over expression of both ghrelin and GOAT 
under the rat insulin promoter. These mice have normal portal vein ghrelin levels, glucose 
homeostasis, insulin levels and islet morphology. A suggested possibility is that the islet beta 
cells are unable to make acylated ghrelin due to the absence of critical cellular components that 
are present in the gastric ghrelin cells. Further studies are required to determine the tissue 
specific presence and function of GOAT. 
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1.5 NUCB2/Nesfatin-1 - Ghrelin Relationship  
NUCB2/nesfatin-1 and ghrelin have been found to be co-expressed in the X/A or ghrelin 
cells of the stomach (Stengal et al., 2009). However, nesfatin-1 and ghrelin are present in 
different vesicles of the same cell suggest differential roles in feeding regulation (Stengel et al., 
2012b).   NUCB2 is processed by PC 1/3 and PC 2. Previous studies have determined that the 
same enzymes also process proghrelin and GOAT. Being processed by the same enzymes and 
localized in the same cell but different vesicles raises the possibility of opposing actions for these 
peptides. Nesfatin-1, an anorexigen, decreases food intake and body weight gain, while ghrelin, 
an orexigen, increases food intake and body weight gain (Stengel et al., 2012a, Stengel et al., 
2013). In non-mammals, NUCB2/nesfatin-1 and ghrelin immunoreactivity was observed in the 
enteroendocrine cells of the goldfish anterior intestine (Kerbel et al., 2012). Co-localization of 
both these peptides was observed in the posterior nucleus lateralis tuberis of the goldfish 
hypothalamus, a region involved in regulating food intake.  I.c.v. administration of nesfatin-1 
decreased food intake and mRNAs encoding preproghrelin, ghrelin receptor and NUCB2 in the 
forebrain of fed fish (Kerbel et al., 2012). In contrast, i.c.v. injection of ghrelin stimulated food 
intake and suppressed NUCB2 and preproghrelin mRNAs, Ghrelin had no effect on ghrelin 
receptor mRNA expression in the forebrain (Kerbel et al., 2012). The Unniappan lab performed 
an additional study in Fischer 344 Rats to determine whether such relationships between 
nesfatin-1 and ghrelin exist in mammals. It was found that nesfatin-1 indeed colocalizes with 
ghrelin, GOAT and GHS-R1a in gastric endocrine cells. Ghrelin infusion significantly increased 
dark phase cumulative food intake and duration of feeding bouts, but decreased light phase total 
activity. Ghrelin infusion tissue-specifically decreased NUCB2 mRNA in the liver, but did not 
affect NUCB2 and preproGOAT mRNA in the stomach and serum NUCB2 levels. Nesfatin-1 
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infusion in postprandial conditions significantly decreased preproGOAT and preproghrelin 
mRNA expression levels. Ghrelin and nesfatin-1 co-administration cancelled out all metabolic 
effects. These results (manuscript under preparation) indicate opposing metabolic effects for 
ghrelin and nesfatin-1.     
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1.6 Rationale 
The neuroendocrine regulation of energy homeostasis in mammals is the core focus of 
this thesis research. Hormones play an integral role in energy homeostasis. Since its discovery in 
2006, there are just over 250 articles on nesfatin-1 in PubMed. Ongoing research on 
NUCB2/nesfatin-1 has identified it as multifunctional protein, but many of the biological actions 
found are mainly based on the studies where exogenous nesfatin-1 was administered. The goal of 
the studies outlined in this thesis is to gain a deeper understanding of nesfatin-1. They were 
focused on addressing the void in our knowledge base on nesfatin-1. 
NUCB2 is co-expressed with insulin and is an insulinotropic peptide (Foo et al., 2010, 
Gonzalez et al., 2009, Gonzalez et al., 2011, Gonzalez et al., 2012a). PCs, the same enzymes that 
process proinsulin and proghrelin, cleave NUCB2 to produce nesfatin-1 (Stengel et al., 2009, 
Stengel et al., 2012a, Stengel et al., 2013). How are NUCB2/nesfatin-1, ghrelin and their 
processing enzymes expressed during pancreatic development? NUCB2/nesfatin-1 is widely 
distributed in several peripheral tissues (Zhang et al., 2010). Hormone secretion from endocrine 
cells of these tissues can be influenced by nutrient intake (Dauncey et al., 2001). Nesfatin-1 
indeed is a meal responsive hormone (Stengel et al., 2009a, Gonzalez et al., 2009, Gonzalez et 
al., 2011), and circulating nesfatin-1 increases after the ingestion of a meal (Stengel et al., 2009a, 
Gonzalez et al., 2009, Gonzalez et al., 2011). Which nutrients regulate nesfatin-1 synthesis and 
secretion? If nutrients do regulate nesfatin-1, are such effects tissue-specific? While nesfatin-1 is 
a multifunctional peptide, whether NUCB2/nesfatin-1 is critical for energy homeostasis remain 
unclear. Disruption of the NUCB2 gene resulting in a lack of the bioactive protein will allow us 
to identify specific functions of this gene and its encoded proteins. This thesis aims to address 
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the above questions. Outcome of this thesis is expected to better our understanding of nesfatin-1, 
an important, naturally occurring bioactive orphan ligand. 
1.7 Hypothesis and Specific Objectives 
The central hypothesis of this thesis research is that the tissue specific expression of 
NUCB2/nesfatin-1 is regulated developmentally, and by nutrients, and that the endogenous 
NUCB2/nesfatin-1 is critical for the maintenance of energy homeostasis. 
Specific Objective 1: To investigate the ontogenic expression of NUCB2 mRNA and 
NUCB2/nesfatin-1 immunoreactivity in the rat stomach, duodenum and pancreas; to compare the 
developmental co-localization of insulin and NUCB2/nesfatin-1 in the pancreas; and to 
determine the circulating levels of NUCB2/nesfatin-1 during various developmental stages of 
Sprague Dawley rats. 
Specific Objective 2: To elucidate the developmental expression of GOAT mRNA and 
colocalization of ghrelin, GOAT, NUCB2/nesfatin-1, PC 1/3 and PC 2 immunoreactivity in the 
pancreas during fetal and postnatal periods in Sprague Dawley rats. 
Specific Objective 3: To determine how different nutrients modulate NUCB2/nesfatin-1 and 
ghrelin secretion in vitro in cultured stomach ghrelinoma (MGN3-1) cells from mice and in vivo 
in male mice. 
Specific Objective 4: To learn whether the genetic loss of nesfatin-1 alters whole body energy 
homeostasis, islet morphology, islet hormone release, and glucose homeostasis in NUCB2 
knockout (NKO) mice. 
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Transition 
The following chapter focuses on my first set of objectives: To investigate the ontogenic 
expression of NUCB2 mRNA and NUCB2/nesfatin-1 immunoreactivity in the stomach, 
duodenum and pancreas, to compare the developmental co-localization of insulin and 
NUCB2/nesfatin-1 in the pancreas, and to determine the circulating levels of NUCB2/nesfatin-1 
during various developmental stages of Sprague Dawley rats. As stated earlier, NUCB2 is 
expressed in the gastrointestinal tissues and is co-expressed with insulin in islet β-cells with 
glucose-responsive insulinotropic actions. Although it has been identified as a multifunctional 
hormone, there are no reports on the developmental expression of NUCB2/nesfatin-1. We found 
that all islet β-cells colocalize NUCB2/nesfatin-1 in an age-dependent manner. In the stomach 
and duodenum, NUCB2/nesfatin-1 expression shows a tissue specific developmental expression 
in rats. Serum NUCB2/nesfatin‐1 gradually increased with growth and was highest in adults, 
suggesting an increase in its production and secretion from tissues including the gastrointestinal 
tract and pancreas. This is the first study that has focused on the tissue specific expression of 
NUCB2/nesfatin-1 in rats during development. These results collectively suggest that 
NUCB2/nesfatin-1 has important age- and tissue-specific roles in the developmental physiology 
of rats.  
 
Publication: Mohan, H., Unniappan, S. 2012. Ontogenic pattern of nucleobindin-2/nesfatin-1 
expression in the gastroenteropancreatic tissues and serum of Sprague Dawley rats. Regulatory 
Peptides, 175 (1-3), 61-9. 
 
Contributions: Haneesha Mohan conducted all in vivo studies, collected and processed the 
tissue samples for RNA extraction, conducted immunohistochemistry, protein assays, analysed 
data and wrote the first draft of the manuscript. Suraj Unniappan helped with the experimental 
design, provided the research infrastructure, edited the manuscript and funded the project to 
completion. 
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Chapter 2 
 
Ontogenic Pattern of Nucleobindin-2/Nesfatin-1 Expression in the 
Gastroenteropancreatic Tissues and Serum of Sprague Dawley Rats 
 
2.1 Introduction 
Nesfatin-1 is an eighty two amino acid anorexigenic peptide encoded in the N-terminal 
region of its precursor protein, nucleobindin 2 (NUCB2). NUCB2 is a 396 amino acid protein 
with approximately 85% amino acid sequence homology among humans, mice, and rats (Oh-I et 
al., 2006, Myres et al., 2006, Cowley et al., 2006). Prohormone convertases, PC-1/3 and PC-2, 
the same enzymes responsible for the proteolytic conversion of proinsulin to insulin (Steiner et 
al., 1992) are proposed to cleave NUCB2 to nesfatin-1 (1–82 amino acids), nesfatin-2 (85–163 
amino acids), and nesfatin-3 (166–386 amino acids) respectively (Oh-I et al., 2006). To date, the 
processed nesfatin-1 has been detected only in the cerebrospinal fluid (Oh-I et al., 2006). In rats, 
NUCB2/nesfatin-1 is expressed in many brain regions including the arcuate 
nucleus (ARC), paraventricular nucleus (PVN) and the supraoptic nucleus (SON), which are 
involved in the regulation of energy balance (Oh-I et al., 2006, Yosten et al., 2010, Brailoiu et 
al., 2007, Foo et al., 2008, Kohno et al., 2007). NUCB2 mRNA expression analysis of purified 
endocrine cells of the gastric mucosa has shown that mRNA levels at this region are higher than 
in the brain (Stengel et al., 2009b). NUCB2/nesfatin-1 immunoreactivity has also been identified 
in the middle and lower segments of the gastric mucosal glands and in the submucosal layer of 
the duodenum in rats (Zhang et al., 2009). NUCB2/nesfatin-1 is also co-localized with insulin in 
the pancreatic islet β-cells, but not in other islet cell types in rats and mice (Gonzalez et al., 
2009) and human pancreas (Foo et al., 2010). This extensive distribution of NUCB2/nesfatin-1 in 
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tissues that are involved in metabolic regulation suggests important physiological roles for this 
novel protein. 
Several studies have found that nesfatin-1 induces anorectic responses after central and 
peripheral administration in rodents (Oh-I et al., 2005, Yosten et al., 2010, Shimizu et al., 2009, 
Stengel et al., 2009a, Goebel et al., 2011, Atsuchi et al., 2010, Maejima et al., 2009). Rats 
receiving chronic intracerebroventricular (i.c.v) injection of nesfatin-1 for 10 days resulted in a 
reduction in food intake and body weight. A decrease in the weights of subcutaneous, epididymal 
and mesenteric fat tissues was also detected (Oh-I et al., 2006). Similarly, continuous 
administration of nesfatin-1 into the third ventricle of the rat brain gradually decreased body 
weight with a reduction in white adipose tissue weight (Shimizu et al., 2009). Our own studies 
on the whole-body metabolic effects revealed that peripheral infusion of nesfatin-1 reduces food 
intake, lowers the duration of feeding bouts, and increases the total number of feeding 
bouts (Gonzalez et al., 2012a). A decrease in respiratory exchange ratio (RER) was also 
observed, that coincided with an increase in energy production being met by increased fat 
oxidation (Gonzalez et al., 2012a). Together, these studies provide considerable data supporting 
the metabolic effects of nesfatin-1. 
Nesfatin-1 also regulates glucose metabolism and insulin secretion. In MIN6 cells, a 4-
fold increase in nesfatin-1 levels was observed when the cells were incubated in high glucose 
(16.7 mM) compared to low glucose (2.0 mM) (Gonzalez et al., 2011). In addition, nesfatin-1 
stimulates glucose stimulated insulin secretion from rat and mouse β-cells that were incubated in 
high glucose in a dose dependent manner (Gonzalez et al., 2011, Gonzalez et al., 2012a). In the 
pancreas of streptozotocin (STZ)-injected mice with type 1 diabetes, it was found that both 
NUCB2 and preproinsulin mRNA expression were significantly lower while there was a 
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significant increase in proglucagon mRNA expression. In contrast, nesfatin-1 and insulin 
colocalizes in β-cells in the pancreatic islets of high-fat diet (HFD)-induced obese (DIO) mice 
with Type 2 Diabetes. There was a significant increase in the density, size, and distribution of 
pancreatic islets in diet induced obese (DIO) mice (Gonzalez et al., 2012a). Intravenous injection 
of nesfatin-1 has shown to induce an antihyperglycemic effect lowering blood glucose in 
hyperglycaemic db/db mice for 6 h (Su et al., 2010). Furthermore, nesfatin-1 also stimulates 
insulin secretion in vivo in rats (Gonzalez et al., 2012a). Our studies have identified that nesfatin-
1 treatment induced insulin-stimulated glucose uptake in adipocytes, but not muscle cells, 
implicating nesfatin-1 in regulating glucose homeostasis. In human studies, glucose treated 
subjects have shown higher basal nesfatin-1 levels compared to control subjects (Li et al., 2010). 
Overall, these results provide several results in support of nesfatin-1 as an insulinotropic protein 
with modulatory effects on glucose homeostasis. 
While data available to date implicate nesfatin-1 on metabolic regulation, many aspects 
of this protein remain undetermined. One such question that still remains unanswered is whether 
and how NUCB2/nesfatin-1 is expressed in the peripheral tissues during development. From 
earlier studies on NUCB2/nesfatin-1 in the periphery, it appears that NUCB2/nesfatin-1 is 
mainly expressed in the gastrointestinal tract and pancreas. Studying the developmental 
expression of NUCB2/nesfatin-1 in the gastroenteropancreatic tissues will be beneficial for 
future functional studies. The objectives of this study were to determine the ontogenic expression 
of NUCB2 mRNA and NUCB2/nesfatin-1 immunoreactivity in the rat stomach, duodenum and 
pancreas, to compare the developmental co-localization of insulin and NUCB2/nesfatin-1 in the 
pancreas, and to determine the circulating levels of NUCB2/nesfatin-1 during various 
developmental stages. Our findings indicate that NUCB2/nesfatin-1 mRNA and protein 
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expression are tissue specific and in general increases from embryonic day 21 through postnatal 
day 27. These results suggest an age- and tissue-specific role for NUCB2/nesfatin-1in the 
developmental physiology of rats. 
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2.2 Materials and Methods 
2.2.1 Animals 
Timed pregnant Sprague Dawley rats (Charles River Laboratories, St Constant, QU, 
Canada) were housed from day 13 of pregnancy in a 12 h light:12 h dark cycle (lights off at 
7 PM and on at 7 AM), temperature and humidity controlled vivarium. Pregnant dams had ad 
libitum access to standard rat chow (60% carbohydrate, 27% protein, and 13% fat; with energy 
density = 3.43 kcal/g; LabDiets Inc., St. Louis, MO) and water. All experiments using rats 
complied with the Canadian Council of Animal Care guidelines, and the animal care protocol (# 
2010-31-R3) was reviewed and approved by the York University Animal Care Committee. 
2.2.2 Immunohistochemistry 
For immunohistochemical studies, we used 2 pregnant rats that were housed in the 
vivarium. All dissections and tissue collection were conducted at the same time of the day 
(13:00–14:00 h) to provide consistency. One pregnant rat was euthanized under deep carbon 
dioxide inhalation followed by cardiac puncture on day 21 of pregnancy. Out of 13 embryos, 
tissues (corpus region of the stomach, the duodenal region immediately after the pyloric 
sphincter, and the head region of the pancreas) from 5 embryos on gestational day 21 (embryonic 
day 21) were dissected. The second pregnant dam was allowed to deliver (n = 11 pups) and nurse 
normally. Tissues were collected as described above from neonatal pups on postnatal days 1 
(n = 3), 6 (n = 2), 13 (n = 2), 20 (n = 2) and 27 (n = 2) and fixed in 4% formaldehyde for 24 h at 
4 °C. Fixative was replaced with ethanol (three 70% ethanol), each followed by a 10 minute 
incubation at 4 °C. Tissues were then stored in 70% ethanol at 4 °C and were processed and 
sectioned at the Pathology Core Facility of the Centre for Modeling Human Disease, Toronto 
Center for Phenogenomics. Paraffin sections of 4 μm thickness were prepared for 
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immunostaining. These sections were deparaffinized with xylene (incubated twice in 100% 
xylene; 5 min, 25 °C) and rehydrated in a graded ethanol series (incubated twice in 100% 
ethanol, and once in each 95% ethanol, 70% ethanol, 50% ethanol; 2 min each, 25 °C). The 
sections were then incubated with 3% hydrogen peroxide in distilled water to block 
endogenous peroxidase activity (30 min at room temperature). The sections were then blocked 
with serum-free protein block reagent (DAKO® Corporation, California) for 10 min before 
being incubated with primary antibodies. These sections, except for the stomach (Rabbit anti-
nesfatin-1; catalog number H-003-22; 1:100 dilution; Phoenix Pharmaceuticals, California) were 
then incubated with rabbit anti-nesfatin-1 (Catalog number H-003-22; 1:500 dilution; Phoenix 
Pharmaceuticals, California) alone or co-incubated with rabbit anti-nesfatin-1, mouse 
monoclonal anti-chromogranin A (Catalog number ab 80787; 1:500 dilution; Abcam, 
Massachusetts) and guinea pig anti-insulin (Catalog number ab 7842; 1:100 dilution; Abcam, 
Massachusetts) for 24 h at room temperature. All primary and secondary antibodies were diluted 
in antibody diluent reagent (DakoCytomation®, Mississauga, Ontario). 
All slides were subsequently washed three times with 1 × PBS and incubated with goat 
anti-rabbit Texas Red® IgG (Red-Nesfatin-1; Catalog number TI-1000; 1:100 dilution; Vector 
Laboratories, California), goat polyclonal anti-mouse FITC IgG (H & L) (Green-Chromogranin 
A (CgA); Catalog number ab 6785; 1:100 dilution; Abcam, Massachusetts) and either goat anti-
guinea pig FITC IgG (Green-Insulin; Catalog number ab 6904; 1:200 dilution; Abcam, 
Massachusetts) secondary antibodies for 1 h at room temperature. The slides were washed three 
times with 1 × PBS and seven times with distilled water. Finally, the slides were mounted with 
Vectashield® medium that contain nuclear dye DAPI (Blue; Vector Laboratories, Burlingame, 
California) (Gonzalez et al., 2011). Sections were viewed under a Nikon Eclipse Ti-E inverted 
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fluorescence microscope (Nikon Canada, Mississauga, Canada). Images were captured using a 
Nikon DS-QI1MC cooled monochrome camera connected to a Dell HP Workstation computer 
and NIS elements basic research imaging software (Nikon Canada, Mississauga, 
Canada) (Gonzalez et al., 2011). Approximately 8 slides (from multiple rats) containing two 
sections each of the stomach, duodenum and pancreas from each developmental stage were 
stained using the above protocol and analyzed. Only representative images of tissues from each 
stage staining for NUCB2/nesfatin-1 alone, co-localization of NUCB2/nesfatin-1 and CgA, and 
colocalization of NUCB2/nesfatin-1 and insulin are shown in the Results section. 
The NUCB2/nesfatin-1 antibody has been tested and validated in our lab before and 
preabsorption controls did not show any immunoreactivity (Gonzalez et al., 2011, Gonzalez et 
al., 2009, Kerbel et al., 2011). The primary antibody used in this study can detect the 
unprocessed precursor (NUCB2) in addition to the nesfatin-1 fragment. Therefore, the 
immunoreactivity detected is presented as NUCB2/nesfatin-1. 
2.2.3 Real time quantitative PCR 
For real time quantitative PCR analysis, 6 rats were housed in the vivarium from day 13 
of pregnancy. Three pregnant dams were sacrificed on day 21 of pregnancy to gather tissues 
(stomach, duodenum and pancreas) from the embryos on embryonic day 21. Tissues (stomach, 
duodenum and pancreas) were collected from neonatal pups born from the remaining 3 pregnant 
dams on postnatal days 1, 6, 13, 20 and 27. Similar to immunohistochemical studies, tissue 
regions were harvested for RNA extraction. In addition, the whole pancreas including the head, 
corpus and tail was extracted for total RNA. The tissues collected above were harvested at the 
same time of the day and thus, this study was repeated thrice to ensure reproducibility in the data 
obtained. Tissues were also collected from 4 adult male SD rats (n = 4, average 
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weight = 200.35 g and approximate age: 43–46 days) to compare NUCB2 mRNA expression 
during each development stage versus adult hood. 
Total RNA was extracted from the embryonic, postnatal and adult rat stomach, 
duodenum and pancreas using the TRIzol® RNA isolation reagent (Invitrogen, Canada). RNA 
purity was validated by optical density (OD) absorption ratio (OD 260 nm/OD 280 nm) using a 
Multiskan® Spectrum spectrophotometer (Thermo, Vantaa, Finland). Only samples with an 
absorption ratio greater than 1.7 were used for cDNA synthesis. Synthesis of cDNAs was 
conducted using iScript™ cDNA synthesis kit as directed by the manufacturer (BioRad, 
Canada). The cDNAs were used as templates for reverse transcription-PCR (RT-PCR) with 
forward and reverse primers and the primer sequences are listed in Table 2.1. The qRT-PCR 
protocol used for NUCB2 was 95 °C for 3 min heat activation, followed by 43 cycles of 95 °C 
for 30 s denaturation of double stranded DNA (dsDNA), 63 °C for 30 s annealing of primers, and 
73 °C for 30 s elongation on the Chromo4™ Multicolor Real-Time PCR Detection System (Bio-
Rad, Canada). For the analysis, mRNA expression of NUCB2 was normalized using beta-
actin as a housekeeping gene. Based on previous studies conducted (Oliver et al., 2002, 
Chanoine et al., 2004, Cunha et al., 2006), we used beta-actin as an internal control to normalize 
the signal of NUCB2 mRNA. When using stomach, duodenal and pancreatic total RNA where 
mRNA quantification was very precise, the critical threshold values for beta-actin showed no 
variability. All values were reported as means ± SEM. Tukey's multiple comparison test was 
performed to compare the difference between each pair of means of different growth stages with 
appropriate adjustment for multiple testing. Data were analyzed with GraphPad Prism Version 
5.0 (GraphPad Software Inc.). The absolute levels of NUCB2 mRNA for each of the tissues 
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collected from the adult rat and at different stages of development are depicted in the results 
section. 
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Table 2.1. Primers used for quantitative real-time PCR of NUCB2 cDNA from 
embryonic and prenatal SD rat tissue 
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2.2.4 Serum NUCB2/Nesfatin-1 levels 
Enzyme-linked immunosorbent assay (ELISA) was used to measure the circulating levels 
of nesfatin-1. To investigate age-related variation in nesfatin-1 levels, serum samples were 
collected from the embryos of ad libitum rats (n = 8), neonatal pups on postnatal days 1 (n = 8), 
6 (n = 5), 13(n = 4), 20 (n = 4), 27 (n = 4) and adult rats (n = 4). Blood samples were collected 
immediately pre-dissection. In order to preserve the integrity of blood serum proteins, serum was 
immediately separated from the blood samples were withdrawn (Hanash, 2002). Therefore, to 
avoid ongoing movement of analytes as well as limit cellular metabolic activities between serum 
and blood, serum was immediately separated (Boyanton and Blick, 2002) by centrifugation 
(7000 rpm for 9 min at 4 °C) and stored at − 20 °C. Similar methodology was performed by 
studies conducted previously (Gonzalez et al., 2011, Gonzalez et al., 2012a). We did not use any 
anticoagulant such as lithium heparin and ethylenediaminetetraacetic acid (EDTA) to collect 
plasma. The blood was allowed to clot and centrifuged as mentioned above to separate pure 
serum, devoid of additives. The collected serum has the same composition of plasma, but is 
devoid of clotting factors, including fibrinogen. Serum nesfatin-1 levels were measured using the 
Nesfatin-1 (1–82) (Rat) ELISA kit (Catalog number EK-003-22, Phoenix Pharmaceuticals Inc., 
California). The limit of assay sensitivity was 1.2 ng/ml for nesfatin-1, with detectable range 
from 0.1 to 1000 ng/ml. This assay was previously validated in our lab for use in rodents and 
fish. We used a new tip between repeat samples and ensured that the tip was secure and free of 
air bubbles. For better intra-assay variation, the serum sample was aspirated and expelled back 
into the container few times prior to loading. The amount of immunoreactive material was 
determined using a non-linear regression curve-fit, which was used to quantify and compare the 
concentration of nesfatin-1 in serum samples during different growth stages versus adulthood. 
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Although this ELISA kit is able to detect both nesfatin-1 and NUCB2, many studies have used it 
despite its cross-reactivity (Foo et al., 2010, Stengel et al., 2009a, Gonzalez et al., 2011). 
Therefore results obtained from using this kit are referred to as NUCB2/nesfatin-1.  
 
2.3 Results 
2.3.1 NUCB2/nesfatin-1 IR in the rat stomach 
NUCB2/nesfatin-1 IR was detected in the gastric cells present in the oxyntic glands of the 
stomach at all stages of development. NUCB2/nesfatin-1 immunoreactive cells were rare at 
embryonic day 21 and relatively less NUCB2/nesfatin-1 immunoreactive cells were observed in 
the gastric mucosal glands at postnatal days 1 (data not shown), 6 and 13 (data not shown). The 
NUCB2/nesfatin-1 IR in the oxyntic mucosa progressively increased from postnatal days 20 
(Figures 2.1A–B), 27 (Figures 2.1B–C) to adult (Figures 2.1D–E) 
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             Figure 2.1 NUCB2/nesfatin-1 IR in the rat stomach 
Figure 2.1. NUCB2/nesfatin-1 immunohistochemical staining of the rat stomach at postnatal 
days 20 (A and B), 27 (C and D) and adult (E and F). Figures 1 displays a merged image of cells 
immunoreactive for NUCB2/nesfatin-1 (red) and DAPI (nuclei; blue). There is a gradual 
increase in the number of NUCB2/nesfatin-1 immunopositive cells detected in the oxyntic glands 
of the stomach.Immunohistochemical images display a distributive pattern of endocrine gastric 
cells staining for NUCB2/nesfatin-1 at postnatal day 20, postnatal day 27, and adult (selected 
area) final magnification, 20 ×; and higher power view of the selected area, final magnification, 
40 ×. Representative images were taken of 8 slides (16 sections) from 2 neonatal stomach tissues 
at postnatal days 20, 27, and adult. Scale bar (A, C, and E) = 50 μm and (B, D and F) = 100 μm. 
(E, embryonic day; P, postnatal).  
64 
 
2.3.2 NUCB2/nesfatin-1 IR in the rat duodenum 
NUCB2/nesfatin-1 IR was undetectable from embryonic day 21 to postnatal day 6 in the 
duodenum (data not shown). NUCB2/nesfatin-1 IR was first identified in the enteroendocrine 
cells of the duodenum beginning from postnatal days 13 to 27. NUCB2/nesfatin-1 IR was 
detected on postnatal day 13 (Figures 2.2A–B) and postnatal day 27 (Figures 2.2C–D) in the 
enteroendocrine cells present in the villi. 
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           Figure 2.2 NUCB2/nesfatin-1 IR in the rat duodenum 
 
Figure 2.2. NUCB2/nesfatin-1 immunohistochemical staining of the rat duodenum at postnatal 
days 13 (A and B) and 27 (C and D). Figures 2 displays a merged image of cells immunoreactive 
for NUCB2/nesfatin-1 (red), and DAPI (nuclei; blue). NUCB2/nesfatin-1 IR was detected in the 
enteroendocrine cells of the duodenal submucosa. Immunohistochemical images of 
enteroendocrine cells staining for NUCB2/nesfatin-1 at postnatal day 13 and postnatal day 27, 
(selected area) final magnification, 40 ×; and higher power view of the selected area, final 
magnification, 100 ×. The open arrows point at enteroendocrine cells immunoreactive for 
NUCB2/nesfatin-1 in the villi of the rat duodenum. Representative images were taken of 8 slides 
(16 sections) from 2 neonatal duodenal tissues at postnatal days 13 and 27. Scale bar (A and 
C) = 50 μm and (B and D) = 100 μm. (E, embryonic day; P, postnatal). 
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2.3.3 Co-localization of NUCB2/nesfatin-1and Chromogranin A (CgA) IR in the rat 
duodenum 
Co-localization of NUCB2/nesfatin-1 and CgA was not observed at postnatal days 13 and 
27 (data not shown), but co-expression was evident in the enteroendocrine cell present in the 
adult duodenal villi (Figures 2.3A–F). 
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              Figure 2.3 Co-localization of NUCB2/nesfatin-1and Chromogranin A (CgA) IR              
in the rat duodenum 
 
 
Figure 2.3. Co-localization of NUCB2/nesfatin-1 and chromogranin A 
(CgA) immunohistochemical staining of an adult rat duodenum. Figures 3 displays cells 
immunoreactive for NUCB2/nesfatin-1 (A, D; red), CgA (B, E; green) and the merged image of 
nesfatin-1, CgA and DAPI (C, F; yellow). NUCB2/nesfatin-1 and CgA IR was detected in the 
enteroendocrine cells of the adult duodenal submucosa. Immunohistochemical images of 
enteroendocrine cells staining for NUCB2/nesfatin-1, CgA at adult stage, (selected area) final 
magnification, 40x; and higher power view of the selected area, final magnification, 100x. The 
open arrows point at enteroendocrine cells immunoreactive for NUCB2/nesfatin-1(D), CgA(E) 
and NUCB2/nesfatin-1 co-expressed with CgA(F) in the villi of the rat duodenum. 
Representative images were taken of 4 slides (8 sections) from adult duodenal tissues. Scale bar 
(A, B and C) = 50 μm and (D, E and F) = 100 μm. 
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2.3.4 NUCB2/nesfatin-1 IR in the rat pancreas 
NUCB2/nesfatin-1 immunostaining was observed at all developmental stages in the rat 
endocrine pancreas. At embryonic day 21 (Figure 2.4A), NUCB2/nesfatin-1 immunoreactive 
islet cells were observed in the pancreatic tissue. These immunoreactive islet cells appear to be 
individual NUCB2/nesfatin-1 immunopositive endocrine cells. At postnatal day 1 (Figure 2.4B) 
and postnatal day 6 (Figure 2.4C), NUCB2/nesfatin-1 immunoreactive islet cells were identified 
in a number of regions where small clusters of islet-cell groups were observed in the pancreatic 
tissue. Clusters of endocrine cells immunopositive for NUCB2/nesfatin-1 were observed at 
postnatal day 13 (Figure 2.4D). At postnatal day 20 (Figure 2.4E), postnatal day 27 
(Figure 2.4F), and adult (Figure 2.4G), there was an increase in NUCB2/nesfatin-1 IR, which 
was more abundant than what was detected in postnatal day 13. 
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Figure 2.4 NUCB2/nesfatin-1 IR in the rat pancreas 
 
Figure 2.4. NUCB2/nesfatin-1 immunohistochemical staining of the rat pancreas at 
embryonic day 21 (A) and postnatal days 1 (B), 6 (C), 13 (D), 20 (E), 27 (F) and adult 
(G). Pancreatic islet cells immunoreactive for NUCB2/nesfatin-1 (red) and DAPI (nuclei; 
blue) are shown in A–G. Image A displays a magnified image of a NUCB2/nesfatin-1 
immunoreactive cell in the pancreatic tissue at embryonic day 21 represented by an 
(white) arrow. Representative images were taken of 8 slides (16 sections) from an adult, 3 
embryonic and 5 neonatal pancreatic tissues at embryonic day 1 and postnatal days 1, 6, 
13, 20 and 27. Scale bar = 50 μm. (E, embryonic day; P, postnatal). 
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2.3.5 Co-localization of NUCB2/nesfatin-1 and insulin IR in the rat pancreas 
Some, but not all islet cells immunopositive for insulin (Figures 2.5B, E, H) showed 
NUCB2/nesfatin-1 IR (Figures 2.5A, D, G), co-localizing both proteins on embryonic day 21 
(Figure 2.5C), postnatal days 1 (Figure 2.5F) and 6 (Figure 2.5I). But all NUCB2/nesfatin-1 
immunopositive islet cells were immunoreactive for insulin (Figures 2.5C, F, I). During 
development, on postnatal days 13, 20 and 27 all islet cells immunoreactive for insulin 
(Figures 2.6B, E, H) were immunopositive for NUCB2/nesfatin-1 (Figures 2.6A, D, G), 
showing co-localization of both proteins (Figures 2.6C, F, I). 
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Figure 2.5 Co-localization of NUCB2/nesfatin-1 and insulin IR in the rat pancreas 
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Figure 2.5. Co-localization of NUCB2/nesfatin-1 and insulin immunohistochemical staining of 
the rat pancreas at embryonic day 21 (A, B, C) and postnatal days 1 (D, E, F) and 6 (G, H, I). 
Islet cells immunoreactive for NUCB2/nesfatin-1 (A, D, G; red), insulin (B, E, H; green), and the 
merged image of nesfatin-1, insulin and DAPI (C, F, I; yellow). Not all insulin immunopositive 
islet cells are positive for NUCB2/nesfatin-1 but all NUCB2/nesfatin-1 immunopositive cells are 
immunoreactive for insulin. Representative images were taken of 8 slides (16 sections) from 3 
embryonic and 2 neonatal pancreatic tissues at embryonic day 1 and postnatal days 1and 6. Scale 
bar = 50 μm. (E, embryonic day; P, postnatal). 
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Figure 2.6 Co-localization of NUCB2/nesfatin-1 and insulin IR in the rat pancreas 
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Figure 2.6. Co-localization of NUCB2/nesfatin-1 and insulin immunohistochemical staining of 
the rat pancreas at postnatal days 13 (A, B, C), 20 (D, E, F) and 27 (G, H, I). Islet cells 
immunoreactive for NUCB2/nesfatin-1 (A, D, G; red), insulin (B, E, H; green), and the merged 
image of NUCB2/nesfatin-1, insulin and DAPI (C, F, I; yellow). A gradual increase in islet cells 
immunopositive for insulin are also immunoreactive for NUCB2/nesfatin-1 at postnatal days 13, 
20 and 27 compared to embryonic day 1 and postnatal days 1 and 6 (Figures 5). 
Immunohistochemical images of the islet cells staining for NUCB2/nesfatin-1 at postnatal day 13 
and postnatal day 20 are at final magnification, 40 ×; and lower final magnification, 20 ×, at 
postnatal day 27. All NUCB2/nesfatin-1 immunopositive cells are immunoreactive for insulin. 
Representative images were taken of 8 slides (16 sections) from 3 neonatal pancreatic tissues at 
postnatal days 13, 20 and 27. Scale bar = 50 μm. (E, embryonic day; P, postnatal). 
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2.3.6 Developmental expression of NUCB2 mRNA in the rat gastroenteropancreatic 
tissues 
In the rat stomach, no significant differences were found in the expression of NUCB2 
mRNA at various stages of development (Figure 2.7A). In contrast, NUCB2 mRNA expression 
in the rat duodenum on postnatal day 27 was higher than the NUCB2 mRNA expression in the 
adult duodenum (Figure 2.7B). No significant difference in NUCB2 mRNA expression was 
detected in the pancreas during developmental stages tested (Figure 2.7C). 
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Figure 2.7 Developmental expression of NUCB2 mRNA in the rat                  
gastroenteropancreatic tissues 
 
Figure 2.7. Analysis of NUCB2 mRNA levels at different development stages in the stomach 
(A; E21 (n = 7), P1 (n = 7), P6 (n = 6), P13 (n = 7), P20 (n = 6), P27 (n = 6) and Adult (n = 4)), 
duodenum (B; E21 (n = 5), P1 (n = 7), P6 (n = 7), P13 (n = 7), P20 (n = 6), P27 (n = 6) and Adult 
(n = 4)) and the pancreas (C; E21 (n = 5), P1 (n = 7), P6 (n = 7), P13 (n = 7), and P20 (n = 3)) of 
Sprague Dawley (SD) Rats tissues. (E, embryonic day; P, postnatal). (*): The mRNA levels of 
NUCB2 determined by real-time PCR showed that NUCB2 mRNA expression in the duodenum 
at postnatal day 27 was higher than the NUCB2 mRNA expression in the adult (p < 0.05, 
ANOVA followed by Tukey's Multiple Comparison Test). 
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2.3.7 Serum NUCB2/nesfatin-1 levels during development 
Serum NUCB2/nesfatin-1 levels on embryonic day 21 and postnatal day 1 were 
significantly lower than adults and levels found in postnatal days 6, 13, 20 and 27. No significant 
differences were found in serum NUCB2/nesfatin-1 levels in adults and postnatal days 6, 13, 20 
and 27 (Figure 2.8). 
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       Figure 2.8 Serum NUCB2/nesfatin-1 levels during development 
 
Figure 2.8. Circulating levels of serum NUCB2/nesfatin-1 in Sprague Dawley (SD) rats during 
various development stages (E21 (n = 8), P1 (n = 8), P6 (n = 5), P13 (n = 4), P20 (n = 4), P27 
(n = 4) and Adult (n = 4)). (E, embryonic day; P, postnatal). (*): The serum NUCB2/nesfatin-1 
levels pre-birth at embryonic day 21 and postnatal day 1 are lower than postnatal days 6, 13, 20, 
27 and adult (p < 0.05, ANOVA followed by Tukey's Multiple Comparison Test). 
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2.4 Discussion 
The results presented here is the first report on the developmental expression of NUCB2 
mRNA and NUCB2/nesfatin-1 like immunoreactivity (IR) in the gastroenteropancreatic tissues 
and serum. The NUCB2/nesfatin-1 IR detected in the stomach is in agreement with previous 
reports that showed NUCB2/nesfatin-1 IR in the lower third and middle regions of the gastric 
oxyntic glands (Stengel et al., 2009b, Zhang et al., 2010). A large number of gastric endocrine 
cells displayed NUCB2/nesfatin-1 IR in the lower third regions of the gastric oxyntic glands in 
the Institute of Cancer Research (ICR) mice (Zhang et al., 2010). The distribution of 
NUCB2/nesfatin-1 IR cells changed with age: the gastric mucosa of suckling rats at postnatal 
day 13 displayed a few number of NUCB2/nesfatin-1 IR cells in the lower segments of the 
mucosa which was detected in the glandular base, but were gradually localized from the 
glandular base to the core of the gastric gland from postnatal day 20 to adult stage. It could be 
thus suggested that NUCB2/nesfatin-1 immunopositive cells extend with increasing age from the 
base to the middle portion of the gastric gland and correlates with high levels of NUCB2 mRNA 
at postnatal days 20 and 27. In the adult rat, NUCB2/nesfatin-1 IR was abundant, but NUCB2 
mRNA was drastically reduced. This age-related variation of NUCB2/nesfatin-1 protein 
expression in the stomach during the perinatal period displays an ontogenic pattern of 
NUCB2/nesfatin-1 IR that could be closely related to the weaning period that is consistent with 
the change in diet from milk to rat chow. 
Similar gastric expression profile for other metabolic hormones was also reported. For 
example, the gastric mucosa of Wistar rats on postnatal day 15 displayed 
increased leptin immunoreactivity in the basal part of the gastric glands but decreased 
immunoreactivity was evident in the superficial layer of the epithelium lining the mucosa (Oliver 
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et al., 2002). At postnatal day 21, leptin immunostaining in the gastric mucosa of weaned rats 
detected an increase in IR in many glandular endocrine cells of the mucosa. This reflects how 
increased amount of endogenous leptin is produced by the stomach coinciding with the transition 
from suckling to solid chow diet (Oliver et al., 2002), similar to what was observed in this study. 
Furthermore, studies on the ontogenic expression of ghrelin in SD rats showed that ghrelin 
immunoreactive cells were rare at embryonic day 21 and increased progressively until 
weaning (Walia et al., 2009). These findings on leptin and ghrelin are in general very similar to 
the stomach expression of NUCB2/nesfatin-1 determined in this study. An increase in NUCB2 
mRNA expression was also observed at postnatal day 13 indicating the change of nutritional diet 
from milk to solid rat chow. In addition, remains of solid chow food were identified in the 
stomach lumen beginning from postnatal day 13, which is in coincident with the increase in 
NUCB2/nesfatin-1 expression suggesting that it would propose to be an ontogenically 
programmed period. These results suggest that macronutrients may affect the expression of 
NUCB2/nesfatin-1. 
In the duodenum, NUCB2/nesfatin-1 IR was not detected at embryonic day 21 and 
postnatal days 1 and 6, but NUCB2/nesfatin-1 protein expression gradually increased during the 
second postnatal week. From postnatal days 13 to 27, NUCB2/nesfatin-1 IR was detected in the 
enteroendocrine cells of the duodenum. Co-localization of NUCB2/nesfatin-1 and chromogranin 
A (CgA) was not detected at postnatal days 13 and 27, but was co-expressed in the 
enteroendocrine cell found in the adult duodenal villi. Chromogranin A plays a major role in the 
secretion of peptide hormones and neurotransmitters of the trans-Golgi network and is expressed 
mostly in all endocrine and neuroednocrine cells (Hendy et al., 1995). Co-expression of 
NUCB2/nesfatin-1 and CgA in the intestinal cells of the adult duodenal villi suggests that the 
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NUCB2/nesfatin-1 IR cells are enteroendocrine cells. In addition, NUCB2 mRNA expression in 
the duodenum at postnatal day 27 was higher than adult NUCB2 mRNA expression. Although 
the function of NUCB2/nesfatin-1 in the duodenum is currently unknown, a gradual increase in 
the expression of NUCB2/nesfatin-1 IR and NUCB2 mRNA expression in the duodenum is 
observed, which suggests that NUCB2/nesfatin-1 protein expression in the duodenum may be 
involved in the absorption of nutrients (Zhang et al., 2010), as well as modulating the secretion 
of intestinal hormones. NUCB2/nesfatin-1IR is also observed in the Brunner's glands of SD rats 
and ICR mice (Zhang et al., 2010). These glands are involved in secreting alkaline products such 
as bicarbonate and mucus that aid in maintaining the structural and biological environment of the 
gastrointestinal tract (Krause, 2000). Further evaluation is required to elucidate the significance 
of NUCB2/nesfatin-1 expression in the enteroendocrine cells and Brunner's glands of the 
duodenal submucosa. 
In fetuses, glucose metabolism depends on the mother (King, 2006), although these 
immature β-cells would synthesize and secrete less insulin than adults (Navarro et al., 
2007) which was similar to the results of this study that detected less insulin IR during 
embryonic day 21. At birth, as the postnatal pups acquire glucose sensitivity, the endocrine islet 
cells of the pancreas begin to secrete insulin in order to modulate glucose metabolism. With 
development, response to glucose sensitivity increases reaching maturity after weaning 
(Asplund, 1973, Hole et al., 1988, Weinhaus et al., 1995). At postnatal day 20, as pups begin to 
wean, insulin secretion increases in order to accommodate their insatiable appetite (Navarro-
Tableros et al., 2007). In this study, we observed age-related variation in insulin IR at all 
developmental stages. The day of birth (postnatal day 1) and postnatal day 20 are two important 
stages for pancreatic morphogenesis and glucose induced insulin secretion (Navarro-Tableros et 
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al., 2007, Ayuayo-Mazzucato et al., 2006). In this study, not all insulin immunopositive cells 
were immunoreactive for NUCB2/nesfatin-1 at embryonic day 21, postnatal day 1 and postnatal 
day 6. Gradually with age, all insulin immunopositive islet cells were immunoreactive for 
NUCB2/nesfatin-1 during the third and fourth week of development. 
In adult SD rats, the pancreas, stomach and duodenum appear to be major sites of 
NUCB2/nesfatin-1 synthesis and secretion. There are also other tissues such as the esophagus, 
liver, small intestine and colon that may secrete nesfatin-1 (Zhang et al., 2009). The primary 
source of circulating NUCB2/nesfatin-1 levels is currently unknown. The abundant expression of 
NUCB2/nesfatin-1 in the gastroenteropancreatic tissues suggests a prominent role for these 
tissues in the synthesis and secretion of NUCB2/nesfatin-1. It was found that serum 
NUCB2/nesfatin-1 levels at embryonic day 21 and postnatal day 1 were significantly low in 
comparison to following postnatal days 13, 20 and 27, and adult. Overall, serum 
NUCB2/nesfatin-1 levels increased with age gradually reaching levels of adult at postnatal day 
27 which is consistent, in part, with NUCB2/nesfatin-1 protein expression in the pancreas. In the 
gastroenteropancreatic tissues, the most abundant NUCB2/nesfatin-1 IR was detected in the later 
postnatal days and in adults. It is possible that NUCB2/nesfatin-1 secreted from the pancreatic 
tissue is released into circulation (Gonzalez et al., 2009) to regulate insulin secretion and glucose 
homeostasis. It is also possible that NUCB2/nesfatin-1 plays a role in the development of the 
tissue itself. 
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2.5 Conclusions 
These findings demonstrate that circulating levels of serum nesfatin-1 increase with 
development. NUCB2/nesfatin-1 IR in the pancreas and gastrointestinal tract could possibly 
contribute to the gradual increase in serum NUCB2/nesfatin-1 levels. In addition, 
NUCB2/nesfatin-1 colocalizes with insulin in the islet β-cells at all developmental stages in an 
age-dependent manner suggesting that NUCB2/nesfatin-1 plays an important role in glucose 
metabolism during growth. NUCB2 mRNA levels in the duodenum at postnatal day 27 are 
higher than the adult NUCB2 mRNA expression, however metabolic effects of NUCB2 
expression in the duodenum still remain elusive. This is the first study that has focused on the 
importance of NUCB2/nesfatin-1 expression in the developmental stages of rats. These results 
collectively suggest that NUCB2/nesfatin-1 has important age- and tissue-specific role in the 
developmental physiology of rats. 
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Transition 
The next chapter focuses on my second objective: To elucidate the developmental 
expression of GOAT mRNA and colocalization of ghrelin, GOAT, NUCB2/nesfatin-1, PC 1/3 
and PC 2 immunoreactivity in the pancreas during fetal and postnatal periods of Sprague Dawley 
rats. As discussed earlier, both ghrelin and nesfatin-1 are derived from their precursors by 
posttranslational processing by prohormone convertases (PC) 1/3 and 2.  Ghrelin requires an 
acylation of its third serine residue to elicit many of its actions which is modified by an enzyme 
called ghrelin O-acyl transferase (GOAT). Both these peptides are expressed in the endocrine 
cells of the pancreatic islets. In addition, both ghrelin and nesfatin-1 are produced in the same 
endocrine cells, but are stored and secreted from distinct vesicles within the gastric mucosa. 
Most importantly both peptides have opposing actions in regulating glucose metabolism and 
whole body energy balance. Thus far, there is no research on the developmental expression of 
GOAT, and the co-expression of both NUCB2/nesfatin-1 and prohormone convertases in the 
pancreas. We found that ghrelin and GOAT, as well as NUCB2/nesfatin-1 and PCs are co-
expressed in the endocrine cells of the pancreatic islets. This is the first study that provided 
information on GOAT mRNA and protein expression, and NUCB2 and PC immunoreactivity 
during development in the rat pancreas. Our findings suggest that ghrelin and nesfatin-1 
expressed in the endocrine pancreas in an age-dependent manner during development of rats.  
 
Publication: Mohan, H., Gasner, M., Unniappan, S. 2015. Ghrelin, Ghrelin-O-Acyl Transferase, 
Nucleobindin-2/Nesfatin-1 and Prohormone Convertases in the Pancreatic Islets of Sprague 
Dawley Rats During Development. Peptides. Manuscript Number: PEPTIDES-D-15-00119. 
Submission Status: Under Review. 
 
Contributions: Michaela Gasner and Haneesha Mohan equally conducted all in vivo studies, 
collected and processed the tissue samples for RNA extraction, conducted 
immunohistochemistry and protein assays. I analysed the data and wrote the first draft of the 
manuscript. Suraj Unniappan helped with the experimental design, provided the research 
infrastructure, edited the manuscript and funded the project to completion. 
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Chapter 3 
 
Ghrelin, Ghrelin-O-Acyl Transferase, Nucleobindin-2/Nesfatin-1 
and Prohormone Convertases in the Pancreatic Islets of Sprague 
Dawley Rats During Development 
 
3.1 Introduction 
 
Hormones play a major role in the formation, growth and maintenance of an organ during 
development (Larsson, 1998, O'Dowd and Stocker, 2013). Tissue specific ontogenic expression 
of these hormones and its processing enzymes provide insight into their potential functional roles 
(Reddy et al., 1988). The islets of Langerhans in the endocrine pancreas of mammals are 
composed of cells that are a major source of glucoregulatory hormones that include insulin 
producing beta (β) cells and glucagon producing alpha (α) cells. Several additional peptides with 
endocrine actions have also been reported in the pancreatic islets of rodents and humans 
(Drucker, 2007, Reddy et al., 1988). Among these, ghrelin, mainly considered as an 
insulinostatic hormone (Dezaki et al., 2011), and nesfatin-1, an insulinotropic peptide (Gonzalez 
et al., 2011), are important regulators of metabolism and glucose homeostasis (Li et al., 2013, Su 
et al., 2010). The pancreatic islets are also ghrelin producing, in a cell named epsilon (Ɛ) cells 
(Prado et al., 2004). Ghrelin is derived from preproghrelin after posttranslational processing by 
prohormone convertase (PC) 1/3. It was discovered as the first endogenous ligand of the growth 
hormone secretagogue receptor 1a (GHS-R1a) (Kojima et al., 1999). The amino acid sequence of 
ghrelin is highly conserved in humans (Kojima et al., 1999) and other species (Kojima et al., 
2005, Stengel et al., 2012b). There is a unique acylation of the third serine residue (Ser 3) in 
ghrelin by n-octanoic acid (Kojima et al., 1999). This acylation is necessary for the binding of 
ghrelin to GHS-R1a and is critical for many of its biological functions. The enzyme responsible 
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for its acylation is ghrelin O-acyl transferase (GOAT) (Gutierrez e al., 2008, Mohan and 
Unniappan, 2013, Shlimun and Unniappan, 2011,  Yang et al., 2008). GOAT belongs to the 
family of membrane-bound O-acyl transferase (MBOAT) that is localized within the membranes 
of the endoplasmic reticulum (Gutierrez e al., 2008, Yang et al., 2008). In contrast, GOAT 
proteins also share a high homology in the amino acid sequence from humans to zebrafish (Yang 
et al., 2008).  
During fetal and postnatal development, ghrelin expression in the pancreas changes. In 
the developing mouse and rat pancreas, ghrelin immunoreactivity can be detected as early as 
embryonic day 9.5 and 15, peaking just before birth (Hill et al., 2009, Wierup et al., 2004). 
Ghrelin mRNA expression and total ghrelin concentration are elevated in the fetal pancreas, and 
is more abundant than in the fetal stomach (Hayashida et al., 2002). Immunohistochemical 
studies performed on pancreatic islets during embryonic day 21 to postnatal day 13 displayed 
few preproghrelin immunoreactive cells, at which they began to reduce and become untraceable 
with increase in age (Wali et al., 2009).  Ghrelin is primarily expressed in Ɛ-cells and glucagon 
(α-cells) producing cells produced in the fetal pancreatic islets (Hill et al.  2009, Prado et al., 
2004). During pancreatic development, insulin and ghrelin were expressed in their specific cell 
types and were not co-localized at any postnatal period (Walia et al., 2009). The developmental 
expression of GOAT in the rodent pancreas is currently unknown.  
Nesfatin-1 is an 82 amino acid peptide originally discovered from the rat hypothalamic 
extracts (Oh-I et al., 2006). PC1/3 and PC2 cause NUCB2 to be cleaved to nesfatin-1 (1-82 
amino acids) (Oh-I et al., 2006). Nesfatin-1 is a meal responsive insulinotropic peptide playing a 
major role in glucose homeostasis (Li et al., 2013, Su et al., 2010] and insulin secretion 
(Gonzalez et al., 2011). Plasma nesfatin-1 concentrations are inversely correlated with glucose 
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levels in rats and diabetic humans (Li et al., 2010). NUCB2 mRNA expression and 
NUCB2/nesfatin-1 immunoreactivity was significantly increased in the pancreatic islets of diet 
induced obese, type 2 diabetic mice (Gonzalez et al., 2011). NUCB2 mRNA and 
NUCB2/nesfatin-1 immunoreactivity was attenuated, but still detectable in the pancreatic islets 
of STZ-induced type 1 diabetic mice (Gonzalez et al., 2011). We found that some, not all beta 
cells were immunoreactive for NUCB2/nesfatin-1 at embryonic day 21, postnatal day 1 and 
postnatal day 6. However, in post-natal day 27 and in adults all beta cells were immunopositive 
for NUCB2/nesfatin-1 (Mohan and Unniappan, 2012). The endocrine pancreas, especially the 
islet beta cells appears an abundant source of endogenous NUCB2/nesfatin-1. However, there is 
paucity of information on whether the prohormone processing enzymes PC1/3 and PC2, and 
NUCB2/nesfatin-1 are co-localized in the endocrine pancreas during development.  
To date, the pancreatic islet specific ontogenic co-expression of prohormone convertases 
and ghrelin, and the expression of NUCB2/nesfatin-1 were studied separately. Developmental 
expression of GOAT in rodent pancreas is yet to be determined. Similarly, ontogenic patterns of 
co-expression of both prohormone convertases and NUCB2/nesfatin-1 are also unclear. It is 
important to understand how two metabolic peptides with opposing actions on insulin secretion 
and its processing enzymes that make them biologically active are locally produced within the 
pancreas. Therefore, the main objective of this research is to determine the expression of GOAT 
mRNA and colocalization of ghrelin, GOAT, NUCB2/nesfatin-1, PC 1/3 and PC 2 
immunoreactivity in the pancreas during fetal and postnatal periods of Sprague Dawley rats. 
These findings indicate that the GOAT mRNA expression, as well as the islet cell specific 
immunolocalization of all proteins tested, are dependent on specific developmental stages. This 
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study, for the first time, shed light on the co-expression of NUCB2/nesfatin-1 and prohormone 
convertases, and GOAT and ghrelin in rat islets of Langerhans. 
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3.2 Material and Methods 
 
3.2.1 Animals 
 
Timed pregnant Sprague Dawley (SD) rats (Charles River Laboratories, St Constant, QU, 
Canada) were housed from day 13 of pregnancy in a 12h light:12h dark cycle (lights off at 7 PM 
and on at 7 AM), temperature and humidity controlled vivarium. Pregnant dams had ad libitum 
access to standard rat chow (60% carbohydrate, 27% protein, and 13 % fat; with energy density 
= 3.43 kcal/g; Lab Diets Inc., St. Louis, MO) and water. All animal experiments complied with 
the Canadian Council of Animal Care guidelines, and were approved by the institutional animal 
care committee. 
3.2.2 Immunohistochemistry 
 
Immunohistochemical studies were conducted as described in Chapter 2, section 1.2.2.2, 
with the following differences in procedures or antibodies used. These pancreatic sections were 
then incubated with mouse anti-ghrelin (Catalogue number ab 57222; 1:100 dilution; Abcam, 
Massachusetts) and with rabbit anti-GOAT (Catalogue number H-032-12; 1:100 dilution; 
Phoenix Pharmaceuticals, California) for 24 hours at room temperature. In addition, pancreatic 
sections were also incubated with goat anti-NUCB2 (Catalogue number sc-65160; 1:100 
dilution; Santa Cruz Biotechnology, CA), and with either rabbit anti-PC 1/3 or rabbit anti-PC 2 
(1:500 dilution; antibodies kindly donated by Dr. Iris Lindberg, University of Maryland, 
Baltimore, USA). All primary and secondary antibodies were diluted in antibody diluent reagent 
(DakoCytomation, Mississauga, Ontario). All slides were subsequently washed three times with 
1x Phosphate Buffer Solution (PBS) and incubated with goat monoclonal anti-mouse FITC IgG 
(Heavy and Light Chain) (Green-Ghrelin; Catalogue number ab 6785; 1:100 dilution; Abcam, 
Massachusetts), goat anti-rabbit Texas Red® IgG (Red-Nesfatin-1; Catalogue number TI-1000; 
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1:100 dilution; Vector Laboratories, California), and/or Alexa Fluor 594 donkey anti-goat IgG 
(H+L) (Catalogue Number A11058; 1:100 dilution; Invitrogen Corporation Carlsbad, CA) 
secondary antibodies for 1 hour at room temperature. Slides were washed, mounted in DAPI and 
imaged as described earlier. Approximately 8 slides (from multiple rats) containing two sections 
of the pancreas from each developmental stage were stained using the above protocol and 
analyzed. Only representative images of tissues from each stage staining for ghrelin, GOAT, 
NUCB2/nesfatin-1, PC 1/3 and PC 2 are shown in the results section. Slides incubated with the 
secondary antibodies only were used as a negative control for NUCB2/nesfatin-1, PC 1/3, PC 2, 
ghrelin and GOAT (data not shown).  NUCB2/nesfatin-1 antibody has been tested and validated 
in our lab. Preabsorption controls do not show any immunoreactivity (Kerbel and Unniappan, 
2011, Gonzalez et al., 2010, Gonzalez et al., 2011). The primary antibody used in this study can 
bind to both the precursor NUCB2 and processed nesfatin-1. Therefore, the immunoreactivity 
detected is presented as NUCB2/nesfatin-1. 
3.2.3 Real Time Quantitative PCR 
 
For real time quantitative PCR analysis, 4 rats were housed in the vivarium from day 13 
of pregnancy. Whole pancreatic tissues were harvested for total RNA extraction. Two pregnant 
dams were sacrificed on day 21 of pregnancy to gather the pancreatic tissue from the embryos on 
embryonic day 21. Pancreatic tissues were collected from neonatal pups born from the remaining 
2 pregnant dams on postnatal days 1, 6, 13, 20 and 27. Pancreatic tissues were also collected 
from 4 adult male SD rats (n = 4, average weight = 200.35 grams and approximate age: 43-46 
days) to analyze GOAT mRNA expression during each developmental stage and adulthood. 
Total RNA was extracted from the embryonic, postnatal and adult rat pancreas using the TRIzol 
RNA isolation reagent (Invitrogen, Canada). RNA purity was validated by optical density (OD) 
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absorption ratio (OD 260 nm/OD 280 nm) using a Multiskan® Spectrum spectrophotometer 
(Thermo, Vantaa, Finland). Only samples with an absorption ratio greater than 1.7 were used for 
cDNA synthesis. Synthesis of cDNAs was achieved using the iScript™ cDNA synthesis kit 
(BioRad, Canada), as directed by the manufacturer. The quantitative RT-PCR (qRT-PCR) 
protocol used for GOAT was 95
o 
C for 3 minutes heat activation, followed by 95 cycles of 95
o 
C 
for 30 seconds denaturation of double stranded DNA (dsDNA), 63
o 
C for 30 seconds annealing 
of primers, and 73
o 
C for 30 seconds elongation.  The reaction for each sample was run in 
duplicates. For the analysis, GOAT mRNA expression was normalized using beta-actin as the 
housekeeping gene as described previously in our work using pancreatic samples (Mohan and 
Unniappan, 2012). The mRNA quantification was very precise, and the critical threshold values 
for beta-actin showed no variability. The gene expression data was obtained using the Pfaffl 
method (Pfaffl, 2001). The specificity of the amplified gene product was determined by 
analyzing the melting curve to limit the expression of non-specific gene products. All values 
were reported as mean + SEM. One-way ANOVA followed by Dunnett’s multiple comparison 
test were performed to compare GOAT mRNA expression at each developmental stage. Data 
were analyzed with GraphPad Prism Version 5.0 for Windows (GraphPad Software, La Jolla 
California, USA). 
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3.3 Results 
 
3.3.1 Ghrelin and GOAT Immunoreactivity in the Rat Pancreas 
 
At postnatal day 20, 27 and the adult stage, some, but not all islet cells immunopositive 
for GOAT (Figures 3.1B, 3.1E, 3.1H) showed ghrelin immunoreactivity (Figures 3.1A, 3.1D, 
3.1G), co-localizing both peptides (Figures 3.1C, 3.1F, 3.1I). No or very low staining for 
ghrelin and GOAT were observed in the pancreas selected from E21-P13 days (data not shown). 
No immunostaining was observed in the exocrine pancreas (Figures 3.1A-I). 
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Figure 3.1 Co-localization of Ghrelin and GOAT in the Pancreatic Islets 
Figure 3.1. Immunostaining displays that not all islet cells immunopositive for GOAT (Figure B, 
E and H; red) showed ghrelin immunoreactivity (Figure A, D and G; green) on postnatal day 20, 
27 and adult, co-localizing for protein, enzyme and DAPI (Figure C, F and I; yellow. 
Representative images were taken of 8 slides (16 sections) from 2 neonatal pancreatic tissues at 
postnatal days 20, 27 and adult. Scale bar = 50 μm. (P, Postnatal)3 
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3.3.2 NUCB2/nesfatin-1, PC1/3 and PC2 Immunoreactivity in the Rat Pancreas  
 
At embryonic day 21, postnatal day 13, 20 and 27, a large number of islet cells 
immunopositive for NUCB2/nesfatin-1 (Figures 3.2A, 3.2D, 3.2G, 3.2J) showed PC1/3 
immunoreactivity (Figures 3.2B, 3.2E, 3.2H, 3.2K), co-localizing for both protein and enzyme 
at these stages (Figures 3.2C, 3.2F, 3.2I, 3.2L). Majority of islets cells immunopositive for 
NUCB2/nesfatin-1 (Figures 3.3A, 3.3D, 3.3G) were also co-immunoreactive for PC2 (Figures 
3.3B, 3.3E, 3.3H), at embryonic day 21, postnatal days 13 and 20 (Figures 3.3C, 3.3F, 3.3I). 
But at postnatal day 27, NUCB2/nesfatin-1 immunoreactivity was only observed in the core of 
pancreatic islets (Figure 3.3J), but PC2 staining was only observed in a ring of cells in the 
periphery (Figure 3.3K). No colocalization of NUCB2/nesfatin-1 and PC2 was observed at 
postnatal day 27 (Figure 3.3L). No immunostaining was observed in the exocrine pancreas 
(Figures 3.2A-L and 3.3A-L). 
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Figure 3.2 Co-localization of NUCB2/nesfatin-1 and PC 1/3 in the Pancreatic Islets 
Figure 3.2. Co-localization of NUCB2/nesfatin-1 and PC 1/3 immunohistochemical staining of 
the rat pancreas at embryonic day 21 (A, B, C), postnatal day 13 (D, E, F), 20 (G, H, I) and 27 (J, 
K, L). Islet cells immunoreactive for NUCB2/nesfatin-1 (A, D, G, J; green), PC 1/3 (B, E, H, K; 
red), and the merged image of NUCB2/nesfatin-1, PC 1/3 and DAPI (C, F, I, L; yellow). 
Representative images were taken of 8 slides (16 sections) from 3 embryonic and 2 neonatal 
pancreatic tissues at embryonic day 21 and postnatal days 13, 20 and 27. Scale bar = 50 μm. (E, 
Embryonic Day; P, Postnatal) 
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Figure 3.3 Localization of NUCB2/nesfatin-1 and PC 2 in the Pancreatic Islets 
Figure 3.3. Co-localization of NUCB2/nesfatin-1 and PC 2 immunohistochemical staining of the 
rat pancreas at Embryonic day 21 (A, B, C), Postnatal day 13 (D, E, F) and 20 (G, H, I). At 
postnatal day 27 prohormone convertase 2 was only evident in the glucagon producing alpha-
cells and NUCB2/nesfatin-1 was observed in the core expressed in the insulin producing beta-
cells (J, K, L). Islet cells immunoreactive for NUCB2/nesfatin-1 (A, D, G, J; green), PC 2 (B, E, 
H, K; red), and the merged image of NUCB2/nesfatin-1, PC 2 and DAPI (C, F, I, L; yellow). . 
Representative images were taken of 8 slides (16 sections) from 3 embryonic and 2 neonatal 
pancreatic tissues at embryonic day 21 and postnatal days 13, 20 and 27. Scale bar = 50 μm. (E, 
Embryonic Day; P, Postnatal) 
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3.3.3 Developmental Expression of GOAT mRNA in the Rat Pancreas 
 
GOAT mRNA expression in the pancreas at postnatal day 27 is higher than its expression 
from embryonic day 21 to postnatal day 13 and adult stage (Figure 3.4). 
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Figure 3.4 GOAT mRNA levels at different development stages 
Figure 3.4. Analysis of GOAT mRNA levels at different development stages in pancreas (E21 
(n=5), P1 (n=7), P6 (n=7), P13 (n=7), and P20 (n=3)) of Sprague Dawley (SD) Rats tissues. (E, 
Embryonic Day; P, Postnatal). In the pancreas, GOAT mRNA expression at postnatal day 27 is 
higher than mRNA expression levels from embryonic day 21 to postnatal day 13 and adult 
GOAT mRNA expression levels. (denoted by an asterisk; p < 0.05, ANOVA followed by 
Dunnett’s multiple comparison test).   
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3.4 Discussion 
 
The results presented here show the developmental stage-specific expression of ghrelin, 
NUCB2/nesfatin-1, GOAT, PC 1/3 and PC 2 in the pancreatic islets of rats.  It is the first report 
on developmental stage specific co-expression of GOAT and ghrelin, and NUCB2/nesfatin-1 and 
prohormone convertases. In the pancreatic islet, both ghrelin and GOAT immunostaining was 
prominent from postnatal day 20 onwards. A major share of, but not all, islet cells in the 
pancreas that are immunopositive for GOAT showed ghrelin immunoreactivity on postnatal days 
20 and 27 and in adults. Similar immunohistochemical studies found ghrelin immunoreactivity in 
islet cells of rat pancreas gradually increasing with development (Walia et al., 2009). It was 
reported that GOAT mRNA increases with age and body weight gain in male and female rats 
(Al-Massadi et al., 2010). Post birth, as neonates begin to gain glucose sensitivity, insulin is 
secreted in the islet cells in order to regulate glucose metabolism (Hole et al., 1988, Asplund, 
1973, Weinhaus et al., 1995). The co-presence of both ghrelin and GOAT within the islets 
suggests the emergence of the ghrelinergic system in the pancreas around the same time the 
functional beta cells gain secretory activity. From a functional point of view, the presence of 
GOAT within the same cells enhances the chances for acylation of ghrelin to take place locally. 
It is likely that around the same time when insulin secretion begins, the ghrelin regulation of 
insulin release also commences. Ghrelin expression has been reported in the developing pancreas 
of rats (Walia et al., 2009). While ghrelin immunoreactivity decreased in post-natal days in this 
study ((Walia et al., 2009), our results indicate abundant expression of ghrelin and GOAT in 
post-natal days. This discrepancy is likely due to the difference in antibodies used. Similar to our 
results, ghrelin localization in islet beta cells was detected found before (Volante et al., 2002). 
We found that GOAT mRNA expression also follows a similar pattern, with the highest 
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expression found in P27. This result on GOAT mRNA expression is in line with our 
immunohistochemistry results, where most abundant expression of GOAT immunoreactivity was 
also detected in adults. This result provides further evidence for a gradual progression of GOAT 
synthesis in pancreatic islets. Considering that GOAT is essential for the acylation of ghrelin, 
which is critical for many of its biological activities, this new information about ghrelin and its 
modifying enzyme is significant.  
While ghrelin is primarily considered insulinostatic (Dezaki et al., 2011), nesfatin-1 is 
insulinotropic (Gonzalez et al., 2011). We previously reported a developmental stage specific 
expression of NUCB2/nesfatin-1 in the gastroenteropancreatic tissues of rats (Mohan and 
Unniappan, 2012). However, whether the processing enzymes that produce nesfatin-1 from its 
precursor NUCB2 co-localizes with it is currently unknown. Here we report the co-localization 
of NUCB2/nesfatin-1 and PC1/3 and PC2 in rat pancreas. We found colocalization of 
NUCB2/nesfatin-1 with PC 1/3 at embryonic day 21 and postnatal day 13, 20 and 27. Similarly, 
colocalization of NUCB2 with PC2 was detected at embryonic day 21 and postnatal day 13 and 
20. However, at postnatal day 27, PC2 was only evident in a ring of cells in the periphery of 
islets. This staining pattern is in agreement with our own (Gonzalez et al., 2009, Stengel et al., 
2009b) and other findings (Foo et al., 2010) of nesfatin-1 exclusively in the islet beta cells, but 
not in the glucagon producing alpha-cells. Previous studies suggest that PC2 plays an important 
role in the development of β-cells (Vincent et al., 2003). Its major substrates are proglucagon and 
proinsulin (Rouille et al., 1995, Rouille et al., 1994) and thus, its immunoreactivity are detected 
in a population of islet cells expressing multiple hormones at early developmental stages 
dependent on growth. It appears that either PC2 or PC1/3, or both enzymes are available to 
process nesfatin-1 during development and in adulthood. Nesfatin-1 co-localizes PCs in the rat 
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hypothalamus (Oh-I et al., 2006), suggesting the processing of NUCB2 to nesfatin-1 in the brain. 
In fact, brain is the only tissue from which the processed nesfatin-1 was purified. The co-
expression of PCs and NUCB2/nesfatin-1 in the pancreatic islets provides further evidence for 
endocrine pancreas as a source of endogenous nesfatin-1. 
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3.5 Conclusions 
 
The outcome of this research for the first time demonstrates the relationships of GOAT 
and ghrelin, and nesfatin-1, and their processing enzymes in the pancreatic islets during 
developmental stages of rats. In the pancreas, GOAT mRNA expression at postnatal day 27 is 
higher than expression levels at rest of the developmental stages tested. These histological 
findings showing the local presence of processing enzymes for NUCB2 and ghrelin are 
suggestive of the endocrine pancreas as an endogenous source of these hormones with opposing 
metabolic actions. In conclusion, this article presented novel aspects of ghrelin, 
NUCB2/nesfatin-1 and its processing enzymes in fetal and postnatal periods. Further studies are 
required to gain a deeper understanding of the age- and tissue-specific roles of ghrelin and 
nesfatin-1 during development of rats.  
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Transition 
Thus far, this thesis research focused on characterizing the developmental expression of 
NUBC2/nesfatin-1, and processing enzymes in gastroenteropancreatic tissues. These tissues 
appear predominant sources of meal responsive, endogenous nesfatin-1. However, the regulation 
of NUCB2/nesfatin-1 is poorly understood. The hypothesis is that macronutrients of diets 
differentially regulate endogenous NUCB2/nesfatin-1 in a tissue-specific manner. The aims of 
chapter 4 is to determine how different nutrients modulate NUCB2/nesfatin-1 secretion in vitro 
in cultured stomach ghrelinoma (MGN3-1) cells from mice and in vivo in male mice. As 
explained earlier, development and nutritional status can influence the transcriptional activity of 
genes tissue specifically regulating energy balance. First, we characterized MGN3-1 cells as 
nesfatin-1 secreting cells with the NUCB2 processing machinery, suggesting that this cell line is 
useful for studying nesfatin-1 biology. We found expression of NUCB2, ghrelin and prohormone 
convertases in MGN3-1 cells. We found that effects of diets on the expression of endogenous 
NUCB2/nesfatin-1 were myriad. Our results indicated that the synthesis and secretion of 
nesfatin-1 were altered by relative amounts of nutrients and such effects were dependent on the 
amount of nutrients, tissues and time of the day or duration of treatment. This was the first study 
that focused on nutrient regulation of NUCB2/nesfatin-1. Our results indicated that 
NUCB2/nesfatin-1 was modulated by nutrients in a tissue specific manner. 
 
 
Publication: Mohan, H., Ramesh, N., Mortazavi, S., Le, A., Unniappan, S. 2014. Nutrients 
differentially regulate nucleobindin-2/nesfatin-1 in vitro in cultured stomach ghrelinoma 
(MGN3-1) cells and in vivo in male mice. PLoS One, 9, e115102. 
 
 
Contributions: Haneesha Mohan conducted all in vivo, and in vitro studies, collected and 
processed the tissue samples for RNA extraction and performed protein assay. H. Mohan also 
performed protein assays, analyzed data and wrote the first draft of the manuscript. Naresh 
Ramesh helped with protein extraction and Western blot detection. Naresh Ramesh and Anthony 
Le conducted immunocytochemistry and microscopy on MGN3 cells. Sima Mortazavi processed 
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tissues for immunohistochemistry, conducted immunohistochemistry and microscopy. Suraj 
Unniappan helped with the experimental design, assisted with in vivo studies, provided the 
research infrastructure, edited the manuscript and funded the project to completion. 
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Chapter 4 
Nutrients Differentially Regulate Nucleobindin-2/Nesfatin-1 In Vitro 
in Cultured Stomach Ghrelinoma (MGN3-1) Cells and                     
In Vivo in Male Mice 
4.1 Introduction 
Nesfatin-1 [NEFA/NUCB2-encoded satiety and fat-influencing protein-1] is a potent 
anorexigenic peptide implicated in the regulation of energy balance and glucose homeostasis 
(Oh-I et al., 2006, Gonzalez et al., 2011). It is an 82 amino acid peptide derived from the 
precursor protein, nucleobindin-2 (NUCB2) (Oh-I et al., 2006). NUCB2 is composed of 396 
amino acids, consisting of two EF hand motifs and a DNA binding domain (Oh-I et al., 2006, 
Barnikol-Watanabe et al., 1994). Post-translational processing by prohormone convertases (PC 
1/3 and PC 2) causes NUCB2 to be cleaved into three peptides, nesfatin-1 (1-82 amino acids), 
nesfatin-2 (85-163 amino acids), and nesfatin-3 (166-396 amino acids). NUCB2/nesfatin-1 
amino acid sequence is highly conserved across vertebrates (Gonzalez et al., 2010). 
NUCB2/nesfatin-1 is found in various hypothalamic nuclei that are involved in energy 
metabolism, such as the arcuate nucleus, paraventricular nucleus, supraoptic nucleus, lateral 
hypothalamic area and zona increta (Kohno et al., 2008, Maejima et al., 2009). Insulin producing 
beta cells co-express nesfatin-1 in the pancreatic islets of rats and mice (Gonzalez et al., 2009, 
Gonzalez et al., 2011, Mohan and Unniappan, 2012), suggesting that nesfatin-1 could play an 
important role in insulin secretion and glucose homeostasis (Gonzalez et al., 2011). Ghrelin and 
NUCB/nesfatin-1 are colocalized in the gastric oxyntic mucosal glands in rodents (Stengel et al., 
2009b) and humans (Stengel et al., 2013). NUCB2 mRNA expression in purified gastric mucosal 
endocrine cells was found to be higher than in the brain of rats (Stengel et al., 2009b). The full 
length NUCB2 protein was observed in the small and large intestines and liver of male rats, and 
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ICR mice (Zhang et al., 2010). The wide distribution of NUCB2/nesfatin-1 in central and 
peripheral tissues points to a role for nesfatin-1 in regulating metabolism. 
Daily administration of nesfatin-1 caused extended reduction in food intake and body 
weight (Oh-I et al., 2006). Intracerebroventricular administration of NUCB2 suppresses food 
intake, body weight and subcutaneous, mesenteric and epididymal fat mass in adult rats in a dose 
dependent manner. In addition, NUCB2 knockdown in rats by infusing antisense morpholino 
oligonucleotide (as-MON) caused an increase in appetite and body weight (Oh-I et al., 2006). 
Intra-paraventricular nucleus injection of nesfatin-1 reduces cumulative food intake at 1 and 3 
hours (Maejima et al., 2009). Intraperitoneal injections of nesfatin-1 resulted in a reduction in 
food intake in leptin resistant db/db mice and high fat diet fed mice (Kohno et al., 2008). 
Nesfatin-1 is composed of 3 structural fragments and only the mid-fragment (residues 24-53; 
M30) of nesfatin-1 is involved in producing anorectic responses (Shimizu et al., 2009, Stengel et 
al., 2012a). Together, these results provide clear evidence that support satiety effects of    
nesfatin-1. 
Nesfatin-1 is a meal responsive glucoregulatory hormone (Stengel et al., 2009a, Stengel 
et al., 2009b), and pancreatic islets of rats release NUCB2 in response to glucose (Foo et al., 
2010). In human studies, glucose treated subjects had higher basal nesfatin-1 levels compared to 
control subjects (Li et al., 2010). In MIN6 cells, a 4-fold increase in nesfatin-1 levels was 
observed when the cells were incubated in high glucose (16.7 mM) compared to low glucose (2.0 
mM) (Gonzalez et al., 2011). Nesfatin-1 enhanced glucose stimulated insulin secretion from 
cultured MIN6 cells that were incubated in high glucose than in low glucose in a dose dependent 
manner (Gonzalez et al., 2011). In the pancreas of streptozotocin (STZ)-injected mice with Type 
1 Diabetes, it was found that both NUCB2 and preproinsulin mRNA expression were 
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significantly lower (Gonzalez et al., 2011). In contrast, enhanced nesfatin-1 co-localization with 
insulin was found in the islet beta cells of high-fat diet-induced obese mice with Type 2 
Diabetes. Nesfatin-1 has tissue specific effects on glucose uptake in rat adipocytes and muscle 
(Gonzalez et al., 2012a). Overall, nesfatin-1 exerts important roles in regulating whole body 
glucose and energy homeostasis. 
While nesfatin-1 is emerging as an important meal responsive peptide (Oh et al., 2006, 
Stengel et al., 2009a, Stengel et al., 2009b, Gonzalez et al., 2011), what triggers its secretion 
remained unclear. What diet components trigger the post-meal secretion of nesfatin-1? This 
question remains unaddressed. The main focus of this study was to determine how different 
nutrients can modulate NUCB2/nesfatin-1 in vitro in cultured stomach ghrelinoma (MGN3-1) 
cells from mice and in vivo in male mice. The results from the in vitro studies indicate that 
MGN3-1 cells respond differently to nutrients in secreting NUCB2/nesfatin-1 and ghrelin. 
Similarly, acute or chronic intake of nutrients does influence NUCB2 mRNA expression and 
NUCB2/nesfatin-1 release in a diet specific manner. 
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4.2 Material and Methods 
4.2.1 Ethics Statement 
All studies using animals complied with the Canadian Council of Animal Care 
guidelines, and were approved by the Animal Research Ethics Board of the University of 
Saskatchewan (Protocol Number 2012-0033).  
4.2.2 In Vitro Studies 
Mouse stomach ghrelinoma (MGN3-1) cells (Iwakura et al., 2010) were cultured in 
DMEM (Invitrogen, Ontario, Canada; Catalogue # 11995-040) that was supplemented with 10% 
fetal bovine serum (Invitrogen; Catalogue # 12484) and 1% penicillin (100 U/mL) and 
streptomycin (100 µg/mL) (Invitrogen; Catalogue # 15140-122) at 37
o
C in 10% CO2. At 80% 
confluency, MGN3-1 cells were seeded at 6 x 10
6
 cells/well in a 12-well plate and the studies 
were performed when cells were 80-90% confluent. Each study was repeated thrice and the data 
from three studies were pooled to obtain an n = 9-12 wells/treatment. To determine whether 
glucose had an effect in a dose and time dependent manner, cells were incubated for 1 hour and 2 
hours with 5.6, 25, 50, and 100 mM glucose DMEM media. The complete growth medium of 
MGN3-1 cells requires them to be growing at a high glucose level, which is 25 mM. In relation 
to the studies conducted with fatty acids and amino acids, we performed these studies using 
DMEM at low glucose levels (5.6 mM), since using a high glucose medium (25 mM) could mask 
the effect of the respective nutrients on NUCB2/nesfatin-1 secretion and synthesis. With respect 
to long chain fatty acids, we tested the effect of three different fatty acids using linolenic acid 
(Sigma-Aldrich, Ontario, Canada; Product # L2376), octanoic acid (Sigma-Aldrich; Product # 
C2875) and oleic acid (Sigma-Aldrich; Product # O1383). The cells were incubated for 4 hours 
with each fatty acids at 0, 1, 10, 100 µM. We used L-Tryptophan (Sigma-Aldrich; Product # 
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T8941) to test the effect of an amino acid on NUCB2 secretion and synthesis. The cells were 
incubated for 4 hours with L-tryptophan at 0.7, 1 and 10 mM. L-Tryptophan is present in the 
control medium (5.6 mM glucose DMEM) at a minimum dose of 0.7 mM, which is essential for 
their growth condition.  
4.2.3 In Vivo Studies 
For the chronic feeding of diets containing varying amounts of specific nutrients, age and 
weight-matched (5 weeks old, average body weight: 20 grams) male C57BL/6 mice (Charles 
River Laboratories, Quebec, Canada) were housed individually for 17 weeks in a 12 hours light: 
12 hours dark cycle (lights off at 7 PM and on at 7 AM), temperature and humidity controlled 
vivarium. Mice were divided into four groups fed on a control (n = 6), high carbohydrate (n = 7), 
high protein (n = 7), and high fat (n = 7) diet with ad libitum access to water and their specific 
diet. All diets were purchased from Research Diets (New Brunswick, NJ). The calorie content of 
diets were: control (Product # D12451): 4.73 kcal/gm with 20% energy derived from protein, 
35% energy derived from carbohydrate and 45% energy derived from fat; high carbohydrate 
(Product # D12450J) had 3.8 kcal/gm with 20% energy derived from protein, 70% energy 
derived from carbohydrate and 10% energy derived from fat; high protein (Product # 
D08091802) had 3.8 kcal/gm with 60% energy derived from protein, 30% energy derived from 
carbohydrate and 10% energy derived from fat, and high fat (Product # D12492) had 5.2 kcal/gm 
with 20% energy derived from protein, 20% energy derived from carbohydrate and 60% energy 
derived from fat. All mice were fed with the control diet for one week prior to starting their 
specific diets. Food intake, body weight, and blood glucose readings post 4 hours fast were 
measured once a week for 17 weeks.  
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For the acute administration of nutrients, age and weight-matched (5 weeks old, average 
body weight: 20 grams) male C57BL/6 Mice (Charles River Laboratories, St Constant, QU, 
Canada) were housed individually for 1 week and 2 days in a 12 h light:12 h dark cycle (lights 
off at 7 PM and on at 7 AM), temperature and humidity controlled vivarium. Mice were 
acclimatized for 1 week upon arrival and had ad libitum access to water and regular mouse chow 
for 11 days. Since we are performing an acute diet study, we needed the animals to acclimatize 
to the oral gavage procedure. We acclimatized the mice to this procedure by gavaging them with 
tap water for 2 days prior to the experimental day. On the 12
th
 day, the mice were fasted for 4 
hours and were gavaged with a specific liquid diet. The mice were divided into 4 groups: High 
protein (Isopure Protein Drink, Zero Carb - Mango peach flavor; Nature’s Best, Clifton Park, 
New York; n=7), High fat (Splendido; Cold Pressed Extra Virgin Olive oil; President’s Choice, 
Canada; n=7), High carbohydrate (D-Glucose; BioShop; Catalogue# GLU501.500; n=7), and 
Water (tap water; n=7).  On the day of the study, 200 microliters of the above nutrients/water 
was administered to the mice by oral gavage. Blood glucose readings was taken at 0, 5, 10, 15, 
20, 30, 60, 90 and 120 minutes, and blood was collected at 15, 30, 60, and 120 minutes for 
ELISA analysis to determine circulating levels of NUCB2/nesfatin-1. Tissues (stomach, small 
intestine [duodenum], large intestine and liver) were collected from each mouse upon 
termination of the study (deep isoflurane euthanasia followed by cervical dislocation). To 
maintain consistency, the timing and the duration of each experiment, surgeries and sample 
collection were kept constant for all studies. 
4.2.4 Total RNA Extraction and cDNA Synthesis 
Cells or tissues were collected from each study to compare NUCB2 mRNA expression. 
From the mice that underwent the chronic diet study, tissues (stomach, small intestine, large 
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intestine and liver) were harvested immediately after euthanasia. Total RNA was extracted from 
the MGN3-1 cells and tissues, using the TRIzol
®
 RNA isolation reagent (Invitrogen). RNA 
purity was validated by optical density (OD) absorption ratio (OD 260 nm/OD 280 nm) using a 
NanoDrop 2000c (Thermo, Vantaa, Finland). Only samples with an absorption ratio greater than 
1.8 were used for cDNA synthesis. Synthesis of cDNAs was conducted using iScript™ cDNA 
synthesis kit as directed by the manufacturer (BioRad, Canada).  
4.2.5 RT-PCR and Quantitative Real Time-PCR 
RT-PCR and qRT-PCR for NUCB2, ghrelin, and RT-PCR for PC 1/3 and PC 2 were 
conducted as per conditions outlined in Table 4.1, using the CFX Connect Real-Time PCR 
Detection System (Bio-Rad). For the qRT-PCR analysis, mRNA expression of NUCB2 was 
normalized using beta-actin as a housekeeping gene. PCR products for NUCB2 in the stomach, 
liver and large intestine and these genes (NUCB2, ghrelin, PC 1/3 and PC 2) in the MGN3-1 
cells were electrophoresed in 1% agarose gel to verify transcripts amplified. Based on previous 
studies (Gonzalez et al., 2011), we used beta-actin as an internal control to normalize the signal 
of NUCB2 mRNA. When using total RNA where mRNA quantification was very precise, the 
critical threshold values for beta-actin showed no variability. Relative NUCB2 mRNA 
expression was normalized with beta-actin from the same sample according to the Livak method 
(Schmittgen and Livak, 2008). 
 
 
 
 
 
112 
 
Table 4.1. Sequences of forward and reverse primers, and the conditions employed in PCR and 
qRT-PCR analyses of the expression of mRNAs of interest 
Gene Sequence (5' to 3') PCR conditions [temperature (°C)/time (s)] 
NUCB2 F: CCAGTGGAAAATGCAAGGAT 35 cycles of 95°/10; 60°/30; 73°/30  
R: GCTCATCCAGTCTCGTCCTC 
Ghrelin F: GCATGCTCTGGATGGACATG 35 cycles of 95°/10; 50.5°/30; 73°/30  
R: CCTGATCTCCAGCTCCTC 
PC1/3 F: AGTGGAAAAGATGGTGAATG 35 cycles of 95°/10; 48.1°/30; 73°/30 
R: CTCCTCATTTAGGATGTCCA 
PC2 F: AATGGGAGGAAGAGGAATC 35 cycles of 95°/10; 50.5°/30; 73°/30 
R: TTGTTTTGAGGGTCAGTACC 
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4.2.6 Immunocytochemistry and Microscopy 
MGN3-1 cells were cultured in a Labtek
TM
 Chamber Slide System
TM
 (Nalge Nunc 
International, Rochester, NY) and were allowed to grow to near confluency. Cells were washed 
with 1X phosphate buffer solution (PBS; 2 x 5 minutes, 25
o
C) and fixed in a 4% 
paraformaldehyde (PFA) solution in 1X PBS for 10 minutes at 25
o
C, followed by another wash 
with 1X PBS (3 x 5 minutes, 25
o
C). The fixed cells were permeabilized in a solution of 0.3% 
Triton-X (Bioshop, Burlington, Ontario, Canada) in 1X PBS for 5 minutes at room temperature. 
Slides were incubated in blocking buffer containing 10% goat serum in 1X PBS for 1 hour at 
room temperature. Cells were then incubated in primary antibody (Table 4.2) at 4
o
C overnight. 
Slides were washed with PBS (3 x 5 minutes, 25
o
C) and incubated with secondary antibody 
(Table 4.2; the PC1/3 antibody was a generous gift from Dr. Iris Lindberg, University of 
Maryland School of Medicine) for 4 hours at room temperature. Finally, slides were washed with 
PBS (3 x 5 minutes, 25
o
C) and mounted with Vectashield® mounting medium containing 4’, 6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlington, Ontario, Canada).  
Cells were viewed using a Nikon Eclipse-Ti inverted fluorescence microscope (Nikon, 
Mississauga, Ontario, Canada) and images were captured using a Nikon DS-Qi1MC camera 
(Nikon). Images were analyzed using NIS-Elements basic research software (Nikon) on a Dell 
HP Workstation. Images shown are representative cells stained for ghrelin, NUCB2, PC 1/3 and 
PC2. For high resolution imaging, the cells were viewed, analysed and images captured using a 
Leica™ TCS SP5 confocal microscope. 
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Table 4.2. Antibodies used for immunofluorescence microscopy  
Antibody  Dilution  Raised In  Manufacturer/Source  
Ghrelin  1:100  Mouse  Abcam, Cambridge, MA, USA  
Nesfatin-1  1:100  Rabbit  Phoenix Pharmaceuticals, Burlingame, CA, USA 
PC1/3  1:100  Rabbit  Dr. Iris Lindberg, University of Maryland, USA  
PC2  1:100  Rabbit  Abcam, Cambridge, MA, USA  
Anti-Rabbit (Texas 
Red)  
1:100  Goat  Vector Laboratories, Burlington, ON, Canada  
Anti-Mouse (FITC)  1:100  Goat  Abcam, Cambridge, MA, USA  
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4.2.7 Western Blot Analysis, Immunohistochemistry and Fluorescence Microscopy 
 
For confirming the presence of nucleobindin-2 (NUCB2) in the intestine and liver, 3 
months old C57BL/6 male mice were used. Briefly, liver, and small and large intestines were 
collected, and separated for Western analysis or immunohistochemistry. Tissues for Western blot 
homogenized in T-PER® tissue protein extraction reagent (Thermo Scientific, #78510) followed 
protein concentration determination by Bradford assay. The samples were prepared in 1X 
Laemmli buffer containing 0.2% 2-mercaptoethanol (Bio-Rad, #161-0737 and -0710) and 
subsequently were boiled at 95°C for 5min followed by vortexing. The whole sample volume 
(20µL) each containing 50 µg protein or synthetic rat nesfatin-1 (ABGENT, 1µg/µL; previously 
used in 4, 29) was loaded on a gel, and run in a Mini-PROTEAN® TGX™ 8-16% gradient gel 
(Bio-Rad, #456-1104). After separation, the proteins were transferred to a 0.2 µm BioTrace™ 
nitrocellulose membrane (PALL Life Sciences, #27377-000) and then the membrane was 
blocked in 1X RapidBlock™ solution (AMRESCO, #M325). NUCB2 protein detection was 
performed using rabbit anti-nesfatin-1 (Catalogue number H-003-22; 1:500 dilution; Phoenix 
Pharmaceuticals, California) and GAPDH protein was detected by use of rabbit antiserum 
directed against mouse GAPDH (AbDSerotec®, #AHP1628) diluted 1:1000. As secondary 
antibody, goat anti-rabbit IgG (H+L) HRP conjugate (Bio-Rad, #170-6515) diluted 1:3000 was 
used. For protein visualization the membrane was incubated for 5 min in Clarity™ Western ECL 
substrate (Bio-Rad, #170-5061) and imaged using ChemiDoc™ MP imaging system (Bio-Rad, 
#170-8280) with chemiluminescence detection. Membrane stripping in between protein detection 
was conducted using Restore™ PLUS western blot stripping buffer (Thermo Scientific, #46430). 
Precision plus protein™ dual xtra standards (Bio-Rad, #161-0377) were used as molecular 
weight markers. 
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For immunohistochemical studies, the tissues collected were fixed in 4% formaldehyde 
for 24 hours at 4
o
C. Fixative was replaced with ethanol (three 70% ethanol), each followed by a 
10 minute incubation at 4
o
C. Tissues were then stored in 70% ethanol at 4
o
C and were processed 
and sectioned at the Prairie Diagnostic Services Inc. (PDS Inc., Western College of Veterinary 
Medicine, University of Saskatchewan). Paraffin sections of 4 µm thickness were prepared for 
immunostaining. These sections were deparaffinized with xylene (incubated twice in 100% 
xylene; 5 minutes, 25
o
C) and rehydrated in a graded ethanol series (incubated twice in 100% 
ethanol, and once in each 95% ethanol, 70% ethanol, 50% ethanol; 2 minutes each, 25
o
C). The 
sections were then incubated with 3% hydrogen peroxide in distilled water to block endogenous 
peroxidase activity (30 minutes at room temperature). The sections were then blocked with 
serum-free protein block reagent (DAKO® Corporation, California) for 10 minutes before being 
incubated with primary antibodies. These sections were then incubated with rabbit anti-nesfatin-
1 (Catalogue number H-003-22; 1:500 dilution; Phoenix Pharmaceuticals, California) for 24 
hours at room temperature. All slides were subsequently washed three times with 1x PBS and 
incubated with goat anti-rabbit Texas Red® IgG (Red-Nesfatin-1; Catalogue number TI-1000; 
1:100 dilution; Vector Laboratories, California) secondary antibody for 1 hour at room 
temperature.  All primary and secondary antibodies were diluted in antibody diluent reagent 
(DakoCytomation®, Mississauga, Ontario). The slides were washed three times with 1x PBS and 
seven times with distilled water. Finally, the slides were mounted with Vectashield® medium 
that contain nuclear dye DAPI (Blue; Vector Laboratories, Burlingame, California). Sections 
were viewed under a Nikon Eclipse Ti-E inverted fluorescence microscope (Nikon Canada, 
Mississauga, Canada). Images were captured using a Nikon DS-QI1MC cooled monochrome 
camera connected to a Dell HP Workstation computer and NIS elements basic research imaging 
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software (Nikon Canada, Mississauga, Canada). Only representative images of small and large 
intestine staining for NUCB2/nesfatin-1 with DAPI are shown in the results section.  
4.2.8 Nesfatin-1/NUCB2 Levels in Serum and Media 
 
To investigate nutrient dependent changes in NUCB2/nesfatin-1 secretion from MGN3-1 
cells, media was collected after specific incubation periods. In order to prevent cell debris, 
samples were centrifuged (13000 rpm for 10 minutes at 4
o
C) and the top 700 µL was stored at 
−20oC until nesfatin-1 measurement. For measuring circulating NUCB2/nesfatin-1, blood was 
collected at 7 a.m (soon after the light phase begins), 1 p.m. (middle of the light phase) and at 7 
p.m (prior to the commencement of the dark phase). Blood samples were allowed to clot on ice, 
and serum was separated by centrifugation (7000 rpm for 9 minutes at 4
o C) and stored at −20o C, 
until assays were conducted. NUCB2/Nesfatin-1 secretion levels in the media were measured 
using the Nesfatin-1 (1–82) (Rat) ELISA kit (Catalogue number EK-003-22, Phoenix 
Pharmaceuticals Inc., California). The limit of assay sensitivity was 1.2 ng/mL for nesfatin-1, 
with detectable range from 0.1-1000 ng/mL. The amount of immunoreactive material was 
determined using a non-linear regression curve-fit, which was used to quantify and compare the 
concentration of NUCB2/nesfatin-1 secretion in the serum and media samples. 
 
4.2.9 NUCB2/Nesfatin-1 Levels in Serum and Media and Total Ghrelin levels In 
media 
 
To investigate nutrient dependent changes in NUCB2/nesfatin-1 and total ghrelin 
secretion from MGN3-1 cells, media was collected after specific incubation periods. In order to 
prevent cell debris, samples were centrifuged (13000 rpm for 10 minutes at 4
o
C) and the top 700 
µL was stored at −20oC until NUCB2/Nesfatin-1 and total ghrelin measurement. Blood samples 
were allowed to clot on ice, and serum was separated by centrifugation (7000 rpm for 9 minutes 
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at 4
o C) and stored at −20o C, until assays were conducted. NUCB2/Nesfatin-1 secretion levels in 
the serum and media were measured using the Nesfatin-1 (1–82) (Rat) ELISA kit (Catalogue 
number EK-003-22, Phoenix Pharmaceuticals Inc., California). The limit of assay sensitivity was 
1.2 ng/mL for nesfatin-1, with detectable range from 0.1-1000 ng/mL. Similarly, the total ghrelin 
secretion levels in the media was measured using the Ghrelin (Rat, Mouse) EIA kit (Catalogue 
number EK-031-31, Phoenix Pharmaceuticals Inc, California). The limit of assay sensitivity was 
1.16 ng/mL for total ghrelin, with detectable range from 0-100 ng/mL. The amount of 
immunoreactive material was determined using a non-linear regression curve-fit, which was used 
to quantify and compare the concentration of NUCB2/nesfatin-1 secretion in the serum and 
media samples. 
4.2.10 Statistical Analysis 
Analyses of the quantified qRT-PCR and ELISA data were conducted using One-Way 
ANOVA followed by Tukey’s multiple comparison test. GraphPad Prism® version 5 (GraphPad 
Software Incorporated, San Diego, CA, USA) was used for statistical analyses and graphs. 
Significance was assigned when p<0.05. Data are expressed as mean ± SEM. 
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4.3 Results 
4.3.1 NUCB2, PC 1/3 and PC 2 mRNAs are expressed in MGN3-1 cells and NUCB2 
mRNA is expressed in the stomach, liver, small intestine and large intestine of 
male mice 
We identified expression of NUCB2 (202 bp), prohormone convertase 1/3 (400 bp), and 
prohormone convertase 2 (406 bp) mRNAs in MGN3-1 cells (Figure 4.1A). NUCB2 (202 bp) 
mRNA expression was also detected in the stomach, liver, small intestine and large intestine of 
male C57/BL6 mice (Figure 4.1B). Absolute levels of NUCB2 mRNA expression in the 
stomach was higher than NUCB2 mRNA expression in the liver, small intestine and large 
intestine (Figure 4.1C).  
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Figure 4.1 NUCB2, PC 1/3 and PC 2 mRNAs are expressed in MGN3-1 cells and NUCB2 
mRNA is expressed in the stomach, liver, small intestine and large intestine of male mice 
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Figure 4.1. NUCB2, PC1/3 and PC2 mRNA Expression in MGN3-1 cells (A) and NUCB2 
mRNA Expression in the Stomach, Liver, Small and Large Intestine from Male C57BL/6 Mice 
Tissues (B and C). Beta-Actin (β-Actin), nucleobindin-2 (NUCB2; 202 bp), prohormone 
convertase 1/3 (PC 1/3; 400 bp), and prohormone convertase 2 (PC 2; 406 bp) mRNAs were 
identified in MGN3-1 cells. No expression of these mRNAs was found in the RT-PCR reaction 
devoid of the cDNA template (A). Beta-Actin (β-Actin) and nucleobindin-2 (NUCB2; 202 bp) 
mRNAs expression were identified in the stomach, liver, small and large intestine from mice. No 
NUCB2 mRNA expression was found in PCR reactions devoid of the cDNA template (B). 
Relative abundance of NUCB2 mRNA expression normalized to β-Actin in the stomach, liver, 
small and large intestine is shown in (C). Letter “b” denotes significant difference from “a”, 
p<0.05, One-Way ANOVA followed by Tukey’s multiple comparison test. 
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4.3.2 MGN3-1 cells are immunopositive for ghrelin, NUCB2/nesfatin-1, PC1/3 and 
PC2 
Fluorescence microscopy displayed MGN3-1 cells stained with anti-nesfatin-1 antibody 
(Texas-Red; Figure 4.2B) and anti-ghrelin antibody (FITC-Green; Figure 4.2A) showed clear co-
localization (Yellow; Figure 4.2C) of nesfatin-1 and ghrelin immunoreactivity. However, some 
ghrelin positive cells were not immunoreactive for nesfatin-1 (Figure 4.2C). MGN3-1 cells 
showed PC 1/3 immunoreactivity (Texas Red; Figure 4.2D) and PC 2 immunoreactivity (Texas 
Red, Figure 4.2E). DAPI (Blue) stained the nucleus of all cells including those cells not positive 
for the proteins studied. Control slides stained with secondary antibody alone (Figure 4.2F) had no 
immunoreactivity. Confocal imaging showed MGN3-1 cells stained with anti-nesfatin-1 antibody 
(Texas-Red; Figure 4.3A) and anti-ghrelin antibody (FITC-Green; Figure 4.3B) showed clear co-
localization (Yellow; Figure 4.3C) of nesfatin-1 and ghrelin immunoreactivity. Negative control is 
stained with only secondary antibodies alone (Figure 4.3D). 
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Figure 4.2 MGN3-1 cells are immunopositive for ghrelin, NUCB2/nesfatin-1, PC1/3         
and PC2 
 
Figure 4.2. MGN3-1 Cells are Immunopositive for NUCB2/Nesfatin-1, Ghrelin, PC 1/3 and  
PC 2. Immunocytochemical staining of MGN3-1 cells for ghrelin immunoreactivity (A; FITC-
Green), nesfatin-1 immunoreactivity (B; Texas-Red) and the nuclear stain DAPI. A merged 
image showing co-localization of nesfatin-1 and ghrelin immunoreactivity is shown in (C; 
Yellow). Immunocytochemical staining of MGN3-1 cells for PC 1/3 immunoreactivity (D; 
Texas-red), PC 2 immunoreactivity (E; Texas-red) and the nuclear stain DAPI. No primary 
antibody controls are shown in (F) for nesfatin-1 and ghrelin, respectively. Images taken at 40X 
magnification. Scale bar = 20 μm. 
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Figure 4.3 MGN3-1 cells are immunopositive for ghrelin, NUCB2/nesfatin-1, PC1/3        
and PC2 
 
Figure 4.3. NUCB2/Nesfatin-1 co-localizes with ghrelin in MGN-3 cells. Confocal micrographs 
of MGN-3 cells stained for NUCB2/nesfatin-1 (A; Texas-Red) and ghrelin (B; FITC-Green). 
Merged image of A and B showing co-localization of NUCB2/nesfatin-1 and ghrelin 
immunoreactive cells (C; Yellow). No primary antibody negative control labeled only with 
secondary antibodies (D). Nuclei are stained with DAPI (Blue; A, B and C). Images were 
merged using Image J™ PC-based software. Scale bar = 25 μm. 
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4.3.3 NUCB2 protein expression in large intestine, small intestine and liver from male 
mice 
NUCB2 protein is expressed in the large intestine, small intestine and liver from male 
mice showing distinct band for NUCB2 corresponding to approximately 50 KDa. Rat nesfatin-1 
peptide used as a positive control is shown as a distinct band corresponding to approximately 10 
kDa (Figure 4.4A; left image). However, no bands showing the fully processed nesfatin-1 were 
visible at 10 kDa in the tissue samples (Figure 4.4A; left image). We also found bands of 
approximately 47 kDa underneath the 50 kDa band in the small intestine and liver, but not in the 
large intestine (Figure 4.4A; left image). A distinct band for GAPDH used as the control house-
keeping gene is observed at 37 kDa shown in all tissues (Figure 4.4A; right image). 
NUCB2/nesfatin-1 immunoreactivity is found in the mucosal cells of small intestine (Figure 
4.4B; left image) and large intestine (Figure 4.4B; right image). 
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Figure 4.4 NUCB2 protein expression in large intestine, small intestine and liver                
from male mice 
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Figure 4.4. NUCB2 is expressed in the small intestine, large intestine and liver of male C57BL/6 
mice. Tissues show distinct bands for NUCB2/nesfatin-1 corresponding to 50 kDa. Rat nesfatin-
1 (Custom synthesized, ABGENT, 1µg/µL) was used as a positive control which is shown as a 
distinct band corresponding to 10 kDa (A; Left Image). Mouse glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) is uniformly expressed in liver, small and large intestine. The blots 
that were loaded with 50µg of total protein/well previously for NUCB2 protein detection were 
stripped and re-blocked with mouse GAPDH primary antibody. Representative blot (n = 4 
independent experiments) showing distinct bands for GAPDH corresponding to 37 kDa (A; 
Right Image). Mucosal cells showing NUCB2/nesfatin-1 (Texas-Red) immunoreactivity, and 
DAPI are found in the small intestine (B; left image) and large intestine (B; right image) from 
male mice. Arrows point to cells that are immunopositive for NUCB2/nesfatin-1 and shows 
distinct DAPI-stained nuclei. Representative images were taken of 4 slides (8 sections/tissue) 
from three adult male mice. Scale bar = 100 μm. 
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4.3.4 Effects of glucose and L-Tryptophan on NUCB2 mRNA expression in, and 
NUCB2/nesfatin-1secretion from MGN3-1 cells 
Cells incubated at 100 mM glucose DMEM had a higher NUCB2 mRNA expression than 
cells incubated at 5.6, 25 and 50 mM DMEM glucose concentrations at 1 hour post-incubation 
(Figure 4.5A).  At 2 hours post-incubation, cells incubated at 100 mM DMEM were 
significantly higher in NUCB2 mRNA expression than cells incubated at 5.6 and 50 mM glucose 
DMEM (Figure 4.5C). At 1 hour (Figure 4.5B) and 2 hours (Figure 4.5D), there were no 
significant differences in NUCB2/nesfatin-1 secretion. NUCB2 mRNA expression was 
significantly higher in cells incubated at 10 mM L-Tryptophan (Figure 4.5E) in comparison to 
cells incubated at 0.07 and 1.0 mM L-Tryptophan. NUCB2/nesfatin-1 secretion from cells 
incubated at 1.0 and 10.0 mM L-Tryptophan were significantly higher than cells incubated at 0.7 
mM L-Tryptophan (Figure 4.5F). 
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Figure 4.5 Effects of glucose and L-Tryptophan on NUCB2 mRNA expression in, and 
NUCB2/nesfatin-1secretion from MGN3-1 cells 
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Figure 4.5. NUCB2 mRNA Expression (A, C, E) and NUCB2/nesfatin-1 Secretion (B, D, F) 
from MGN3-1 Cells Incubated with Different Concentrations of Glucose (5.6 mM, 25 mM, 50 
mM and 100 mM) at Various Incubation Periods (1 Hour and 2 Hours), and with Different 
Concentrations of L-Tryptophan (0.07 mM, 1 mM, 10 mM; 4 Hours). MGN3-1 cells incubated at 
100 mM glucose had a significant increase in NUCB2 mRNA expression at 1 hour post-
incubation (A; p<0.05), but no significant differences was found in nesfatin-1 secreted into the 
media from the same cells (B). Similarly, glucose caused a dose dependent increase in NUCB2 
mRNA expression at 2 hours post-incubation (C; p<0.5) without causing any changes in 
nesfatin-1 secretion (D). n= 9 wells/concentration pooled from 3 different studies. MGN3-1 cells 
incubated at 10 mM L-Tryptophan had a significant increase in NUCB2 mRNA expression than 
cells incubated at 0.07 mM and 1 mM L-Tryptophan (E; p<0.05). Nesfatin-1 secretion 
significantly increased from cells incubated at 1 mM and 10 mM L-Tryptophan than 0.07 mM L-
Tryptophan (F; p<0.05). n= 12 wells/concentration pooled from 3 different studies. Letters b and 
c denote significant differences found between control (a) and various treatment groups, using 
One Way ANOVA followed by Tukey’s Multiple Comparison Test. There are no significant 
differences between groups marked by same letters. 
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4.3.5 Effect of linolenic acid, octanoic acid and oleic acid on NUCB2 mRNA 
expression in, and NUCB2/nesfatin-1 secretion from MGN3-1 cells 
We found NUCB2 mRNA expression significantly reduced in cells treated with 1, 10, 
and 100 µM oleic acid (Figure 4.6E) in comparison to the control. No changes in NUCB2 
mRNA were observed in cells treated with linolenic (Figure 4.6A) and octanoic acid (Figure 
4.6C). Further, NUCB2/nesfatin-1 secretion was unaltered in cells treated with different doses of 
linolenic acid (Figure 4.6B), octanoic acid (Figure 4.6D), and oleic acid (Figure 4.6F). 
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Figure 4.6 Effect of linolenic acid, octanoic acid and oleic acid on NUCB2 mRNA 
expression in, and NUCB2/nesfatin-1 secretion from MGN3-1 cells 
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Figure 4.6. NUCB2 mRNA Expression (A, C, E) and NUCB2/nesfatin-1 Secretion (B, D, F) 
from MGN3-1 Cells Incubated for 4 Hours with Different Concentrations of Linolenic Acid, 
Octanoic Acid and Oleic Acid (0 µM, 1 µM, 10 µM, 100 µM). No change in NUCB2 mRNA 
expression (A, C) and nesfatin-1 secretion (B, D) when MGN3-1 cells were incubated with 
different concentrations of linolenic acid and octanoic acid. MGN3-1 cells incubated at 1, 10, 
100 µM oleic acid had a significant decrease in NUCB2 mRNA expression (E; p<0.05), but no 
significant difference was found in nesfatin-1 secretion at 4 hours post-incubation (F; p<0.05). 
n= 9 wells/concentration pooled from 3 different studies. Different letters (a and b) shows 
significant differences found between control and various treatment groups, using One Way 
ANOVA followed by Tukey’s Multiple Comparison Test. There are no significant differences 
between groups marked by same letters. 
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4.3.6 Effect of L-tryptophan, linolenic acid, octanoic acid and oleic acid 
independently on ghrelin mRNA expression in, and total ghrelin secretion from 
MGN3-1 cells 
No changes in ghrelin mRNA (Supporting Figure S4.1A) and total ghrelin secretion 
(Supporting Figure S4.1B) were found when cells were treated with different doses of glucose 
post 1 hour incubation. Ghrelin mRNA expression was significantly higher in cells incubated at 
1 mM L-Tryptophan (Figure 4.7A) in comparison to cells incubated at 0.07 and 10 mM L-
Tryptophan. No significant difference in total ghrelin secretion from cells treated with different 
doses of L-Tryptophan (Figure 4.7B). We found no change in ghrelin mRNA expression 
(Figure 4.7C), but total ghrelin secretion was high from cells incubated at 100 µM linolenic acid 
(Figure 4.7D) in comparison to control, 1 and 10 µM doses. No changes in ghrelin mRNA 
(Figure 4.7E) and total ghrelin secretion (Figure 4.7F) were found when cells were treated with 
different doses of octanoic acid. Meanwhile, ghrelin mRNA (Figure 4.7H), and total ghrelin 
secretion (Figure 4.7I) were significantly higher in cells treated with 100 µM oleic acid, 
compared to the control, 1 and 10 µM oleic acid.  
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Supporting Figure S4.1 
Ghrelin mRNA Expression (A) and Total Ghrelin Secretion (B) from MGN3-1 Cells 
Incubated for 1 Hour with Different Concentrations of Glucose (5.6 mM, 25 mM, 50 mM 
and 100 mM). No changes in ghrelin mRNA and total ghrelin secretion were found when cells 
were treated with different doses of glucose post 1 hour incubation.  
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Figure 4.7 Effect of L-tryptophan, linolenic acid, octanoic acid and oleic acid independently 
on ghrelin mRNA expression in, and total ghrelin secretion from MGN3-1 cells 
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Figure 4.7. Ghrelin mRNA Expression (A, C, E, H) and Total Ghrelin Secretion (B, D, F, I) 
from MGN3-1 Cells Incubated for 4 Hours with Different Concentrations of L-Tryptophan (0.07 
mM, 1 mM, 10 mM) and with Different Concentrations of Linolenic Acid, Octanoic Acid and 
Oleic Acid (0 µM, 1 µM, 10 µM, 100 µM). MGN3-1 cells incubated at 1 mM L-Tryptophan had 
a significant increase in Ghrelin mRNA expression than cells incubated at 0.07 mM and 10 mM 
L-Tryptophan (A; p<0.05). No change in total ghrelin secretion (B) when MGN3-1 cells were 
incubated with different concentrations of L-Tryptophan. n= 12 wells/concentration pooled from 
3 different studies. No change in ghrelin mRNA expression (C), but a significant increase in total 
ghrelin secreted into the media from the same cells incubated at 100 µM linolenic acid (D; 
p<0.05). No change in ghrelin mRNA expression (E) and total ghrelin secretion (F) when 
MGN3-1 cells were incubated with different concentrations of octanoic acid. A significant 
increase in ghrelin mRNA expression (H; p<0.05) and total ghrelin secreted into the media from 
the same cells incubated at 100 µM oleic acid (I; p<0.05). n= 9 wells/concentration pooled from 
3 different studies. Different letters shows significant differences found between control and 
various treatment groups, using One Way ANOVA followed by Tukey’s Multiple Comparison 
Test. There are no significant differences between groups marked by same letters. 
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4.3.7 Chronic effects of nutrients on NUCB2 mRNA expression and serum 
NUCB2/nesfatin-1 in mice 
The body weight, food intake and blood glucose profile of mice fed on various diets are 
shown in Supporting Figure S4.2. Mice fed on a high fat diet had significantly low expression 
of NUCB2 mRNA in the stomach compared to those fed on a control, high protein or high 
carbohydrate diets (Figure 4.8A). There was no significant difference in the expression of 
NUCB2 mRNA in the small intestine between mice fed on a control, high protein, high 
carbohydrate or high fat diets (Figure 4.8B). Mice fed on the high protein and high fat diets have 
comparatively low expression of NUCB2 mRNA in the large intestine than mice fed on control 
or high carbohydrate diets (Figure 4.8C). Mice fed on a high protein diet had a significant low 
expression of NUCB2 mRNA in the liver than mice fed on the other diets (Figure 4.8D). At 7 
a.m, there were no differences in serum nesfatin-1/NUCB2 levels in mice fed different diets 
(Figure 4.9A). At 1 p.m, the high carbohydrate diet fed mice had significantly higher serum 
nesfatin-1/NUCB2 in circulation (Figure 4.9B). Serum nesfatin-1/NUCB2 was significantly 
lower in mice fed high carbohydrate, high protein or high fat, compared to control diet fed mice 
at 7 p.m (Figure 4.9C). 
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Supporting Figure S4.2 
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Weekly Body Weight (A), Blood Glucose (B) and Food Intake to Body Weight Ratio (C) on 
Mice Fed Chronically on Various Nutrient Diets for 17 Weeks. Mice fed on a control diet and 
a high fat diet had an increase in the body weight compared to mice fed with a high protein and a 
high carbohydrate diet (A; p < 0.05). Mice fed on a high protein diet and high carbohydrate diet 
had lower weekly blood levels than mice fed a control and high fat diet (B; p < 0.05). Mice fed 
on a control diet and a high fat diet was had an increase in the ratio of food intake to body weight 
than mice fed with a high protein and a high carbohydrate diet (C; p<0.05). Mice (n= 6-7 
mice/group) had ad libitum access to water and their specific diet, control diet, high carbohydrate 
diet, high protein diet, and high fat diet. Significant difference was found between the various fed 
groups, using One Way ANOVA followed by Tukey’s Multiple Comparison Test. 
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Figure 4.8 Chronic effects of nutrients on NUCB2 mRNA expression in mice 
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Figure 4.8. NUCB2 mRNA Expression in the Stomach (A), Small Intestine (Duodenum; B), 
Large Intestine (C) and Liver (D) of Mice Fed Various Diets. NUCB2 mRNA was significantly 
reduced in the stomach (A; p<0.05) from mice fed on a high fat diet than mice fed on the control, 
high protein and high carbohydrate diet (n=5-6 mice/group). No significant difference were 
found in NUCB2 mRNA expression in the small intestine from mice fed on various diets [B; 
(CD; n=5), (HP; n=7), (HC; n=7), (HF; n=7)]. Mice fed on high protein and high fat diets had 
significantly low expression of NUCB2 mRNA in the large intestine (C; p<0.05) than mice fed 
on the control and high carbohydrate diet [(CD; n=6), (HP; n=7), (HC; n=6), (HF; n=7)]. Mice 
fed on a high protein diet had low expression of NUCB2 mRNA in the liver (D; p<0.05) than 
mice fed on other diets [(CD; n=6), (HP; n=7), (HC; n=7), (HF; n=7)]. Different letters (a and b) 
shows significant differences found between the various fed groups, using One Way ANOVA 
followed by Tukey’s Multiple Comparison Test. There are no significant differences between 
groups marked by same letters. 
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Figure 4.9 Chronic effects of nutrients on serum NUCB2/nesfatin-1 in mice 
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Figure 4.9. Serum NUCB2/Nesfatin-1 Levels at 7 a.m., 1 p.m., and 7 p.m. in Mice Fed Various 
Diets. Mice were chronically fed on a control diet (n=6), high carbohydrate diet (n=7), high 
protein diet (n=7), and high fat diet (n=7). No significant difference in serum NUCB2/nesatin-1 
levels was found in mice fed on different diets at 7 a.m. (A). High carbohydrate diet fed mice 
had significantly higher serum NUCB2/nesatin-1 in circulation at 1 p.m. (B; p<0.05). Serum 
NUCB2/nesatin-1 was significantly lower in mice fed high carbohydrate, high protein or high 
fat, compared to control diet fed mice at 7 p.m. (C; p<0.05). Different letters (a and b) shows 
significant differences found between the various fed groups, using One Way ANOVA followed 
by Tukey’s Multiple Comparison Test. There are no significant differences between groups 
marked by same letters. 
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4.3.8 Acute effects of nutrients on NUCB2 mRNA expression, blood glucose and 
serum NUCB2/nesfatin-1 in mice 
There were no significant changes in the expression of NUCB2 mRNA in the stomach 
(Figure 4.10A), small intestine (Figure 4.10B), large intestine (Figure 4.10C) and liver (Figure 
4.10D) between mice fed on a high protein, high carbohydrate, high fat or water. We found that 
the group gavaged with the glucose diet had significant high blood glucose levels compared to 
the groups gavaged with water, high protein and high fat liquid diets (Figure 4.11A). In order to 
validate blood glucose tolerance in each group during the oral gavage study, we analyzed the 
area under the curve from 0- 30 minutes. We found that the group gavaged with glucose had a 
significant increase in the concentration of blood glucose levels in the initial 30 minutes post-
gavage. During the intra-peritoneal glucose tolerance test, NUCB2/nesfatin-1 levels in the high 
fat diet gavaged mice at 15, 30, 60, 120 minutes were significantly higher compared to mice fed 
with water, high protein and high carbohydrate diet, at all four time points tested (Figure 4.11B).  
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Figure 4.10 Acute effects of nutrients on NUCB2 mRNA expression NUCB2/nesfatin-1         
in mice 
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Figure 4.10. NUCB2 mRNA Expression in the Stomach (A), Small Intestine (Duodenum; B), 
Large Intestine (C) and Liver (D) of Mice gavaged with water, high protein, high carbohydrate, 
high fat and the No Gavage Group (n=7 mice/group). No significant differences were found in 
NUCB2 mRNA in the stomach of mice gavaged with various liquid diets and no gavage group. 
Same letters (a) indicate no significant differences found between the various groups, using One 
Way ANOVA followed by Tukey’s Multiple Comparison Test. 
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Figure 4.11 Acute effects of nutrients on blood glucose and serum NUCB2/nesfatin-1 in 
mice 
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Figure 4.11. Blood Glucose and Serum NUCB2/Nesfatin-1 in mice during acute administration 
of various liquid diets and in no-gavage group.  (A) Fold change in blood glucose measured 
during an oral gavage study in mice gavaged with a specific liquid diet, divided into 5 groups: 
high protein (n=7), High fat (n=7), High carbohydrate (n=7), water (n=7) and a no gavage group 
(n=7). Mice gavaged with the high carbohydrate liquid diet had high concentrations of blood 
glucose compared to the no-gavage group and the groups gavaged with water, high protein and 
high fat liquid diets (p < 0.05, ANOVA followed by Tukey’s Multiple Comparison Test). Blood 
glucose concentration - Area under the Curve from 0-30 measured during an oral gavage study in 
mice gavaged with a specific liquid diet, divided into 4 groups: high protein, high fat, high 
carbohydrate, and water (n= 7 mice/group). Letter a denotes no difference between the groups 
gavaged with water, high protein and high fat liquid diet. Letter b denotes that the high 
carbohydrate group had significantly elevated glucose levels compared to high protein, high 
carbohydrate, high fat and water gavaged mice during 0-30 minutes post-administration (p < 
0.05, One-Way ANOVA followed by Tukey’s Multiple Comparison Test). (B) Secretion profile 
representing circulating levels of NUCB2/Nesfatin-1 in mice gavaged with a specific liquid diet, 
divided into 4 groups: high protein, high fat, high carbohydrate, and water (n= 7 mice/group). 
Letter a denotes no difference in serum NUCB2/Nesfatin-1 levels between mice gavaged with 
water, high protein, high carbohydrate, high fat liquid diets and the no-gavage group within the 
four time points tested. Letter b denotes that the serum nesfatin-1/NUCB2 levels in the high fat 
diet fed group was significantly higher to the levels in the control mice or mice fed other diets at 
all time points (p < 0.05, One-Way ANOVA followed by Tukey’s Multiple Comparison Test).   
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4.4 Discussion 
The first main contribution of this work was the characterization of MGN3-1 cells as a 
source of nesfatin-1 and a tool for studying the regulation of nesfatin-1 secretion. mRNAs 
encoded for NUCB2, and its processing enzymes PC 1/3 and PC 2 in MGN3-1 cells. These 
findings are supported by NUCB2, PC 1/3 and PC 2 immunoreactivity detected in the same cells. 
Further, it was determined that MGN3-1 cells colocalize both nesfatin-1 and ghrelin, an 
observation that confirmed previous findings of nesfatin-1 in the X/A ghrelin cells in the 
stomach (Stengel et al., 2009b). The cell line MGN3-1 used in this research is a pure population 
of ghrelinoma cells, and it has been characterized that these cells express prohormone 
convertases and ghrelin-O-acyl transferase (Iwakura et al., 2010). Current results, together with 
previous findings indicate that the enzyme machinery required to process NUCB2 to nesfatin-1 
is present in MGN3-1 cells. MGN3-1 cells were then used to identify how nutrients modulate 
NUCB2 synthesis and secretion. Cells incubated for 2 hours at 100 mM glucose containing 
DMEM had significantly higher NUCB2 mRNA expression than cells incubated at lower 
glucose concentrations. However, it was found that NUCB2/nesfatin-1 secretion was not 
influenced by changes in glucose concentrations introduced. Meanwhile, both NUCB2 mRNA 
expression and NUCB2/nesfatin-1 secretion were enhanced by L-Tryptophan. Since previous 
studies on nutrient regulation of hormones looked at the effects of fatty acids on protein secretion 
(Janssen et al., 2012, Hirasawa et al., 2005, Hara et al., 2009, Briscoe et al., 2003), three fatty 
acids, oleic acid, linoleic acid and octanoic acid were tested individually. Only oleic acid was 
found to inhibit NUCB2 mRNA expression, while the other two fatty acids were ineffective in 
modulating NUCB2 mRNA and NUCB2/nesfatin-1 secretion. Both in the glucose and oleic acid 
treatments, changes were found in NUCB2 mRNA expression, with no effects on nesfatin-1 
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secretion. It is possible that the NUCB2 mRNA expression and secretion in response to these 
nutrients are uncoupled in ghrelinoma cells. Further studies are required to elucidate the specific 
effectors in the transcriptional, translational and post-translational regulation of 
NUCB2/nesfatin-1 synthesis and secretion.  
Glucose inhibits ghrelin secretion from stomach endocrine cells (Sakata et al., 2012, 
Brogilo et al., 2004). In current studies using MGN3 cells, glucose was ineffective in causing 
any changes on ghrelin. Meanwhile, glucose elicited stimulatory effect on NUCB2 mRNA 
expression. The difference in our results is possibly due many differences in the experimental 
protocols, types of cells (primary cells versus cell lines) and doses used. Here, effects of amino 
acids and fatty acids on ghrelin mRNA expression and secretion were also explored. As in the 
case of NUCB2 mRNA, the expression of ghrelin mRNA expression was also significantly 
higher in cells incubated with L-Tryptophan, but at a different dose (1 mM). Meanwhile, the 
effects of some fatty acids on ghrelin appear to be the opposite of what was seen on NUCB2 
mRNA expression. Total ghrelin secretion from MGN3-1 cells incubated at 100 µM linolenic 
acid was significantly higher. In addition, ghrelin mRNA and total ghrelin secretion was 
significantly increased from cells incubated at 100 µM oleic acid. This data showed that oleic 
acid stimulated ghrelin, while suppressed nesfatin-1. While nesfatin-1 is produced in stomach 
ghrelin cells, it has been shown that nesfatin-1 is present in distinct secretory vesicles (Stengel et 
al., 2009b). Nutrient regulation of ghrelin secretion is also complex, with diverse effects in a 
tissues specific manner (Al Massadi et al., 2010, Greenman et al., 2004) In general, proteins and 
lipids decreases ghrelin secretion (Koliaki et al., 2010). Although the mechanisms by which 
nutrients are sensed by MGN3-1 cells are yet to be identified, at least in the case of fatty acids, 
that it may involve free fatty acid receptors. Other studies have identified that medium and long 
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chain fatty acids bind to G-protein coupled receptors such as GPR40 and GPR120 (Tanaka et al., 
2008, Edfalk et al., 2008). GPR40 is expressed in the brain and in the pancreatic β-cells and 
binds to free fatty acids stimulating the secretion of insulin (Liou et al., 2011). Dietary fat has 
shown to stimulate cholecystokinin (CCK) by binding to GPR40 (Tanaka et al., 2008). In 
contrast, GPR120 is expressed in the distal intestine, binding to long chain fatty acids such as α-
linolenic acid (Hara et al., 2009). Previous studies on the effects of free fatty acids in the 
enterendocrine cell line STC-1 have shown that fatty acids stimulate glucagon-like peptide-1 
(GLP-1) and CCK (Hara et al., 2009, Krause, 2000). Further studies are required to unravel the 
mechanism of nutrient regulation of nesfatin-1 in gut cells. 
A second major contribution of this work was the determination of NUCB2/nesfatin-1 
mRNA, and protein (immunoreactivity) in the liver and small and large intestines of mice. The 
quantification of NUCB2 mRNA indicated that the relative abundance of NUCB2 was much 
lower in the intestine and liver, when compared to the stomach of mice. Approximately 50 kDa 
bands representing NUCB2 was present in total protein collected from the liver, and small and 
large intestines. However, no bands of the expected 10 kDa size representing the processed 
nesfatin-1 was detected in any of the tissues tested. This result concurs with previous findings of 
a full length NUCB2 protein in the liver, and small and large intestine of male rats and ICR mice 
(Zhang et al., 2010). Meanwhile, Stengel and colleagues (2009b) were unable to find 
NUCB2/nesfatin-1 in the liver and intestinal samples collected from male Sprague Dawley rats. 
This inability to detect NUCB2 in Sprague Dawley rats is unclear. Possible reasons include 
species differences in NUCB2 expression and/or differences in the physiological status of the 
rats used in that study. Similar to both (Zhang et al., 2010, Stengel et al., 2009b) studies 
discussed above, we were unable to find the processed nesfatin-1 in any of the tissues tested. 
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Stengel and colleagues (2009b) also found a processed band of approximately 47 kDa in their 
Western blot. Similar to this, we also detected second band 3 kDa less in molecular weight 
(approximately 47 kDa) in the small intestine and liver, but not in the large intestine. As 
concluded by Stengel and colleagues (2009b), the 47 kDa band suggests that the signal peptide in 
the NUCB2 from liver and small intestine could be cleaved, and the precursor released into 
circulation. The mucosal cells of both small and large intestine showed sparsely distributed cells 
that were immunopositive for NUCB2/nesfatin-1. Whether the nesfatin-1 positive cells were 
indeed intestinal enteroendocrine cells, and nesfatin-1 actions on intestinal physiology require 
further assessment.  
Mice fed on a high fat diet had significantly lower expression of NUCB2 mRNA in the 
stomach compared to mice fed on the other diets. This was also evident in the present in vitro 
studies where MGN3-1 gastric cells had low NUCB2 mRNA expression levels when treated 
with oleic acid. The difference in the levels of NUCB2 mRNA expression could be a result of 
how various gastric cells absorb nutrients in response to chronic intake of carbohydrate and fats. 
The process by which how fats and carbohydrates are processed by gastric mucosal cells likely 
also affects endogenous nesfatin-1. Central administration of nesfatin-1 inhibits gastric acid 
secretion (Xia et al., 2012). It would be interesting to investigate enzymes that are involved in 
the digestion of carbohydrates and fat including pancreatic amylase and lipase to determine 
whether they are modulated simultaneously with NUCB2 mRNA expression in the stomach. No 
significant difference was observed in NUCB2 mRNA expression in the small intestine of 
different diet fed groups. But in the large intestine, it was found that mice fed on the high protein 
and high fat diet had comparatively lower expression of NUCB2 mRNA than mice fed on the 
control and high carbohydrate diet. NUCB2/nesfatin-1 may be involved in the absorption of 
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nutrients as well as controlling the secretion of intestinal hormones (Zhang et al., 2010). Other 
studies report NUCB2/nesfatin-1 immunoreactivity is also observed in the Brunner’s glands of 
SD rats and ICR mice (Zhang et al., 2010. These glands are involved in secreting alkaline 
products such as bicarbonate, mucus containing intestinal lipase, peptidase that could be 
influenced by nutrient absorption (Stengel et al., 2012) affecting NUCB2 gene expression.  
It was revealed that high protein fed mice had significantly lower NUCB2 mRNA 
expression in the liver, compared to mice fed other diets. Previous studies have shown that 
nesfatin-1 is a glucose dependent insulinotropic peptide (Gonzalez et al., 2011). Liver is a major 
insulin responsive tissue involved in glucose homeostasis. It has been shown that peripheral 
infusion of nesfatin-1 upregulates mRNAs encoding phosphoenolpyruvate carboxykinase 1 and 
glucose-6-phosphatase, two enzymes that are critical in hepatic gluconeogenesis in the liver 
(Gonzalez et al., 2012a). The endogenous changes in nesfatin-1 due to nutrient abundance might 
result in local changes in other liver proteins involved implicated in glucose metabolism. No 
changes in NUCB2/nesfatin-1 levels in mice were found, when sampled at 7 a.m, the onset of 
light phase. However, at 1 p.m, the mice fed high carbohydrate had the highest levels of nesfatin-
1. At 7 p.m, all mice, except the ones in the control group had significantly lower nesfatin-1 
levels. Such suppression of an anorexigen prior to the onset of feeding time is also supportive of 
the satiety role of endogenous nesfatin-1. This difference in circulating NUCB2/nesfatin-1 levels 
could be attributed to a possible circadian pattern of NUCB2/nesfatin-1 release. In the acute diet 
study, nutrients had no significant differential effects in the expression of NUCB2 mRNA in the 
stomach, small intestine, large intestine and liver of mice. As expected, the acute administration 
of a high carbohydrate diet increased blood glucose levels within the initial 30 minutes. 
However, no significant increase in NUCB2/nesfatin-1 levels in the glucose gavaged group was 
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found. Meanwhile, NUCB2/nesfatin-1 levels at 15, 30, 60, and 120 minutes post-gavage were 
significantly increased in mice fed on a high fat liquid diet. In addition, in this acute study to 
determine whether gastric distention would cause a release in NUCB2/nesfatin-1 in circulation, 
we had a no-gavage group and the group that was gavaged with water only. There was no 
difference in NUCB2/nesfatin-1 in circulation in these two control groups. This suggests that 
NUCB2/nesfatin-1 changes in circulation indeed require nutrient sensing, as water ingestion 
alone and resulting distension of gut wall did not elicit the same results. On the other hand, a 
recent study has revealed that gastric distention results to the activation of NUCB2/nesfatin-1 
expressing neurons in the nucleus of the solitary tract of rats (Bonnet et al., 2013). Overall, these 
results indicate that the nutrient elicited changes in NUCB2 expression varies depending on the 
mode of treatment and the duration of experiment.  
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4.5 Conclusion 
The study provided the first set of information on nutrient regulation of nesfatin-1. 
Present findings suggested that the effects of diets on the expression of endogenous 
NUCB2/nesfatin-1 were myriad, with specific effects on mRNA expression versus secretion, in a 
dose and time dependent manner. MGN3-1 cells were characterized as nesfatin-1 secreting cells 
with the NUCB2 processing machinery, suggesting that this cell line is useful for studying 
nesfatin-1 biology. Glucose simulated NUCB2 mRNA expression in a dose and time–dependent 
manner in MGN3-1 cells. L-Tryptophan stimulated NUCB2 mRNA expression and nesfatin-1 
secretion. From the in vivo studies, NUCB2 mRNA expression was significantly lower in the 
liver of mice fed on a high protein diet compared to mice fed other diets. High fat fed mice had a 
significant reduction in NUCB2 mRNA expression in the stomach, while high protein and high 
fat diet resulted in the attenuation of NUCB2 mRNA in the large intestine. Mice fed on the high 
protein, high carbohydrate and high fat demonstrated a post-prandial increase in 
NUCB2/nesfatin-1 secretion. These results indicated that the synthesis and secretion of nesfatin-
1 were altered by the relative amount of nutrients and such effects are dependent on the amount 
of nutrients, tissues and time of the day or duration of treatment. While such variations exist, 
these data in general support that fat is inhibitory, while carbohydrate and protein are 
NUCB2/nesfatin-1 stimulatory. Nesfatin-1 is explored as an anti-obesity compound. Nutrient 
dependent changes in endogenous NUCB2/nesfatin-1 should also be considered, especially when 
developing diet or exogenous nesfatin-1 based potential therapies for obesity and related 
metabolic diseases. 
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Transition 
 
The final data chapter focuses on my fourth objective: To study whether the genetic loss 
of nesfatin-1 alters whole body energy homeostasis, islet morphology, islet hormone release and 
glucose and whole body energy homeostasis in NUCB2 knockout (NKO) mice. My research on 
developmental expression of NUCB2/nesfatin-1 (Chapter 2 and 3) and nutrient regulation of 
NUCB2/nesfatin-1 (Chapter 4) provided significant new information on endogenous nesfatin-1. 
Our research, and data from several other researchers independently determined several actions 
of nesfatin-1 in regulating energy balance. However, whether endogenous NUCB2/nesfatin-1 is 
critical in regulating metabolic homeostasis remain unknown. Using a NUCB2/nesfatin-1 
knockout mouse model, we determined whether NUCB2/nesfatin-1 is critical for maintaining 
energy balance. Our preliminary data on the phenotype characterization of NKO mice 
demonstrates a sexually dimorphic effect of NUCB2/nesfatin-1 disruption in mice: an increase in 
body weight, food intake, attenuated glucose stimulated insulin secretion and altered energy 
homeostasis.  
 
Publication: Mohan, H., Tsushima, R., Ceddia, R., Pasupulleti, V., Mortazavi, S., Unniappan, 
S., 2015. Preliminary Characterization of Nucleobindin-2 Knockout Mice: Sexually Dimorphic 
Defects in Whole Body Energy Homeostasis, Glucose Tolerance and Insulin Secretion. 
Manuscript in Preparation. 
 
Contributions: Haneesha Mohan conducted in vivo and in vitro studies, collected and processed 
the tissue samples for various experimental analyses, and prepared the manuscript. Haneesha 
Mohan. processed tissues for immunohistochemistry, conducted immunohistochemistry analysis 
and microscopy. Robert Tsushima helped with in vitro studies with respect to pancreatic islet 
isolation and protein assays. Rolando Ceddia shared equipment to conduct in vivo studies using 
CLAMS. Sima Mortazavi and Venkat Pasupulletti helped with several in vitro and in vivo 
studies. Suraj Unniappan. helped with the research, secured funding for the project and edited the 
manuscript.  
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Chapter 5 
 
Preliminary Characterization of Nucleobindin-2 Knockout Mice: 
Sexually Dimorphic Defects in Whole Body Energy Homeostasis, 
Glucose Tolerance and Insulin Secretion 
5.1 Introduction 
Nesfatin-1 is co-expressed with insulin in rodent and human pancreatic β-cells, and has 
glucoregulatory functions (Gonzalez et al., 2012b, Gonzalez et al., 2011, Gonzalez et al., 2009). 
Nesfatin-1 is a novel metabolic protein implicated in the regulation of energy balance. It is 
derived from the precursor, nucleobindin-2 (NUCB2) that is cleaved by prohormone convertases 
1/3 and 2 (Gonzalez et al., 2011, Oh-I et al., 2006). It is actively being explored as a potential 
anti-obesity and anti-diabetic molecule (Li et al., 2010, Shimizu et al., 2009). It was initially 
discovered by subtraction cloning from both neuronal and adipocytic cell lines (Oh-I et al., 
2006). NUCB2/nesfatin-1 is highly conserved across vertebrates (Gonzalez et al., 2010, Mohan 
and Unniappan, 2013, Zhang et al., 2010) with functions that are species- and tissue-specific 
(Chapter 1). Nesfatin-1 regulates food intake, energy balance, glucose metabolism and insulin 
secretion, reproduction, gastric emptying, development, stress modulation, thermogenesis, and 
cardiovascular functions (Mohan and Unniappan, 2013) as detailed in Chapter 1. Our 
knowledge on NUCB2/nesfatin-1 control of various physiological systems evolved since its 
discovery in 2006. However, a key question remains unanswered: Is endogenous nesfatin-1 
critical for the regulation of all physiological processes it is involved with? In order to address 
this, a NUCB2 knockout (NKO) mouse model was generated. This model allowed us to gain 
further insights on the metabolic significance of NUCB2 gene and nesfatin-1. The hypothesis is 
that the genetic disruption of NUCB2, which leads to the absence of nesfatin-1, results in an 
alteration in whole body energy homeostasis. This chapter focuses on the phenotype 
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characterization of NKO mice, with a special emphasis on insulin secretion, glucose regulation, 
metabolic hormone milieu and whole body energy homeostasis. 
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5.2 Materials and Methods 
5.2.1 Generation of the NKO mice 
To study NUCB2 gene function in mice, a random mutagenesis approach called, ‘gene 
trapping,’ where insertion of a synthetic DNA element into an endogenous gene leads to 
transcriptional disruption was implemented. The gene trapping vector construct used was VICTR 
48 Ominobank Vector. This construct mainly consists of 2 long terminal repeats (LTR), splice 
acceptor (SA), restriction enzymes (BglII and HindIII), a selectable marker gene (neomycin 
phosphotransferase; NEO) and polyadenylation signals (pA and SV40tpA). This construct was 
then placed within a retroviral genome that was used to infect a mutant cell line. The insertion of 
the vector occurred within the transcriptionally active regions. The marker gene NEO was 
expressed and translated, allowing selection of mutant clones (OST287865). 129SvEv
Brd
-derived 
parent embryonic stem cells (Lex-1) were cultured with the mutant clone consisting of the vector 
and subsequently NUCB2 gene in the Lex-1 cells was disrupted by the mutant clone. Gene 
disruption was achieved through the capture of the endogenous NUCB2 gene transcription via 
retroviral insertion of the trapping vector within the intron between the first and second non-
coding exons of the NUCB2 gene (Figure 5.1; Accession Number: NM_016773). Following, 
transcription tagging or 3’ RACE (rapid amplication of cDNA ends) method was used to 
identify whether NUCB2 gene was disrupted by gene trapping in the cells. It was found that 
NUCB2 gene was trapped by the mutant vector in chromosome number 7 (Tag ID: OST287865; 
Tag Location: 116509455-116509600 base pairs). The gene trapping method repressed the 
transcription of NUCB2 gene and therefore no translation of protein will occur. Transgenic Lex-
1 cells were selected and then injected into the early stage of a host mouse embryo. These cells 
integrated with the host’s embryonic stem cells. The embryos were then placed into the uterus of 
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pregnant mice, where they developed into chimeric mice. The chimeric mice were bred to 
C57BL/6-
Tyrc-Brd
 mice to generate F1 heterozygous animals. These progeny were intercrossed to 
generate F2 wild type, heterozygous, and homozygous mutant (NKO) progeny. These mice are 
viable and their preliminary phenotypic characterization was posted at the Mouse Genome 
Informatics site. Lexicon Genetics conducted the above gene manipulations and generated the 
NKO mice. However, these mice were not maintained as a live colony, but frozen sperm and 
cryopreserved embryos were available through a NIH funded repository at the Texas Genome 
Research Institute (TGRI). We purchased the cryopreserved sperm and re-derived the NKO line 
at the Jackson labs under the auspices of the TGRI. The MGI and TGRI preliminary data 
suggests that the NKO mice show an increased heart rate, increased levels of serum alkaline 
phosphatase and decreased insulin levels and impaired glucose tolerance during oral glucose 
load.  
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Figure 5.1 Creation of the NUCB2 KO Model 
Figure 5.1. A graphical representation depicting a trapping vector facilitated insertion; a 
retroviral insertion made within the intron between the first and second non-coding exons of the 
NUCB2 gene in chromosome 7, which was used to create the NKO mouse.  
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5.2.2 Genotyping 
Mouse genomic DNA was isolated from NKO and wildtype (C57BL/6; WT) male and 
females tail biopsies. Tail snip were suspended in a 1.5 mL tube containing 250 µl Direct PCR 
Lysis Reagent (Catalogue Number 102-T, Viagen Biotech, Inc., Los Angeles, California) 
containing 0.05-0.1 mg/mL Proteinase K (Catalogue Number p6556, Sigma-Aldrich, Ontario, 
Canada). Tubes were incubated at 55° C in a rotating hybridizing oven until complete lysis was 
achieved (16-24 hrs). Lysates were incubated at 85°C for 45 min by floating the whole rack 
(containing tubes) on water bath.  Ten microliters of the crude lysate per 100 µl PCR reaction 
was used. Qiagen HotStar Taq DNA polymerase (Catalogue Number 203203, Valencia, 
California) was used for PCR according to the manufacturer’s instructions. PCR was performed 
using the primer pairs to distinguish the wild type (WT; Amplicon size: 439 Base pairs; oligo F 
(0975-5’); 5ʹ-TCTACATCATGCTGGATCAACAGG-3ʹ and oligo R (0975-3’); 5ʹ 
TCTGCCTGCCTGATACCATGCTCCC-3ʹ) and gene trapped-mutant (NKO; Amplicon size: 
441 Base pairs; oligo F (LTR-2); 5ʹ-AAATGGCGTTACTTAAAGCTAGCTTGC-3ʹ and oligo R 
(0975-3’); 5ʹ- TCTGCCTGCCTGATACCATGCTCCC -3ʹ) (Figure 5.1). Negative control PCR 
reactions consisted only of primers and required reagents, but no template DNA.  
5.2.3 Western Blot Analysis 
Tissues (liver, stomach, duodenum, pancreas) from age-matched male and female WT 
and NKO mice were lysed with lysis buffer (0.5mM sodium orthovanadate, 1μM pepstatin A, 
20M phenylmethylsulfonyl fluoride, protease inhibitor, phosphatase inhibitor) followed by 
periodic vortexing for 30-40 minutes. In addition we used five positive control cell lysates - COS 
cells (American Type Culture Collection (ATCC), CRL-1561 Cell Lines, Manassas, VA) that 
were transfected with/without NUCB2, either NUCB2 with PC 1/3, NUCB1 (Miura et al., 1992) 
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with PC 1/3 or NUCB2 with Furin and MGN3-1 cells (Source: Refer to Chapter 4) that were 
lysed by scraping with lysis buffer. We used COS cells as they are easy to maintain in culture 
and several cloning vectors are available to transfect them. 
COS 7 cells were maintained in growth medium which consisted of Dulbecco’s Modified 
Eagle Medium high glucose, containing pyruvate, L-glutamine (DMEM,  Catalogue Number 
319-005-CL; Wisent, St. Bruno, QC, Canada) supplemented with 10% fetal bovine serum (Fetal 
Bovine Serum; Catalogue Number 080-150; Wisent, St. Bruno, QC, Canada) and 
penicillin/streptomycin (Catalogue Number 450-201-EL; Wisent, St. Bruno, QC, Canada). Cells 
for transfection were seeded in 6-well cell culture plates (Greiner; Sigma-Aldrich, Ontario, 
Canada) at least 2 days prior to the start of transfection. When cells were 80% confluent, they 
were refed with 1.5 mLs of growth medium three hours before the start of transfection. Plasmid 
DNA was transfected using TurboFect (Fermentas; Catalogue Number R0531; Thermo Fischer 
Scientific, Mississauga, ON, Canada) as per manufacturer instructions. Briefly, 200 µl of serum 
free DMEM was aliquoted into autoclaved eppendorf tubes. A total of 2 µg of plasmid DNA was 
added and 6 µl of TurboFect reagent. Mixtures were immediately vortexed and incubated for 18 
minutes at room temperature. To each of 2 wells, 100 µl of this DNA mixture was added (for 
duplicate wells) and cells were returned to incubator overnight. The next morning, transfection 
medium was aspirated, cells were washed twice with 2 mL of phosphate buffered saline 
(Phosphate Bovine Serum; Catalogue Number 311-010-CL; Wisent, St. Bruno, QC, Canada) and 
refed with 2 mL/well of growth medium. Expression of GFP and DsRed were examined to 
determine approximate efficiency which was typically 70% of cells being positive for GFP 
expression. For transfections, each well received 0.5 µg of NUCB1, NUCB2, PC1/3 or Furin 
plasmids, 0.25 µg pcGFP, 0.25 µg pBlueDsRed, 0.5 µg pGEM9Z and empty pcDNA3 if only 
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one expression plasmid was examined (NUCB1, NUCB2, PC1/3 and Furin were in CMV-based 
expression plasmids identical or near-identical to the pcDNA3 plasmid backbone). Cells were 
returned to the incubator for 30-48 hours and then harvested for Western Blotting. Briefly, 
medium was removed and cells were washed twice with cold PBS and extracted on ice with an 
NP-40 lysis buffer (0.5% NP-40, 50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 10 mM sodium 
pyrophosphate, 1 mM EDTA [pH 8.0], 0.1 M sodium fluoride) containing 10 μg/mL leupeptin 
and aprotinin, 5 μg/mL pepstatin A, 0.2 mM PMSF and 0.5 mM sodium orthovanadate. Lysates 
were extracted on ice for 30 minutes with periodic vortexing. Cleared lysates were transferred to 
new eppendorf tubes (combined duplicate wells) and protein concentrations were determined 
using the Bradford method (BioRad) with bovine serum albumin (BSA) as a standard. Extracts 
used for immunoblotting were diluted in sample buffer containing SDS/β-mercaptoethanol and 
boiled. For Western Blotting, equal µg amounts of cell lysates were examined. These cells allow 
us to clone genes and enzymes to study gene expression and test mammalian expression vector 
constructs. For endogenous control specificity rat nesfatin-1(1-82) 
[VPIDVDKTKVHNVEPVESARIEPPDTGLYYDEYLKQVIEVLETDPHFREKLQKA 
DIEEIRSGRLSQELDLVSHKVRTRLDEL] was synthesized by Abgent Technologies (San 
Diego, CA). Synthetic nesfatin-1 was purified using HPLC to more than or equal to 95% purity. 
The mass and purity were confirmed by mass spectrometry. 
The lysate of tissue or cells was centrifuged and the supernatant containing soluble 
protein was extracted. Protein concentration was determined by the Bradford method (Bio-Rad 
Laboratories). LaemmLi buffer (0.5 M Tris-HCl, glycerol, 10% SDS, 0.5% Bromophenol Blue, 
5% β-mercaptoethanol) was added to the samples and stored at   -80° C until needed. Prior to 
use, samples were boiled at 95° C for 4 minutes. Equal quantities of protein were 
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electrophoresed on a 10% or 15% SDS-polyacrylamide gel, followed by electroblotting onto a 
polyvinylidene fluoride (PVDF) membrane overnight at room temperature. Membranes were 
washed in 1X TBSTN wash buffer (Tris-buffered saline, 0.05% Tween-20, 0.05% NP-40) (30 
min, 25°C) and blocked in a solution of 3% BSA in 1X TBSTN for 4-6 hours. Membranes were 
then probed with Rabbit anti-nesfatin-1 primary antibody (Catalogue Number H-003-22; 1:1000 
dilution, Phoenix Pharmaceuticals) or Rabbit anti-preproghrelin primary antibody (Catalogue 
Number SC-50297; 1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) 
overnight at 4°C. Membranes were then washed in 1X TBSTN (3 × 10 min, 25°C) and incubated 
with goat anti-rabbit IgG (H+L)-HRP secondary antibody (Bio-Rad, 1:3000 dilution) for 2 hours 
at room temperature. Membranes were washed in 1X TBSTN 5-7 times over 1.5 hours. Immune 
complexes were viewed on CL-Xposure™ film (Thermo-Scientific, Waltham, MA, USA) and 
developed using Immobilon™ Western Chemiluminescent HRP Substrate (Millipore, Billerca, 
MA, USA) according to the manufacturer’s instructions.  
5.2.4 Immunohistochemistry 
For immunohistochemical studies, 2 male and 2 female NKO and WT mice were used. 
All dissections and tissue collection were conducted at the same time of the day (13:00-14:00 
hours) to provide consistency. The pancreatic tissues were processed and slides were obtained 
for staining (Refer to Chapter 2 for details on fixation, paraffin embedding, sectioning, staining, 
viewing and capturing of tissue image).  These pancreatic sections were incubated with Mouse 
anti-nesfatin-1 primary antibody (Catalogue Number ALX-804-854-C100; 1:100 dilution, Enzo 
Life Science, Inc.) and guinea pig anti-insulin (Catalogue number ab 7842; 1:100 dilution; 
Abcam, Massachusetts) for 24 hours at room temperature. The slides were incubated with goat 
monoclonal anti-mouse FITC IgG (Heavy and Light Chain) (Green-Ghrelin; Catalogue number 
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ab 6785; 1:100 dilution; Abcam, Massachusetts) and goat anti-guinea pig TEXAS RED IgG 
(Heavy and Light Chain) (TEXAS Red-NUCB2/Nesfatin-1; Catalogue number ab 6906; 1:100 
dilution; Abcam, Massachusetts) secondary antibodies for 1 hour at room temperature. 
Approximately 8 slides containing two sections of the pancreas from each mouse were stained 
using the above protocol and analyzed. Only representative images of the pancreas from each 
mouse are shown in the results section. 
5.2.5 Weekly Body Weight and Food Intake Measurement 
To determine the preliminary phenotypic changes in male (C57BL/6; n=4 and NKO; 
n=5) and female (C57BL/6; n=5 and NKO; n=4) age-matched mice, weekly measurements on 
body weight and food intake were recorded 4 hours post-fast using a digital weighing scale 
(VWR, Mississauga, Ontario) once a week for 18 weeks. Mice were age-matched and their body 
weight and food intake measurements commenced from 16 weeks of age in both genders. In a 
separate study, for 17 weeks, male and female age-matched mice (from 13 to 29 weeks of age) 
were fed on a low fat diet (Product # D12450i; Research Diets, New Brunswick, NJ) that had 3.8 
kcal/gm with 20% energy derived from protein, 70% energy derived from carbohydrate and 10% 
energy derived from fat, and high fat diet (Product # D12451i; Research Diets, New Brunswick, 
NJ) that had 4.73 kcal/gm with 20% energy derived from protein, 35% energy derived from 
carbohydrate and 45% energy derived from fat. Similarly, weekly measurements on body weight 
and food intake were recorded 4 hours post-fast. The numbers of mice in each group are 
provided in the respective figure legend. We used the Mann-Whitney test of a non-Gaussian 
distribution or one-way ANOVA followed by Tukey’s Multiple Comparison Test or Student-
Newman Keuls multiple comparisons test to compare the mean ± SEM of body weight and/or 
food intake to body weight ratio between the two groups of male and female mice. 
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5.2.6 In Vitro Effects on Glucose Stimulated Insulin Secretion (GSIS) from  
Isolated Islets 
In order to determine whether glucose has direct effects on islets to stimulate insulin 
secretion, a GSIS assay was conducted. There were to two studies performed. For the first study 
islets were gathered from three male and female NKO mice. For the second study, islets were 
gathered from three C57BL/6 and NKO female mice. We made 1 mg/mL of collagenase (Cat# 
C7657-500MG, Lot# SLBD3783V, Sigma-Aldrich, Ontario, Canada) solution in 1X Hank’s 
Balanced Salt Solution (HBSS) and diluted it to 0.05 mg/mL. Once the mouse was anesthetized, 
a cervical dislocation was performed. An incision was made above the abdomen. Once the 
location of the ampulla was identified, it was blocked with surgical clamps on the duodenum 
wall to restrict the collagenase flow from the bile pathway into the duodenum. In a 5 mL syringe, 
3 mL of the collagenase was filled with a 30 G1/2-G needle (Becton Dickinson and Company, 
Mississauga, Ontario, Canada). By viewing under the microscope, the needle was inserted into 
the common bile duct. The pancreas distends slowly as the collagenase is perfused. The pancreas 
was then excised from the stomach and the duodenum and placed in a 15 mL falcon tube 
containing 500 ul of 0.05 mg/mL collagenase. The tube was then placed in a water bath set at 
37
o
C for 10 minutes. The tube was shaken and then placed in the water bath at 37
o
C for 2 
minutes. After pancreatic digestion, 1XHBSS was added to the tube to stop the digestion and 
kept on ice. After termination of digestion was completed using 1X HBSS, the tube was 
centrifuged at 1200 rpm (13.9 x G) for 2 minutes. After centrifugation, the supernatant above the 
pellet was then removed and discarded. Using an electronic pipetter, 5 mL of Histopaque was 
slowly added. Using the method of suction and ejection, the pellet was broken for the Histopaque 
to mix with pellet. After this step, using an electronic pipetter, 5 mL of 1XHBSS was slowly 
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added on the top layer. Spin at 1800 rpm for 10 minutes. Since Histopaque is toxic to islets, the 
top supernatant is poured off into a new falcon tube (50 mL) and cold 1X HBSS was added over 
the top. The islets were handpicked using a microscope from one culture dish to another culture 
dish which contained the 1X HBSS. Once all islets were handpicked, the islets were transferred 
to a dish containing 5.5 mM RPMI. The islets were washed twice and then transferred into a dish 
containing 5.5 mM RMPI for overnight incubation at 5% CO2. Keeping islets in a sterile 
environment at 37
o 
C at 5% CO2 limits exposure to contamination and changes in pH.  
The following morning, the culturing medium was replaced with 2 mL of 2.0 mM RPMI 
glucose and incubated for 2 hours. When performing a GSIS, it is essential that the islets are 
cultured in Krebs-Ringer Bicarbonate Buffer (KRB) solution. The KRB solution consists of salts 
that play an important role in cell culture experiment. It consists of basic salts that help in 
maintaining the pH and osmotic balance in the medium. It provides the cells with an 
environment that is rich in inorganic ions and basic solutions that are essential for survival 
during an in-vitro assay. Different glucose concentrations of KRB were made which include 2.0 
mM and 16.7 mM KRB to represent hypoglycemic and hyperglycemic condition. After 
incubating the islets at 2.0 mM RPMI, the medium was removed and the islets were washed 
twice with 2 mL of 2.0 mM KRB. For the GSIS study, an 8 well plate was used. Each well 
consisted of 1 mL of 2.0 mM KRB. The islets were removed from the 35 mm dish and then 20 
islets were counted and placed into each well. The plate was kept in a sterile incubator in 37
o
C at 
5% CO2 for 30 minutes. After 30 minutes, the supernatant was discarded, and the islets were 
incubated with 1 mL of 2.0 mM KRB for 1 hour. The supernatant was collected into a 1.5 mL 
tube and 1 mL of 5.5 mM KRB was added in each well and was kept at 37
o
C at 5% CO2 for 1 
hour. After an hour, the supernatant was collected into a 1.5 mL tube and 1 mL of 16.7 mM KRB 
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was added in each well and was kept at 37
o
C at 5% CO2 for 1 hour. After 1 hour, the supernatant 
was collected into a 1.5 mL tube. The islets were washed by adding 1 mL of phosphate buffer 
solution into each well and the solution was discarded. Potassium chloride (KCL; 1 mL) was 
added to each well and the islets were collected with the KCL. Potassium Chloride (KCl) induces 
β-cell depolarization in the islet cells allowing for calcium influx which activates exocytotic 
insulin release. The islets in each tube were sonicated for 10 seconds and were kept on ice. The 
tubes were spun at 15000 rpm for 5 minutes and the top 500 μL of the supernatant were 
transferred into new tubes. The tubes were stored at -20
o
C. Meanwhile the supernatant collected 
during incubation periods of 2.0 mM, 5.6 mM and 16.7 mM KRB media were spun at 1500 rpm 
and the top 700 ul supernatant was collected into new pre-labelled 1.5 mL microcentrifuge tubes. 
The supernatant collected was used to measure insulin secreted from the islets extracted from 
wildtype and NKO female mice. We used an in-house mouse radioimmunoassay (Robert 
Tsushima Lab, York University) to measure secretion of insulin induced by glucose. ANOVA 
followed by a post-hoc Bonferroni test was used to compare the mean ± SEM of insulin levels 
secreted into media between the two groups in the study.  
5.2.7 Assessment of Whole-Body Energy Homeostasis Using Comprehensive 
Laboratory Animals Monitoring System (CLAMS)  
To assess whole-body metabolic homeostasis in C57BL/6 and NKO male mice, they 
were housed in the CLAMS (Columbus Instruments, OH) for three days for automatic 
monitoring of multiple metabolic parameters. Four age-matched male mice in each group were 
used. The CLAMS is equipped with an open-circuit calorimeter for measuring accumulative 
oxygen (O2), O2 consumption (VO2), carbon dioxide production (VCO2), and respiratory 
exchange ratio (RER). RER was calculated by dividing VCO2 by VO2 with values ranging from 
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0.7 to 1.0. A shift of RER values toward 0.7 indicates that fatty acids contribute the most to 
energy production, while a shift towards 1.0 indicates the carbohydrates are the main substrates 
used. The percent of fatty acids and carbohydrates utilized at every time point for each animal 
was determined from the RER.  Each cage is also equipped with a system of infrared (IR) beams 
that detects animal movement in the X (the length of the cage) and Z (the height of the cage) 
axes. We measured the total number of X-axis IR beam breaks (X-TOT), number of ambulatory 
X-axis IR-beam breaks (X-AMB) and total number of vertical rearing motions (Z-TOT). The 
data was analyzed using Graphpad Prism® version 5. The CLAMS system was calibrated 
according to manufacturer’s instructions prior to beginning the experiments. We used the Mann-
Whitney test of a non-Gaussian distribution to compare the mean ± SEM of various metabolic 
parameters between the two groups of male mice.  
5.2.8 Intraperitoneal Glucose Tolerance Test (IPGTT) 
To elucidate the effects of the loss of NUCB2 gene on intraperitoneally injected glucose 
clearance, we conducted an IPGTT. It will help us detect whether loss of NUCB2 gene has an 
influence in glucose metabolism during glucose administration. IPGTT was conducted in male 
(C57BL/6; n=4 and NKO; n=5) and female (C57BL/6; n=5 and NKO; n=4) age-matched mice. 
After a tail snip, blood was collected to the One-Touch® Ultra Glucometer strip (LifeScan, 
Canada) for measurement of blood glucose using the One-Touch® Ultra Glucometer (LifeScan, 
Canada). Blood glucose was measured 6 hours post-fast. D-Glucose (Catalogue number 
GLU501.500; Bioshop; Canada) dissolved in saline was then injected intraperitoneally 
(1 gram/kilogram Body Weight of mice) and blood glucose was measured again at time points of 
5, 10, 20, 30, 60, 90, 120, and 150 minutes, post injection. In addition to blood glucose 
monitoring, blood was collected from the tail into capillary tubes (100 μL) at 5 and 30 minutes to 
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measure insulin levels during the IPGTT.  Circulating insulin levels in the serum were measured 
using the Mouse Ultrasensitive Insulin ELISA kit (Catalogue number 80-UNSMU-E01, ALPCO, 
Salem, New Hampshire). The limit of the assay sensitivity was 0.115 ng/mL (5 μL) for insulin, 
with a detectable range from 0.025 – 6.9 ng/mL. The amount of immunoreactive material was 
determined using a sigmoidal relationship curve. In a separate study, IPGTT (as described 
above) was also performed on male and female age-matched mice fed on a low fat diet and high 
fat diet (Details on diet and mice number in each group are described above). We measured the 
area under the curve (AUC) of blood glucose (0-150 minutes) and insulin (5-30 minutes) profile. 
The data was analyzed using an Unpaired t-test to measure the difference in AUC of blood 
glucose and insulin profile between the groups.   
5.2.9 Insulin Tolerance Test (ITT) 
In order to determine the effects of loss of NUCB2 gene on insulin sensitivity, an ITT 
was performed. ITT helps monitor glucose concentration over time, but in response to insulin 
administration rather than of glucose as in IPGTT. The degree to which glucose falls following 
insulin administration is indicative of whole body insulin action. Insulin tolerance test was 
conducted in male (C57BL/6; n=4 and NKO; n=5) and female (C57BL/6; n=5 and NKO; n=4) 
age-matched mice. After a tail snip, blood was collected to the One-Touch® Ultra Glucometer 
strip (LifeScan, Canada) for measurement of blood glucose using the One-Touch® Ultra 
Glucometer (LifeScan, Canada). Fasting blood glucose was measured 6 hours post-fast. Insulin 
(1 Unit/kilogram body weight) was then injected intraperitoneally and blood glucose was 
measured again at time points of 5, 10, 20, 30, 60, 90, 120, and 150 minutes, post injection. In a 
separate study, ITT (as described above) was also performed on male and female age-matched 
mice fed on a low fat diet and high fat diet (Details on diet and mice number in each group are 
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described above). One-way ANOVA followed by Student-Newman Keuls multiple comparisons 
test. Data are expressed as mean ± SEM of blood glucose levels between the two groups in each 
gender. 
5.2.10 Absolute Terminal Organ/Tissue Weight  
Male (C57BL/6; n=3 and NKO; n=5) and female (C57BL/6; n=5 and NKO; n=4) age-
matched mice were dissected at 40 weeks of age and weight of their organs/tissue (Heart, Spleen, 
Brown Adipose Tissue (BAT), Epididymal/Perigonadal Fat, Soleus Muscle) were measured 
using a digital weighing scale (VWR, Mississauga, Ontario). An Unpaired t-test was used to 
measure the difference in organs/tissue weight between the groups. 
5.2.11 Serum Insulin, Glucagon, Ghrelin and Leptin Levels 
Enzyme-linked immunosorbent assay (ELISA) was used to measure the circulating levels 
of insulin, glucagon, ghrelin and leptin in the blood. As these NKO mice are derived in a mixed 
background of 2 strains (C57BL/6 and 129Sv), we had gender specific comparative control strain 
groups for each group of NKO mice. Blood was collected from male and female C57BL/6, 
129Sv and NKO mice. Blood samples were allowed to clot on ice, and serum was separated by 
centrifugation (7000 rpm for 9 minutes at 4
o
C) and stored at -20
o
C, until assay was conducted. 
 Insulin secretion levels in the serum was measured using the mouse ultrasensitive insulin 
ELISA kit (Catalogue number 80-UNSMU-E01, ALPCO, Salem, New Hampshire) according to 
the manufacturer’s instructions to measure serum insulin levels in each group (Mouse 
Ultrasensitive Insulin ELISA kit specification details are described in the above IPGTT section). 
Glucagon secretion levels in the serum was measured using the Glucagon (Human, Mouse, Rat) 
ELISA kit (Catalogue number 48-GLUHU-E01, ALPCO, Salem, New Hampshire). The limit of 
the assay sensitivity was 10000 pg/mL (5 μL) against the C-terminal (19-29 amino acids) of 
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glucagon, with a detectable range from 41 - 10000 pg/mL. The amount of immunoreactive 
material was determined using a standard relationship curve-fit. Ghrelin secretion levels in the 
serum were measured using the Rat/Mouse ghrelin (Active) ELISA kit (Catalogue number 
EZRGRA-90K, EMD Millipore, Darmstadt, Germany). The minimal limit of the assay 
sensitivity was 8 pg/mL for active ghrelin, with a detectable range from 25 – 2000 pg/mL .The 
amount of immunoreactive material was determined using a linear standard curve. Leptin 
secretion levels in the serum was measured using the leptin (Mouse/Rat) ELISA kit (Catalogue 
number EK-003-17, Phoenix Pharmaceuticals Inc., California). The limit of the assay sensitivity 
was 4000 pg/mL for leptin, with a detectable range from 62.5 – 4000 ng/mL. The amount of 
immunoreactive material was determined using a linear standard curve. For each assay, the 
amount of immunoreactive material was measured using the correlation or linear regression 
model recommended to quantify and compare the concentration of protein in the serum samples 
between the various groups of mice in both genders. All values were reported as mean ± SEM. 
Unpaired t-test or Two way ANOVA followed by a post-hoc Bonferroni multiple 
comparison test to compare between each strain (C57BL6 or 129Sv) and NKO in both genders 
was used.  
5.2.12 Statistical Software 
Statistical analyses on the data were analyzed using the GraphPad Prism Version 4.0 
(GraphPad Software Inc.)  
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5.3 Results 
5.3.1 Confirmation of NUCB2 Gene Disruption in NKO Male and Female Mice 
The insertion of a vector disabled the NUCB2 gene in the NKO male and female mice. 
Mutant primers created are specific to the retroviral insertion. Figure 5.2A, 5.2B display 
wildtype NUCB2 male and female mice gene that binds specifically to the wildtype primers 
(WT; 439 bp).  No bands representing the NUCB2 mRNA were observed in the NKO male and 
female mice samples. Figure 5.3A, 5.3B displays amplicon bands only in the NKO male and 
female gene lanes that are specific to the retroviral insertion present and not in the wildtype mice 
lanes (MT; 441 bp). 
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Figure 5.2 Confirmation of NUCB2 Gene Presence in WT Male and Female Mice 
Figure 5.2. Wildtype (Strain: C57BL/6), NUCB2 gene in the male (2A) and female (2B) mice 
binds specifically to wildtype primers (439 bp).  No bands are observed in the NKO male and 
female mice lanes as primers are specific to the wildtype (WT) mice which do not bind to the 
NUCB2 knock out male and female mice gene.  
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Figure 5.3 Confirmation of NUCB2 Gene Disruption in NKO Male and Female Mice 
Figure 5.3. NKO mice display a band for the mutant primers (MT) created specific to the 
retroviral insertion. The band is observed in the NKO male (3A) and female (3B) mice gene 
lanes that are specific to the insertion present (441 bp). No bands of NUCB2 are observed in the 
wildtype (Strain: C57BL/6) male mice and female gene lanes. 
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5.3.2 Loss of NUCB2/nesfatin-1 protein expression in the Liver, Stomach, Duodenum,  
Pancreas from NKO Male and Female Mice 
NUCB2 protein is expressed in the liver (Figure 5.4; Lanes 2 and 4), stomach (Figure 
5.5; Lanes 2 and 4), duodenum (Figure 5.6; Lanes 2 and 4) and pancreas (Figure 5.7; Lanes 2 
and 4) of male and female WT mice, showing distinct band for NUCB2 corresponding at 50 
kDa. No NUCB2 protein expression was observed in the liver (Figure 5.4; Lanes 3 and 5), 
stomach (Figure 5.5; Lanes 3 and 5), duodenum (Figure 5.6; Lanes 3 and 5) and pancreas 
(Figure 5.7; Lanes 3 and 5) from males and female NKO mice. No bands showing the fully 
processed nesfatin-1 was visible at 10 kDa in any of the tissue sample from both the groups in 
either genders. Controls used were COS cells transfected with/without NUCB2, NUCB2 and PC 
1/3, NUCB1 and PC 1/3 and NUCB2 and furin, MGN-3 cell lines which displayed specific 
expression of the genes transfected into the cells. Rat nesfatin-1 peptide used as a positive 
control is shown as a distinct band corresponding to 10 kDa (Figure 5.4; Lane 10, Figure 5.5; 
Lane 9, Figure 5.6; Lane 9, Figure 5.7; Lane 9). 
Preproghrelin protein expression appears reduced in the stomach of NKO male and 
female mice (Lanes 3 and 5) compared to WT mice (Lanes 2 and 4), showing a distinct band for 
preproghrelin corresponding at 13 kDa (Supporting Figure S5.1). 
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Figure 5.4 Western Blot Display the Loss of NUCB2 Protein Expression in the Liver from                                  
NKO Male and Female Mice 
Figure 5.4. Western Blot display the loss of NUCB2 protein expression in Lanes 3 and 5 
observed in male and female liver tissue of NKO mice in comparison to wildtype male and 
female mice shown in lane 2 and 4 observed at 50 kDa. Controls used were COS cells 
transfected with NUCB2, NUCB2 and PC 1/3, NUCB1 and PC 1/3, COS cell line and the 
nesfatin-1 peptide.   
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Figure 5.5 Western Blot Display the Loss of NUCB2 Protein Expression in the Stomach 
from NKO Male and Female Mice 
Figure 5.5. Western Blot display the loss of NUCB2 protein expression in Lanes 3 and 5 
observed in male and female stomach tissue of NKO mice in comparison to wildtype male and 
female mice shown in lane 2 and 4 observed at 50 kDa. Controls used were COS cells 
transfected with NUCB2 and PC 1/3, NUCB2 and furin, MGN-3 cell line and the nesfatin-1 
peptide.   
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Figure 5.6 Western Blot Display the Loss of NUCB2 Protein Expression in the Duodenum 
from NKO Male and Female Mice 
Figure 5.6. Western Blot display the loss of NUCB2 protein expression in Lanes 3 and 5 
observed in male and female duodenum tissue of NKO mice in comparison to wildtype male and 
female mice shown in lane 2 and 4 observed at 50 kDa. Controls used were COS cells 
transfected with NUCB2 and PC 1/3, NUCB2 and furin, MGN-3 cell line and the nesfatin-1 
peptide.   
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Figure 5.7 Western Blot Display the Loss of NUCB2 Protein Expression in the Pancreas 
from NKO Male and Female Mice 
Figure 5.7. Western Blot display the loss of NUCB2 protein expression in Lanes 3 and 5 
observed in male and female pancreatic tissue of NKO mice in comparison to wildtype male and 
female mice shown in lane 2 and 4 observed at 50 kDa. Controls used were COS cells 
transfected with NUCB2 and PC 1/3, NUCB2 and furin, MGN-3 cell line and the nesfatin-1 
peptide.   
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Supporting Figure S5.1 
 
Western Blot Display the Attenuation of Preproghrelin Protein Expression in the Stomach 
from NKO Male and Female Mice 
 
Supporting  Figure S5.1. Western Blot displays the attenuation of perproghrelin protein 
expression in Lanes 3 and 5 observed in male and female stomach tissues of NKO mice in 
comparison to wildtype male and female mice shown in lane 2 and 4 observed at 13 kDa. 
Controls used were MGN-3 cell line and ghrelin peptide.   
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5.3.3 Insulin producing β-cells are immunonegative for NUCB2/nesfatin-1 but Not for 
Insulin in NKO Male and Female Pancreatic Islets 
There was no NUCB2/nesfatin-1 immunoreactivity (FITC-Green; Figure 5.8F, 5.8J) in 
the insulin producing β-cells from NKO male and female pancreatic islets which depicts staining 
for insulin (TEXAS-Red; Figure 5.8G, 5.8K). Merged image displays NKO pancreatic male and 
female islet cells immunopositive for insulin and not for NUCB2 (Figure 5.8H, 5.8L). Control 
used was a wildtype male pancreatic islet that displayed co-immunoreactivity for insulin 
(TEXAS-Red; Figure 5.8C) and NUCB2/nefatin-1 (FITC-Green; Figure 5.8B) in the insulin 
producing β-cells shown in the merged image immunopositive for both proteins (Yellow; Figure 
5.8D). DAPI stained for nuclei in the cells of the pancreatic tissue are shown in blue (Figure 
5.8A, 5.8E, 5.8I).  
 
 
 
 
 
 
 
 
 
185 
 
 
 
Figure 5.8 Insulin producing β-cells are immunonegative for NUCB2/nesfatin-1 but Not for 
Insulin in NKO Male and Female Pancreatic Islets 
 
Figure 5.8. Immunohistochemical analysis displays the co-presence of insulin and 
NUCB2/nesfatin-1 in the wildtype (WT) male pancreatic islets (β-cells) used as a control. Insulin 
positive β-cells display the lack of NUCB2/nesfatin-1 staining in a NKO male and female 
pancreatic islets. Nuclei is stained with DAPI; blue. NUCB2/nesfatin-1 is stained with FITC-
Grn. Insulin is stained with TEXAS-Red. Scale bar = 25μm. 
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5.3.4 Body weight of NKO Male and Female Mice 
NKO male (Figure 5.9A) and female (Figure 5.9B) mice had significantly higher body 
weight compared to wildtype (C57BL/6) male and female mice fed ad libitum on regular chow. 
NKO male mice (Figure 5.10A) fed on 45% kcal fat diet had significantly increased body 
weight compared to NKO male fed ad libitum on 10% kcal fat diet and wildtype male mice fed 
on 10% and 45% kcal fat diet. NKO female mice (Figure 5.10B) fed ad libitum on 10% kcal and 
45% kcal fat diet had significantly increased body weight than wildtype female mice fed on 10% 
and 45% kcal fat diet.   
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Figure 5.9 Body Weight of NKO and WT Mice fed Ad Libitum on Regular Chow 
Figure 5.9. Line graph represents body weight measured in C57BL/6 (●; wildtype) and NKO (○) 
male (A) and female (B) mice recorded over a period of 17 weeks fed ad libitum on regular 
chow. NKO male and female mice have increased body weight compared to wildtype male and 
female mice fed ad libitum on regular chow. Mann-Whitney test of a non-Gaussian distribution 
to compare the mean ± SEM of body weight between the two groups of male and female mice 
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Figure 5.10 Body Weight of NKO and WT Mice fed Ad Libitum on 10% and                           
45% kcal Fat Diet 
Figure 5.10. Line graph represents body weight measured in C57BL/6 (wildtype) and NKO 
male (A) and female (B) mice recorded over a period of 17 weeks fed ad libitum on 10% and 
45% kcal fat diet. NKO male mice fed on 45% kcal fat diet (□; p<0.05) have increased body 
weight compared to NKO male fed on 10% kcal fat diet (○) and wildtype male mice fed on 10% 
(●) and 45% kcal fat diet. (■). NKO female mice fed on 10% kcal fat diet (○; p<0.05) have 
increased body weight than wildtype female mice fed on 10% (●) and 45% kcal fat diet (■).  
NKO female mice fed on 45% kcal fat diet (□; p<0.05) have increased body weight compared to 
NKO female fed on 10% kcal fat diet and wildtype female mice fed on 10% and 45% kcal fat 
diet. We used one-way ANOVA followed by Student-Newman Keuls multiple comparisons test 
to compare the mean ± SEM of body weight between the two groups of male and female mice. 
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5.3.5 Food Intake of NKO Male and Female Mice 
NKO male (Figure 5.11A) mice have increased food intake compared to wildtype 
(C57BL/6) male mice fed ad libitum on regular chow. No significant difference in food intake 
was found between NKO female (Figure 5.11B) mice and wildtype female mice. NKO male 
mice (Figure 5.12A) fed on 45% kcal fat diet have increased food intake compared to NKO 
male fed ad libitum on 10% kcal fat diet and wildtype male mice fed on 45% kcal fat diet. No 
significant difference was found in food intake between wildtype male mice fed on 10% kcal and 
45% kcal fat diet and NKO male mice fed on 10% kcal fat. No significant difference was found 
in food intake between wildtype and NKO female mice fed on 10% kcal and 45% kcal fat diet 
(Figure 5.12B). 
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Figure 5.11 Food Intake of NKO Mice and WT Mice fed Ad Libitum on Regular Chow 
Figure 5.11. Line graph represents food intake (food intake to body weight ratio) measured in 
C57BL/6 (●; wildtype) and NKO (○) male (A) and female (B) mice recorded over a period of 17 
weeks fed ad libitum on regular chow. NKO male mice have increased food intake compared to 
wildtype male mice fed ad libitum on regular chow (p<0.05). Mann-Whitney test of a non-
Gaussian distribution to compare the mean ± SEM of food intake between the two groups of 
male and female mice 
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Figure 5.12 Food Intake of NKO and WT Mice fed Ad Libitum on 10% and                           
45% kcal Fat Diet 
Figure 5.12. Bar graph represents food intake (food intake / week) measured in C57BL/6 
(wildtype) and NKO male (A) and female (B) mice recorded over a period of 17 weeks fed ad 
libitum on 10% and 45% kcal fat diet. NKO male mice fed on 45% kcal fat diet (p<0.05) have 
increased food intake compared to NKO male fed on 10% kcal fat diet and wildtype male mice 
fed on 45% kcal fat diet but not 10% kcal fat diet. No significant difference was found in food 
intake between wildtype (10% kcal and 45% kcal fat diet) and NKO female mice (10% kcal and 
45% kcal fat diet). We used one-way ANOVA followed by Tukey’s multiple comparisons test to 
compare the mean ± SEM in food intake between the two groups of male and female mice. 
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5.3.6 GSIS from Wildtype and NKO Female Mice Pancreatic Islets  
NKO female pancreatic islets present at 16.7 mM glucose KRB buffer solution and 16.7 
mM glucose KRB buffer solution + KCl had a significantly lower insulin level than to that of 
female wildtype mice pancreatic islets (Figure 5.13). There was no significant difference in 
glucose stimulated insulin secretion from female pancreatic islets gathered from NKO and 
wildtype mice present in 2.0 mM and 5.6 mM glucose KRB buffer solution.  
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Figure 5.13 GSIS on Pancreatic Islets Isolated from Wildtype (C57BL/6) and NKO       
Female Mice 
Figure 5.13. Bar graph representing glucose stimulated insulin secretion (GSIS) on pancreatic 
islets gathered from wildtype (C57BL/6) and NKO female mice present in 2.0 mM gluocse, 5.6 
mM glucose, 16.7 mM glucose and 16.7 mM glucose + KCL. NKO female pancreatic islets 
present at 16.7 mM glucose KRB buffer solution and 16.7 mM glucose KRB buffer solution + 
KCL had a significantly lower insulin level than to that of female wildtype mice pancreatic islets 
(P<0.001). An in house radioimmunoassay was used to determine the insulin levels. We used a 
post test following two-way ANOVA using the Bonferroni method to compare the mean ± SEM 
of insulin levels secreted into media between the two groups in each study. 
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5.3.7 Organ/Tissue Weight of NKO Male and Female Mice 
Organs/Tissue were dissected from the wildtype (C57BL/6) and NKO male (Figure 5.14) 
and female (Figure 5.15) mice. No significant difference was found in the weight of the heart 
(Figures 5.14A, 5.15A), spleen (Figures 5.14B, 5.15B), brown fat (Figures 5.14C, 5.15C), 
epididymal fat (Figures 5.14D), perigonadal fat (Figures 5.15D) and soleus muscle (Figures 
5.14E, 5.15E) in two groups of male and female mice. 
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Figure 5.14 Organ/tissue Weight of WT and NKO Male Mice 
Figure 5.14. Bar graph displays the organ/tissue weight of WT (C57BL/6) and NKO male mice. 
No significant difference was found in the weight of the heart (A), spleen (B), brown fat (C), 
epididymal fat (D) and soleus muscle (E) between the two groups of male mice. We used an 
Unpaired t-test to measure the difference in organs/tissue weight between the two groups of male 
mice. 
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Figure 5.15 Organ/tissue Weight of WT and NKO Female Mice 
Figure 5.15. Bar graph displays the organ/tissue weight of wildtype (C57BL/6) and NKO female 
mice. No significant difference was found in the weight of the heart (A), spleen (B), brown fat 
(C), epididymal fat (D) and soleus muscle (E) between the two groups of female mice. We used 
an Unpaired t-test to measure the difference in organs/tissue weight between the two groups of 
female mice. 
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5.3.8 Whole-Body Energy Homeostasis in NKO Male Mice Using CLAMS 
The volume of oxygen consumption (Figure 5.16B) and Z-TOT (Figure 5.16G) of NKO 
was significantly higher than wildtype male mice. In contrast, the respiratory exchange ratio 
(Figure 5.16D) of NKO was significantly lower than wildtype male mice. No significant 
difference in accumulative oxygen (Figure 5.16A), carbon dioxide consumption (Figure 5.16C), 
X-TOT (Figure 5.16E) and X-AMB (Figure 5.16F) was found between male C57BL/6 and 
NKO mice.  
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Figure 5.16 Whole-Body Energy Homeostasis in NKO Male Mice Using CLAMS  
Figure 5.16. Line graph represents metabolic parameter [Accumulative oxygen (A; O2), O2 
consumption (B; VO2) carbon dioxide production (C; VCO2), respiratory exchange ratio (D; 
RER), total number of X-axis IR beam breaks (E; X-TOT), number of ambulatory x-axis IR-
beam breaks (F; X-AMB), total number of vertical rearing motions (G; Z-TOT)] measured in 
C57BL/6 (●; wildtype) and NKO (○) male mice. The volume of oxygen consumption and Z-
TOT of NKO was significant higher than wildtype male mice (p<0.0001). In contrast, the 
respiratory exchange ratio of NKO was significantly lower than wildtype male mice (p<0.0001). 
We used the Mann-Whitney test of a non-Gaussian distribution to compare the mean ± SEM of 
various metabolic parameters between the two groups of male mice.  
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5.3.9 Blood Glucose and Insulin Levels in NKO Male and Female Mice during an 
IPGTT 
 Area under the curve (AUC) of glucose profile (0-150 minutes) shows NKO was 
significantly lower than WT male mice (Figure 5.17A) fed on regular chow. No significant 
difference in the AUC of glucose profile (0-150 minutes) was found between the NKO and WT 
female mice (Figure 5.18A). Similarly, no significant difference in the AUC of insulin profile 
(5-30 minutes) was found between NKO and wildtype male (Figure 5.17B) and female (Figure 
5.18B) mice fed on regular chow. No significant difference in the AUC of glucose profile (0-150 
minutes) was found between NKO and wildtype male (Figure 5.19A) and female (Figure 
5.19B) mice fed on different fat diets.  
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Figure 5.17 IPGTT in NKO and WT Male Mice fed Ad Libitum on Regular Chow 
Figure 5.17. Line graph represents blood glucose levels (A)  measured at 0, 5, 10, 20, 30, 60, 90, 
120, and 150 minutes and insulin secretion levels (B) measured at 5 and 30 minutes during an 
intraperitoneal glucose tolerance test (IPGTT) measured in C57BL/6 (●; wildtype) and NKO (○) 
male mice. An inset in each figure shows the area under the curve for glucose (A) and insulin (B) 
profiles. AUC of glucose profile shows NKO was significantly lower than WT male mice. No 
significant difference in the AUC of insulin profile was found between the NKO and WT male 
mice. We used an Unpaired t-test to measure the difference in AUC of glucose and insulin 
profiles between the two groups of male mice. 
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Figure 5.18 IPGTT in NKO and WT Female Mice fed Ad Libitum on Regular Chow 
Figure 5.18. Line graph represents blood glucose levels (A)  measured at 0, 5, 10, 20, 30, 60, 90, 
120, and 150 minutes and insulin secretion levels (B) measured at 5 and 30 minutes during an 
intraperitoneal glucose tolerance test (IPGTT) measured in C57BL/6 (●; wildtype) and NKO (○) 
female mice. An inset in each figure shows the area under the curve for glucose (A) and insulin 
(B) profiles. No significant difference in the AUC of glucose and insulin profile was found 
between the NKO and WT female mice. We used an unpaired t-test to measure the difference in 
AUC of glucose and insulin profiles between the two groups of female mice. 
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Figure 5.19 IPGTT in NKO and WT Mice fed Ad Libitum on 10% and                                        
45% kcal Fat Diet 
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Figure 5.19. Line graph represents blood glucose levels measured at 0, 5, 10, 20, 30, 60, 90, 120, 
and 150 minutes during an intraperitoneal glucose tolerance test (IPGTT) measured in C57BL/6 
(wildtype; 10% (●) and 45% (■) kcal fat diet) and NKO (10% (○) and 45% (□) kcal fat diet male 
(A) and female (B) mice. An inset in each figure shows the area under the curve for glucose 
profiles. No significant difference in the AUC of glucose profile was found between the NKO 
and WT female mice in both diet fed groups. We used one-way ANOVA followed by Tukey’s 
multiple comparisons test to compare the mean ± SEM to the measure the difference in AUC of 
glucose profile. 
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5.3.10 ITT and Blood Glucose Levels in NKO Male and Female Mice  
No significant difference in the AUC of glucose profile was found between NKO and 
WT male (Figure 5.20A) and female (Figure 5.20B) mice fed on regular chow. No significant 
differences in the AUC of glucose profile were found between NKO and WT male mice fed on 
the different fat diets (Figure 5.21).  
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Figure 5.20 ITT in NKO and WT Mice fed Ad Libitum on Regular Chow 
Figure 5.20. Line graph represents blood glucose levels measured at 0, 5, 10, 20, 30, 60, 90, 120, 
and 150 minutes during an insulin tolerance test (ITT) measured in C57BL/6 (●; wildtype) and 
NKO (○) male and female mice.  No significant difference in the AUC of glucose profile was 
found between the NKO and WT male and female mice fed ad libitum. We used an Unpaired t-
test to measure the difference in AUC of glucose profiles between the two groups mice. 
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Figure 5.21 ITT in NKO and WT Male Mice fed Ad Libitum on 10% and 45% kcal Fat Diet 
Figure 5.21. Line graph represents blood glucose levels measured at 0, 5, 10, 20, 30, 60, 90, 120, 
and 150 minutes during an insulin tolerance test (ITT) measured in C57BL/6 (wildtype; 10% (●) 
and 45% (■) kcal fat diet) and NKO (10% (○) and 45% (□) kcal fat diet male mice. No 
significant difference in the AUC of glucose profile was found between the NKO and WT male 
mice in both diet fed groups. We used one-way ANOVA followed by Tukey’s multiple 
comparisons test to compare the mean ± SEM to the measure the difference in AUC of glucose 
profile. 
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5.3.11 Serum Insulin, Glucagon, Ghrelin and Leptin in NKO Male and Female Mice 
Serum insulin levels of male NKO mice were significantly lower than wildtype 
(C57BL/6) mice (Figure 5.22A). Serum leptin levels of male NKO mice were significantly 
higher than wildtype (C57BL/6) mice (Figure 5.22B). No significant difference in serum leptin 
and insulin levels was found between female wildtype (C57BL/6) and NKO mice. No significant 
difference in serum insulin levels (Figure 5.23A) and leptin (Figure 5.23B) was found between 
NKO and wildtype (129sv) male and female mice. No significant difference in serum glucagon 
levels was found between NKO and wildtype (C57BL/6; Figure 5.22C and 129sv; Figure 
5.23C) male and female mice. No significant difference in serum ghrelin levels was found 
between NKO and wildtype (C57BL/6; Figure 5.22D and 129sv; Figure 5.23D) male and 
female mice.  
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Figure 5.22 Serum Protein Levels in NKO and WT (C57BL/6) Mice fed                                         
Ad Libitum on Regular Chow 
Figure 5.22. Bar graph represents serum insulin (A), leptin (B), glucagon (C) and ghrelin (D) 
levels in wildtype (C57BL/6) and NKO male and female mice. Serum insulin levels of male 
NKO mice were significantly lower than wildtype and NKO mice. Serum leptin levels of male 
NKO mice were significantly higher than wildtype mice (p<0.05). We used an Unpaired t-test to 
measure the difference in serum protein levels between the two groups of male and female mice. 
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Figure 5.23 Serum Protein Levels in NKO and WT (129Sv) Mice fed                                         
Ad Libitum on Regular Chow 
Figure 5.23. Bar graph represents serum insulin (A), leptin (B), glucagon (C) and ghrelin (D) 
levels in wildtype (129Sv) and NKO male and female mice. No change in serum insulin, 
glucagon, ghrelin and leptin levels between WT and NKO male and female mice. We used an 
Unpaired t-test to measure the difference in serum protein levels between the two groups of male 
and female mice. 
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5.4 Discussion 
Several laboratories studied the anorexigenic effects of nesfatin-1, modulation of 
endogenous nesfatin-1 under different metabolic conditions (Nakata et al., 2013, Cao et al., 
2013), and its interaction with other proteins (Nakata et al., 2013). This chapter reports that the 
deletion of endogenous NUCB2 affects body weight, food intake, insulin secretion and glucose 
levels, and whole body energy homeostasis, in a sexually dimorphic manner. NUCB2 ablation 
caused an increase in body weight in both male and female NKO mice fed ad libitum on regular 
chow and fed on a high fat diet, when compared to WT mice. The increase in food intake was 
only observed in NKO male mice fed ad libitum on regular mouse chow or on a high fat diet 
versus low fat diet compared to female NKO mice. These results are in agreement with 
previously published studies where they created a NUCB2 knockdown rat via adenoviral-
mediated RNA interference and observed an increase in food intake (Wu et al., 2014).  
Nesfatin-1 is anorexigenic and it influences fat mass by decreasing depot specific fat 
weight (Oh I et al., 2006). This research shows that the absence of NUCB2 and nesfatin-1 causes 
an increase in bodyweight, and a male specific increase in food intake. Several contributing 
factors likely exist for this increase in bodyweight. These include altered food intake, increased 
fat mass, lean mass, reduced physical activity and a decrease in energy expenditure. Preliminary 
visual observations provided an impression of increased fat depots in NKO mice, but this was 
not substantiated when we weighed the fat contents from several depots. Nesfatin-1 plays a role 
in adipogenesis (Osaki et al., 2012, Ramanjaneya et al., 2013, Ramanjaneya et al., 2010) and has 
an effect in reducing fat mass (Oh-I et al., 2006, Ramanjaneya et al., 2013, Ramanjaneya et al., 
2010). This could partly suggest why an increase in the fat depots was observed in NKO mouse. 
Other factors such as weight of internal organs, bone density, free fluid content (collectively 
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referred to as the lean mass) that were not measured in this study could have also attributed to the 
increase in body weight in addition to fat mass. Imaging technqiues, especially MRI scans are 
being considered to quantify the lean versus lipid mass of these mice.  
In order to determine the whole body energy homeostasis, the CLAMS was used.  It was 
found that the respiratory exchange ratio was lower in the NKO male compared to the wildtype 
mice suggesting one reason for increased body weight. However, an increase in total activity was 
also observed in NKO mice. Although some leads to the increase in body weight is deductible 
from these data, the low sample numbers and the fact that this study was only conducted in male 
mice restricts our ability in making solid conclusions. Moreover, in NKO male mice, there is a 
decrease in serum insulin and an increase in leptin levels. This altered metabolic hormone milieu 
might also contribute to the increased body weight. Gender and body weight are known to 
significantly affect serum leptin levels in circulation (Frederich et al., 1995, Niskanen et al., 
1997). Also studies have shown that leptin and insulin together regulate food intake and body 
weight in rats (Air et al., 2002). An increase in food intake is associated with an increase in 
adipocyte stores and can contribute to an increase in plasma leptin levels (Muzumdar et al., 
2003). Circulating leptin levels are directly proportional to fat mass (Rosenbaun et al., 1996, 
Racussin et al., 2014). The observed increase in circulating leptin levels could be attributed to 
increase in fat depots observed in the NKO male mice. Increased leptin levels can cause a 
decrease in glucose stimulated insulin secretion by activating melanocortin receptors in the brain 
(Muzumdar et al., 2003). Therefore, it could be suggested that increase in circulating leptin could 
result in a decrease in insulin levels found in male NKO mice. Both insulin and leptin are known 
to produce adiposity signals to maintain long-term regulation of body weight sending to the 
brain. Studies have found that when changes in insulin and leptin levels occur, energy 
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homeostasis and adiposity is altered. Accordingly, we found that NKO male mice display 
changes in insulin and leptin levels and it could be suggested that the brain responds by adjusting 
food intake to regulate adipose tissue mass in the body (Air et al., 2002).  An interesting 
observation is the more noticeable changes observed in the metabolic phenotype of male mice 
only. There appears to be a sexually dimorphic effect for nesfatin-1 loss.  
Other knockout studies (Ramanathan et al., 2014) have also reported gender-specific 
variation in food intake and body weight which is attributed to the functional roles of hormones 
that are gender dependent. Hypothalamic neuropeptide, hypocretin (Hcrt), also known as orexin 
is known to be involved in the regulation of body weight and energy metabolism (Tsuneki et al., 
2008) and has shown to regulate gender specific effects. Research on HcrtKO mice revealed that 
only female HcrtKO mice displayed an increase in body weight, body fat, muscle, free fluid 
levels and circulating serum levels compared to age matched controls. No difference was 
observed between male HcrtKO and wildtype controls (Ramanathan et al., 2014). In addition, 
kisspeptin receptor knockout studies have revealed that kisspeptin is not only involved in 
reproduction, but also has a sexual dimorphic role on body weight, energy expenditure, and 
glucose homeostasis (Seminara et al., 2003, Topaloglu et al., 2012). Thus far, research has 
shown that kisspeptin is involved in regulating the reproductive axis by stimulating the 
gonadotropin-releasing hormone neurons by binding to its receptor (Kiss1r). As kiss1r is found 
in many central (Lehman et al., 2013) and peripheral tissues (Brown et al., 2008, Hauge-Evans et 
al., 2006) involved in metabolism raises the curiosity to unravel other physiological roles in 
addition to reproduction. Studies on Kiss1r knockouts have shown that Kiss1rKO females have 
higher body weight, leptin levels, and adiposity, with impaired glucose tolerance compared to 
wildtype controls (Tolson et al., 2014). Kiss1rKO females also displayed reduced locomotor 
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activity, respiratory rate, and energy expenditure. Males displayed normal body weight and 
glucose regulation (Tolson et al., 2014). Sexual dimorphic role is also observed in other receptor 
knockout models, which include the vasopression V1a receptor knockout (V1aRKO) mouse 
model. It was found that reduced anxiety-like behavior was only observed in V1aRKO males 
compared to females (Bielsky et al., 2005). Reduced anxiety like behavior is also found in male 
oxytocin KO (OTKO) males compared to female mice (Winslow et al., 2000). These studies 
reveal that ablation of a hormone or its receptor can induce sexual dimorphic changes in 
physiology. Research suggests that differences in body weight, food intake, hormone secretion 
manifest after puberty, indicating the importance and activation of gonadal hormones and 
therefore it is important to perform phenotypic characterization in a gender dependent manner 
(Arnold et al., 2012). One study identified that multiple genes are expressed at different levels in 
the liver of male and female mice (Van Nas et al., 2009). After the gonads were removed, the 
difference in gene expression between the sexes was attenuated (Van Nas et al., 2009), 
suggesting that genetic differences are dependent on the production of gonadal hormones. Also, 
hormonal and non-hormonal mechanisms are known to alter the epigenome and regulate sex 
differences via epigenetic mechanisms (Arnold et al., 2012).  
Previous research described in chapters 2-3 found that NUCB2 is expressed in the β-cells 
and plays an important role in glucose stimulated insulin secretion (Gonzalez et al., 2012a, 
Gonzalez et al., 2011). NKO male and female pancreatic β-cells and pancreatic tissue displayed a 
loss of NUCB2/nesfatin-1 protein expression compared to wildtype controls. Paraffin sections of 
pancreatic tissue from NKO female mice had comparatively larger islets than male mice. 
Although preliminary in nature, it was observed that the NKO male mice have fewer numbers of 
pancreatic islets. Glucose stimulated insulin secretion from the NKO mice islets was attenuated 
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compared to WT pancreatic islets. In agreement with this reduced number of islets, male mice 
appear to have less GSIS compared to female mice. In addition, glucose and KCl stimulated 
insulin secretion was also attenuated in female mice. While the mechanisms of this defect still 
remain unclear, NUCB2 ablation disrupts glucose stimulated insulin production from islets. 
These results suggest that NKO pancreatic islets have decreased insulin production and/or 
impaired secretion and glucose responsiveness. The results of this research show that 
NUCB2/nesfatin-1 is important for normal islet function and islet formation: in the absence of 
NUCB2, males have smaller islets and are fewer in number, with decrease in insulin production 
compared to female NKO mice. Other KO studies have also emphasized the importance of 
hormones in islet structure and function. For instance, neuroligin-2 KO mice have shown that 
absence of neuroligin-2 resulted in smaller, fewer and decreased insulin content in beta cells 
(Zhang et al., 2013). Now, to determine whether the effects of NUCB2 deletion on islet 
formation in males were due solely to the loss of NUCB2 gene in the islets, future studies using a 
conditional, islet-specific NKO mouse would be necessary. Overall, these results are in 
agreement with the in vitro insulinotropic effects of nesfatin-1 reported before (Gonzalez et al., 
2011, Nakata et al., 2011). Interestingly, we did not see any defects in serum insulin levels in 
vivo in ad libitum fed mice before or after a glucose load. This result is in contrast to the 
preliminary findings gathered from TGRI. 
Sex specific differences in glucose homeostasis in male and female NKO mice were 
observed during an IPGTT and ITT.  IPGTT found an improvement in glucose handling in chow 
fed male NKO mice during 60-150 minutes post-glucose administration. Meanwhile, in chow fed 
female NKO mice, blood glucose was significantly higher at 30 minutes, but no differences were 
found at other time points. This pattern was also visible in NKO mice fed a high fat diet. Further, 
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in an ITT, NKO mice displayed persistent decrease in blood glucose compared to the WT 
controls, while in females a decrease was observed at the later stages of sampling. This shows 
that the absence of NUCB2 and/or nesfatin-1 enhances glucose handling, even when there are no 
changes in insulin levels in vivo. This could be due to an increase in glucose uptake in target 
tissues and change in insulin sensitivity as a result of NUCB2 ablation. Previous studies showed 
that nesfatin-1 treated ad libitum rats had normal blood glucose levels with higher insulin and 
lower glucagon levels during an oral glucose tolerance test (Gonzalez et al., 2012a). Nesfatin-1 
altered insulin sensitivity without a change in glucose suggesting that insulin mediated glucose 
uptake is altered in the peripheral tissue. Decrease in glucose levels by nesfatin-1 treatment was 
prevented as gluconeogenesis in the liver along with inhibition of glucose uptake in the skeletal 
muscle would have occurred (Gonzalez et al., 2012a). This suggests that presence of nesfatin-1 
controls insulin mediated glucose uptake in peripheral tissue to main glucose homeostasis. 
Removing nesfatin-1 demonstrates an increase in insulin sensitivity, thus enhancing glucose 
homeostasis. It is likely that glucose uptake in peripheral tissues is improved. In contrast, another 
study demonstrated that intravenous injections of nesfatin-1 significantly reduced blood glucose 
levels in db/db mice compared to ad libitum mice (Su et al., 2010). Also, peripheral infusion of 
nesfatin-1 showed reduction in blood glucose levels in mice fed regular chow and high fat diet 
(Li et al., 2013). Both of the studies discussed above suggest that nesfatin-1 enhances insulin 
sensitivity regulating glucose metabolism. The difference in results obtained among studies 
warrants that additional studies on nesfatin-1 effect on insulin mediated glucose uptake in 
peripheral tissues must be performed. In the NKO male and female liver, stomach, duodenum, 
and pancreatic tissues, NUCB2 protein expression was absent. The loss of NUCB2 protein 
expression in the NKO male and female stomach tissues coincides with a decrease in 
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preproghrelin (See Supplementary Figure S5.1) protein expression in the stomach of NKO 
male and female mice supporting the knowledge that the loss of NUCB2 can affect the 
production of other hormones co-expressed in the same tissue, in this case, ghrelin. NUCB2 and 
ghrelin are known to be expressed in the gastric X/A-endocrine like cells of the stomach (Mohan 
et al., 2014, Stengel et al., 2013, Stengel et al., 2012b).  The absence of NUCB2/nesfatin-1 could 
cause gender-specific fluctuations in the secretion of other metabolic hormones it interacts or is 
co-expressed with, modulating whole body energy metabolism and regulating glucose 
homeostasis.  
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5.6 Limitations of the Study and Reasons for the Lack of Complete 
Characterization 
A major limitation in this study is that it is not complete, and sample sizes are low. This 
stems from the mixed background of the NKO mice used. Once the question about the 
background was raised, TGRI was contacted and based on the genome scan data, they confirmed 
that the NKO mice used here are 75% C57BL/6 or 25% 129Sv strain. Variability in backgrounds 
might lead to altered metabolic phenotype and reflect in food intake, body weight, and whole 
body energy homeostasis. In order to limit these confounding factors, it was necessary to 
generate the NKO mice on a pure genetic background. This can be achieved by consistently 
breeding the genetically modified mice on a pure genetic background.  Therefore, the phenotype 
characterization was terminated in 2012, and all efforts were focused on generating the NKO on 
pure C57BL/6 background.  
Briefly, an outcross, backcross and intercross to obtain pure genetically modified NKO mice 
on a pure C57BL/6 background. In the first step, we performed an outcross by breeding a wild 
type C57BL/6 from Charles River with a homozygous NKO mouse to obtain genetically 
modified NKO mice that is 75% of pure genetic background (C57BL/6). We observed that all 
the progenies were heterozygous. Next we performed step 2, where we mated the heterozygous 
male pups from step 1 with wildtype Charles River female C57BL/6 mice to get N1 progenies. 
We repeated this step three times (N2-N4).  For each cross in N2-N4, the male heterozygous 
pups obtained from the previous N cross were mated with a wildtype female. By N2 they should 
be pure C57BL/6 background (0% 129 Sv), but we repeated it for two more crosses to ensure 
they are indeed pure C57BL/6. In step 3, the pure male and female heterozygous mice were 
crossed to obtain homozygous NKO mice.  The homozygous NKO mice obtained in step 3 were 
218 
 
then crossed to generate more homozygous progenies for studies to be repeated. By performing 
these crosses, we benefited in having a genetically modified mice on a pure genetic background 
that will help interpretation of results with confidence. Finally, to ensure that the breeding 
strategy provided desired results, a genome scan was conducted at Jackson Labs on these 
homozygous mice. The results of the genome scan confirmed that the mice are indeed 99% pure 
C57BL/6 background.  
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5.7 Ongoing Studies on NKO Mice Characterization and Future Directions 
Currently, the phenotype characterization of this newly generated homozygous NKO 
mice in pure C57BL/6 background is in progress. We aim to perform quantitative analysis (qRT-
PCR and Western Blot) on islet derived endocrine factors. We will also perform a simultaneous 
multiparameter assessment of NKO mice and their wild type controls by using metabolic cages 
(Comprehensive Laboratory Animal Monitoring System; CLAMS) that will  measure their food 
intake, feeding bouts, and food eaten per bout, water intake, activity, VO2, VCO2, respiratory 
exchange ratio, heart rate and body temperature for 24 hours. In addition, in vitro studies will be 
performed to determine the glucose responsive insulin release from islets of NKO mice and their 
wild type controls. We will also repeat the above studies in mice fed high fat diet to see 
whether/how the NKO mice develop high fat diet induced obesity and diabetes. Overall, all 
studies presented in this chapter, and more, with an increased “n” are being conducted. The 
results of these studies will be available by the time of the thesis defense. 
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Transition 
The final chapter focuses on my general discussion with respect to the findings detailed 
in chapters 2-5. This chapter summarizes and discusses the collective contributions of this 
research specifically to the nesfatin-1 field, and in general to the body of literature on the 
neuroendocrine regulation of energy balance. It highlights shortfalls of this research, and some 
possible logical future directions arising from the current findings. 
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Chapter 6 
General Discussion 
Since 2006, the year nesfatin-1 discovery was first reported, just over 250 articles 
on nesfatin-1 were published in PubMed. From these publications, we already know that 
nesfatin-1 is an important meal responsive multifunctional hormone with metabolic 
effects. This thesis, by providing some novel information, also contributes significantly to 
the growing knowledge base on nesfatin-1. The main contributions of this research, some 
limitations and future considerations are outlined in this chapter. 
6.1 Contribution 1: Tissue Specific Expression of NUCB2/Nesfatin-1-PCs, 
and Ghrelin-GOAT – Developmental Perspectives 
The research outlined in chapters 2 and 3 presents the findings on the 
developmental expression of NUCB2/nesfatin-1 in the gastroenteropancreatic tissues and 
serum of rats. We found that NUCB2/nesfatin-1 colocalizes with insulin in the islet β-
cells at all developmental stages in an age-dependent manner suggesting that 
NUCB2/nesfatin-1 plays an important role in glucose metabolism during growth (Mohan 
and Unniappan, 2012). NUCB2 is processed by PC 1/3 and/or PC 2 to nesfatin-1. PC 2 is 
present only in the pancreatic alpha cells at postnatal day 27, but at all other stages, both 
PC 1/3 and PC 2 colocalize with NUCB2/nesfatin-1 in β-cells. NUCB2 mRNA levels in 
the duodenum at postnatal day 27 are higher than the adult NUCB2 mRNA expression, 
however metabolic effects of NUCB2 expression in the duodenum still remain elusive 
(Mohan and Unniappan, 2012). Circulating levels of serum nesfatin-1 increased with 
development. NUCB2/nesfatin-1 IR in the pancreas and gastrointestinal tract could 
possibly contribute to the gradual increase in serum NUCB2/nesfatin-1 levels (Mohan 
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and Unniappan, 2012). This was the first study that has focused on NUCB2/nesfatin-1 
expression in the developmental stages of rats suggesting it has an age- and tissue-
specific role in the developmental physiology of rats (Mohan and Unniappan, 2012). It is 
known that hormones exert tissue- and age-specific effects during development (Dauncey 
et al. 2001).  Hormones can be growth stimulatory and growth inhibitory during fetal and 
postnatal periods (Dauncey et al., 2001, Fowden and Forhead, 2009). The hormones act 
as environmental and maturational signals to regulate the accretion and differentiation of 
tissue pre- and post-birth ensuring proper development based on the nutrient supply 
available (Fowden and Forhead, 2009). From the results outlined in this thesis, it could be 
suggested that NUCB2/nesfatin-1 is a growth regulatory peptide. The identification of  
intra- and extra-islet nesfatin-1 specific roles in the pancreas requires further studies.  
6.2 Contribution 2: MGN3 Cells as a Tool to Study Regulation of 
NUCB2/Nesfatin-1 
 Some experiments in Chapter 4 determined whether stomach ghrelinoma cells, 
MGN3-1, express NUCB2/nesfatin-1. One of the major contributions to nesfatin-1 
research is that we characterized MGN3-1 cells as a source of nesfatin-1. This provided 
us a tool for studying the regulation of nesfatin-1 secretion in vitro. mRNAs encoding 
NUCB2, and its processing enzymes PC 1/3 and PC 2 in MGN3-1 cells were detected in 
MGN3 cells. These findings are further supported by the identification of NUCB2, PC 
1/3 and PC 2 immunoreactivity in the same cells. It was also found that MGN3-1 cells 
co-localize both nesfatin-1 and ghrelin, an observation that confirms previous findings 
(Stengel et al., 2009b). This now enables researchers to use MGN3-1 cells as a tool to 
study the regulation of nesfatin-1. 
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6.3 Contribution 3: NUCB2/Nesfatin-1 in the Small Intestine 
 The expression of nesfatin-1 in the intestine was a contentious issue, with some 
reports finding nesfatin-1 in the intestine (Zhang et al., 2010), while some others not 
(Stengel et al., 2009b). A relatively small, yet significant finding reported in chapter 2 
and in chapter 4 is the identification of NUCB2 mRNA and nesfatin-1 immunoreactivity 
in the intestine of both rats (chapter 2) and mice (chapter 3). Using RT-PCR, qRT-PCR, 
Western blot analysis and immunohistochemistry,  confirmed that NUCB2/nesfatin-1 
exists within the enteric tissues. The intestinal roles of nesfatin-1 are yet to be identified.  
6.4 Contribution 4: Nutrient Regulation of NUCB2/Nesfatin-1 
Availability of nutrients is profoundly important for fetal and postnatal 
development and expression of genes encoding proteins of importance (Dauncey et al., 
2001). Intake of nutrients can affect numerous genes involved in differentiation, growth 
and metabolism (Dauncey et al., 2001, Hall et al., 2012). To date, there is no information 
available on the regulation of NUCB2 mRNA expression or nesfatin-1 secretion, other 
than some reports that found that meal intake (Oh-I et al., 2006, Stengel et al., 2009a, 
Stengel et al., 2009b, Gonzalez et al., 2012a) or glucose (Gonzalez et al., 2011) 
stimulated nesfatin-1 release into circulation. Are meal contents or individual nutrients 
modulators of NUCB2/nesfatin-1 synthesis and expression? Studies in chapter 4 
addressed this, where acute (liquid) and chronic (solid) feeding of mice with a high fat, 
high carbohydrate and high protein diet was achieved. It was determined that nesfatin-1 is 
regulated by macronutrients in a tissue specific manner. These effects were again found 
to be different between acute and chronic exposure. While the above studies elucidated 
the regulation of NUCB2/nesfatin-1 in vivo, another approach using MGN3-1 cells 
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explored how components of macronutrients tested influence NUCB2 mRNA and 
NUCB2/nesfatin-1 secretion in stomach cells, a major source of this peptide. 
Collectively, the results from this research, for the first time indicate that nesfatin-
1/NUCB2 is modulated by nutrients and these effects are specific to the nutrients and the 
tissues and cells it is produced from. 
6.5 Contribution 5: Is NUCB2/Nesfatin-1 Critical for Energy Homeostasis? 
Gene deletion in mice is a widely used approach to determine the biological 
necessity of an endogenous protein. A NUCB2 knockout (NKO) mice model was 
generated. This provides a valuable tool to gather additional information on the 
importance of nesfatin-1. It was found that deletion of NUCB2 affects body weight, food 
intake, insulin secretion and glucose metabolism, and whole body energy homeostasis 
(Table 6.1). An increase in body weight in both genders of NKO mice fed ad libitum on 
regular chow and fed on a high fat diet compared to WT mice was observed. The increase 
in food intake was only observed in NKO male mice fed ad libitum on regular mouse 
chow or on a high fat diet versus low fat diet compared to female NKO mice. NKO male 
and female pancreatic β-cells and pancreatic tissue displayed a loss of NUCB2/nesfatin-1 
protein expression compared to wildtype controls. Insulin secretion was attenuated from 
NKO versus WT pancreatic islets when incubated in high glucose suggesting that 
NUCB2 ablation disrupted glucose stimulated insulin production from islets. In the NKO 
male and female liver, stomach, duodenum, and pancreatic tissues, NUCB2 protein 
expression was absent. The loss of NUCB2 protein expression in the NKO male and 
female stomach tissues coincides with a decrease in preproghrelin. Moreover, in NKO 
male mice, we observed a decrease in serum insulin and increase in leptin levels in 
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circulation suggesting impairment in protein secretion in NKO males mice only. We 
believe that absence of NUCB2/nesfatin-1 can cause gender-specific fluctuations in the 
secretion of other metabolic hormones, modulating whole body energy metabolism. The 
respiratory exchange ratio was lower in NKO males compared to wildtype mice 
suggesting a mix of fat and carbohydrate utilizations. An increase in oxygen consumption 
and total activity was also observed. NUCB2 knockdown in rats causes an increase in 
food intake and body weight (Wu et al., 2014), similar to what we found in the NKO 
mice. Together, the data presented in chapter 5 provide important information supporting 
a metabolic role for nesfatin-1. Table 6.1 provides a summary on the preliminary 
characterization of NKO male and female mice. While the NKO mice are fertile and 
viable, it appears that an intact NUCB2 gene producing the nesfatin-1 protein is 
important for maintaining energy balance and metabolic hormonal milieu.  Although this 
research is conducted in mice, the findings significantly enhance our knowledge, and are 
extendable to human health and disease. For example, both NUCB2 mutations are 
reported in obese children (Zegers et al., 2012) and in obesity in men (Zegers et al., 
2011). Altered body weight and glucose homeostasis appear to be the most striking and 
common phenotype resulting from NUCB2/nesfatin-1 disruption in mice (chapter 5 and 
preliminary results using NKO mice in pure C57BL/6 background) and in children and 
adults in the human population (Zegers et al., 2011, Zegers et al., 2012).  
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Table 6.1: Preliminary Characterization of NKO Male and Female Mice 
↑ - Increase, ↓ - Decrease, ↔ - No Change, ND - Not Determined, ᴓ - Absent 
 
 
 
 
 
 
Findings Male Female 
Body Weight ↑ ↑ 
Food Intake ↑ ↔ 
NUCB2 Protein Expression ᴓ ᴓ 
Preproghrelin Protein 
Expression ↓ ↓ 
Blood Glucose Levels ↓ ↔ 
Insulin Secretion ND ↓ 
Insulin Sensitivity ↑ ↔ 
Serum Insulin Levels ↓ ↔ 
Serum Leptin Levels ↑ ↔ 
Respiratory Exchange 
Ratio ↓ ND 
Oxygen Consumption ↑ ND 
Total Activity ↑ ND 
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6.6 Nesfatin-1 and the Neuroendocrine Regulation of Energy Balance  
As indicated in chapter 1, the endocrine regulation of metabolism is achieved by 
multiple, redundant factors secreted from central and peripheral tissues. The brain, gut, 
pancreas and adipose tissue are major sources of metabolic hormones, and are also sites 
of their action. How does nesfatin-1 fit in with this system? The research outlined in 
chapters 2-4 provides important new information on the tissue sources of nesfatin-1. It is 
now clear that the endocrine pancreas and the gastrointestinal tract are major sources of 
endogenous nesfatin-1. Nesfatin-1 is also meal dependent, but its tissue-specific 
expression and secretion appear to vary and is dependent on the nature of the nutrient and 
the duration of exposure to the nutrient. While several pharmacological and tissue 
knockdown strategies were used to elucidate the physiological functions, to date, no 
results on the complete absence of nesfatin-1 has been studied. Our results clearly 
indicate that the lack of nesfatin-1 disrupts energy homeostasis in multiple ways. The 
developmental expression, meal related expression and secretion as well the results of 
complete absence of nesfatin-1 – all provide strong support to the existing notion that 
nesfatin-1 is also a key player in the already existing multifactorial system that regulates 
energy balance (Figure 6.1). In addition to the defects in whole body energy 
homeostasis, the lack of nesfatin-1 also caused alterations in leptin and insulin, two long-
term satiety signals. Thus, it is likely that the metabolic phenotype of NKO mice is due to 
abnormalities in other hormones, including leptin and insulin.   
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Figure 6.1 Summary of Thesis Findings 
Figure 6.1. The development stage (embryonic, post-natal, adult) and the intake of 
macronutrients (carbohydrates, protein, fat) affect endogenous production of nesfatin-1. 
Development and macronutrients are dependent on gender and duration of specific 
macronutrient intake, which modulate the synthesis and secretion of nesfatin-1 in 
important metabolic tissues that include the liver, stomach, pancreas and intestine. 
Endogenous nesfatin-1, mainly produced from the gastroenteropancreatic tissues and 
liver, affect body weight, food intake, insulin sensitivity, islet formation, glucose levels, 
RER and hormone secretion, thereby contributing to the neuroendocrine regulation of 
energy homeostasis. 
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6.7 Limitations of this Research  
6.7.1 Antibody Specificity 
For immunohistochemistry, immunoassays and Western blot analysis, the 
NUCB2 antibody (Phoenix) used by several studies, including this research, binds to both 
NUCB2 and nesfatin-1. We found out that the nesfatin-1 region in NUCB2 shares similar 
amino acid sequence to a nesfatin-1 like region in NUCB1. In our NKO mice (which 
could be considered as a negative control), this antibody is not effective in detecting any 
signals, although smearing in Western gels and isolated immunopostive cells in 
immunohistochemistry were detected. It is likely that the antibody used here, to some 
extent, also binds to NUCB1 and/or its processed peptides. Therefore, it would be 
beneficial to use an antibody that binds specifically to nesfatin-1 region of NUCB2, not 
NUCB1. It was recently made in our laboratory, and we commenced using this antibody 
to further enrich our data from immunohistochemical studies and Western blot analysis.   
6.7.2 Gender Specific Expression of NUCB2/Nesfatin-1 
From chapter 5, it appears that the lack of NUCB/nesfatin-1 results in sexually 
dimorphic phenotypes. There was a lack of gender specific mRNA quantification in 
peripheral tissues of rats during development. In Chapter 2 and 3, embryonic and 
postnatal tissues extracted for RNA extraction and quantified data presented were a 
mixed pool of male and female tissues. Similarly, in chapter 4 also only male mice were 
used. These studies must be repeated in future where we separate male and female tissues 
and quantify NUCB2 mRNA expression tissue- and gender-specifically. During puberty, 
sex hormones can also play a major role in influencing the production of metabolic 
hormones in tissues of male and female rats important for development. Therefore, it 
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would be interesting to determine whether NUCB2/nesfatin-1 synthesis and secretion are 
divergent in males and females.  
6.7.3 Lack of Protein Determination 
Although secreted milieu of nesfatin-1 was measured, tissue-specific protein 
expression in peripheral tissues from mice fed on different nutrient diets was missing in 
Chapter 4. Only mRNA expression was used to determine NUCB2. It would have been 
beneficial to perform protein extraction on tissues dissected from mice fed on different 
diets to detect the nesfatin-1 protein levels in each tissue using Western blot techniques. 
Future studies should consider how chronic intake of nutrients modulates nesfatin-1 
protein in specific tissues. 
6.7.4 NKO = NUCB2 knockout or Nesfatin-1 knockout? 
 In addition to the mixed background issue discussed in chapter 5, another topic 
worth considering is the absence of both NUCB2 and nesfatin-1 in NKO mice. NUCB2 is 
also a secreted protein, which could elicit cellular functions. In the NKO mice, both 
precursor and the processed peptide are absent. Therefore, the phenotype observed in 
these mice could be due to the absence of either nesfatin-1 or NUCB2 alone or both 
peptides. To determine whether the NKO metabolic phenotype is exclusively due to the 
absence of nesfatin-1, it is possible to reintroduce nesfatin-1 into the system by 
pharmacological or genetic approaches. If the metabolic defects in NKO mice are masked 
by the administration of nesfatin-1, then it will be clear that the lack of nesfatin-1 is 
indeed the reason for defects in NKO mice. 
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6.8 Ongoing Research and Future Directions 
As several pilot studies were conducted for the preliminary characterization of 
NKO mice in Chapter 5, the number of mice used in each study was limited. We did not 
expand the colony as it was found that the mice used were of mixed background. 
Therefore, instead of increasing the “n” and repeating the studies, we decided to pursue 
backcrossing to generate mice in pure C57BL/6 background. This was partly done to 
limit wastage of funds, and to focus in obtaining more meaningful data. It is important to 
note that we were able to perform statistical analysis on all data obtained in the pilot 
study. However, in order to account for multiple factors that include age, diet and gender, 
we require an increase in subject numbers in each study. These aspects, including a 
higher “n” and more appropriate statistical analyses will be considered in future studies 
using the pure bred mice. Currently all experiments in chapter 5 are being repeated in 
NKO mice that are of 99% C57BL/6 strain obtained after repeated backcrossing. This 
approach limits the possible variability of results (qualitative and quantitative) due to the 
mixed background of mice used. When analyzing data obtained from our new studies, 
factorial and repeated measures ANOVA will be used. Each study will have at least 6-8 
mice per group.  
The mouse mutagenesis approach used here has focused on a global NUCB2 gene 
deletion. Mutations to achieve cell- and tissue-specific gene modification provide a more 
valuable and accurate strategy. Such a strategy would help delineate the specific effects 
of NUCB2/nesfatin-1 absence on individual tissues. Efforts are currently underway in our 
lab to generate tissue specific NKO mice using the cre-lox technology. Research in our 
lab now also focuses to determine whether nesfatin-1 modulates gastric hormones 
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including ghrelin, and enteric hormones including GLP-1, GIP, CCK and PYY. There 
is very limited evidence that suggest that the neuronal and islet beta cell effects of 
nesfatin-1 are mediated via a G-protein coupled receptor (Nakata et al., 2011, Brailoiu et 
al., 2007, Iwasaki et al., 2009). Preliminary findings suggest that GPR3, GPR6 and/or 
GPR12 are potential receptors for nesfatin-1 (Mori et al., 2008, Osei-Hyiaman et al., 
2011), although further research is required. As previous studies discovered that the 
stomach, pancreas and liver are tissues where endogenous expression of NUCB2 is found 
regulating glucose and energy homeostasis, we further investigated whether these 
receptors are found in these tissues of mice. All three receptors are present in the 
stomach, pancreas and liver of mice (Appendix, Figure A). Moreover, it was found that 
GPR12 colocalizes with insulin in islets β-cells (Appendix, Figure B), but not glucagon 
producing α-cells (Appendix, Figure C).  This result suggests a possible direct action of 
the ligands of these GPR12 on islet beta cells. Further studies must be conducted to learn 
the receptor-mediated mechanism of action of nesfatin-1. 
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6.9 Conclusions 
The aim of this thesis research was to better understand NUCB2/nesfatin-1 as an 
endogenous bioactive peptide. Since NUCB2/nesfatin-1 is implicated in both metabolic 
physiology and pathophysiology, it is a vital contributor to whole-body energy 
homeostasis. This research identified or provided novel and conclusive evidences to 
support nesfatin-1 as a metabolic regulator. In conclusion, it was determined that 
NUCB2/nesfaitin-1 is indeed a meal regulated metabolic factor predominantly produced 
from the gastroenteropancreatic tissues. The data obtained here supports all of the 
hypotheses that led to this research. It further supports nesfatin-1 as a prospective 
candidate molecule for the treatment of metabolic diseases.  
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Appendix 
 
 
Figure A GPR3, GPR6 and GPR12 mRNAs are expressed in the                                   
stomach, liver, pancreas of male mice 
 
Figure A. GPR3 (Amplicon Size: 187 base pairs), GPR6 (Amplicon Size: 214 base pairs) and 
GPR12 mRNAs (Amplicon Size: 232 base pairs) are expressed in the stomach, liver, and 
pancreas of male mice. Beta-Actin (β-Actin; Amplicon Size: 123 base pairs) mRNAs 
expressions were identified in the stomach, liver and pancreas from mice. No GPR3, GPR6 and 
GPR12 and β-Actin mRNA expression was found in PCR reactions devoid of the cDNA 
template. 
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          Figure B Co-localization of GPR12 and insulin IR in the mouse pancreas 
 
Figure B. Co-localization of GPR12 and insulin immunohistochemical staining of the mouse 
pancreas was evident in the insulin producing beta-cells. Islet cells immunoreactive for GPR12 
(red), insulin (green), nuclei (blue) and the merged image of  GPR12, insulin and DAPI (yellow). 
Representative images were taken of 4 slides. Scale bar = 50 μm.  
 
 
 
 
 
236 
 
 
 
             
 
Figure C Localization of GPR12 and glucagon IR in the mouse pancreas 
 
Figure C. Localization of GPR12 and glucagon immunohistochemical staining of the mouse 
pancreas. No-colocalization was found as GPR12 was evident in the insulin producing beta-cells 
and glucagon was evident in the glucagon producing alpha-cell. Islet cells immunoreactive for 
GPR12 (red), glucagon (green), nuclei (blue) and the merged image of  GPR12, glucagon and 
DAPI (yellow). Representative images were taken of 4 slides. Scale bar = 50 μm.  
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